UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the quarterly period ended June 30, ~~2022~~2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File No. 001-38403

__________________________

CRONOS GROUP INC.

(Exact name of registrant as specified in its charter)

__________________________


British Columbia, Canada						N/A
(State or other jurisdiction of						(I.R.S. Employer
incorporation or organization)						Identification No.)

111 Peter St. Suite 300
Toronto, Ontario						M5V 2H1
(Address of principal executive offices)						(Zip Code)

416-504-0004

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Shares, no par value

CRON

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

☐

Non-accelerated filer

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x

As of August ~~5, 2022,~~4, 2023, there were ~~377,896,371~~381,089,357 common shares of the registrant issued and outstanding.

Table of Contents

PART I

FINANCIAL INFORMATION

Item 1.

Financial Statements.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk.

4243

Item 4.

Controls and Procedures.

4344

PART II

OTHER INFORMATION

Item 1.

Legal Proceedings.

Item 1A.

Risk ~~Factors~~Factors.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

4645

Item 3.

Defaults upon Senior Securities.

4645

Item 4.

Mine Safety Disclosures.

Item 5.

Item 6.

Unless otherwise noted or the context indicates otherwise, references in this Quarterly Report on Form 10-Q (this “Quarterly Report”) to the “Company”, “Cronos Group”, “we”, “us” and “our” refer to Cronos Group Inc., its direct and indirect wholly owned subsidiaries and, if applicable, its joint ventures and investments accounted for by the equity method; the term “cannabis” means the plant of any species or subspecies of genus Cannabis and any part of that plant, including all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers; the term “U.S. hemp” has the meaning given to term “hemp” in the United States (“U.S.”). Agricultural Improvement Act of 2018 (the “2018 Farm Bill”), including hemp-derived cannabidiol (“CBD”); and the term “U.S. Schedule I cannabis” means cannabis excluding U.S. hemp.

This Quarterly Report contains references to our trademarks and trade names and to trademarks and trade names belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Quarterly Report may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies’ trademarks or trade names to imply a relationship with, or endorsement or sponsorship of us or our business by, any other companies. In addition, this Quarterly Report includes website addresses. These website addresses are intended to provide inactive, textual references only. The information on or referred to on these websites is not part of or incorporated into this Quarterly Report.

All currency amounts in this Quarterly Report are stated in U.S. dollars, which is our reporting currency, unless otherwise noted. All references to “dollars” or “$” are to U.S. dollars; all references to “C$” are to Canadian dollars; all references to “A$” are to Australian dollars; and all references to “ILS” are to New Israeli Shekels.

(Exchange rates are shown as C$ per $)

As of

(Exchange rates are shown as C$ per $)

As of

June 30, 2022

June 30, 2021

December 31, 2021

June 30, 2023

June 30, 2022

December 31, 2022

Quarter-to-date average rate

1.2765

1.2293

N/A

Spot rate

1.2874

1.2395

1.2746

Spot rate

1.3242

1.2874

1.3554

Year-to-date average rate

1.2715

1.2481

1.2541

Year-to-date average rate

1.3474

1.2715

N/A

(Exchange rates are shown as ILS per $)

As of

June 30, 2023

June 30, 2022

December 31, 2022

Spot rate

3.7051

3.4936

3.5178

Year-to-date average rate

3.5892

3.2670

N/A

All summaries of agreements described herein are qualified by the full text of such agreements (certain of which have been filed as exhibits with the U.S. Securities and Exchange Commission).

PART I
FINANCIAL INFORMATION

Table of Contents


Cronos Group Inc.
Condensed Consolidated Balance Sheets

(In thousands of U.S. dollars, except share amounts)			Table of Contents


		As of June 30, 2022		As of December 31, 2021			As of June 30, 2023		As of December 31, 2022
Assets	Assets	(Unaudited)		(Audited)		Assets
Current assets	Current assets					Current assets
Cash and cash equivalents	Cash and cash equivalents	$	789,543	$	886,973	Cash and cash equivalents	$	409,428	$	764,644
Short-term investments	Short-term investments	155,352		117,684		Short-term investments	431,510		113,077
Accounts receivable, net	Accounts receivable, net	19,375		22,067		Accounts receivable, net	12,540		23,113
Interest receivable						Interest receivable	9,452		2,469
Other receivables	Other receivables	2,175		5,765		Other receivables	4,839		3,298
Current portion of loans receivable, net	Current portion of loans receivable, net	7,613		5,460		Current portion of loans receivable, net	5,035		8,890
Inventory, net	Inventory, net	39,842		32,802		Inventory, net	45,190		37,559
Prepaids and other current assets	Prepaids and other current assets	12,150		8,967		Prepaids and other current assets	6,780		7,106

Total current assets	Total current assets	1,026,050		1,079,718		Total current assets	924,774		960,156
Equity method investments, net	Equity method investments, net	21,731		16,764		Equity method investments, net	17,646		18,755
Other investments	Other investments	108,669		118,392		Other investments	67,925		70,993
Non-current portion of loans receivable, net	Non-current portion of loans receivable, net	78,436		80,635		Non-current portion of loans receivable, net	71,080		72,345
Property, plant and equipment, net	Property, plant and equipment, net	66,316		74,070		Property, plant and equipment, net	57,695		60,557
Right-of-use assets	Right-of-use assets	6,113		8,882		Right-of-use assets	1,571		2,273
Goodwill	Goodwill	1,087		1,098		Goodwill	1,057		1,033
Intangible assets, net	Intangible assets, net	23,722		18,079		Intangible assets, net	25,462		26,704
Other		89		100
Deferred tax asset						Deferred tax asset	1,137		$	193
Total assets	Total assets	$	1,332,213	$	1,397,738	Total assets	$	1,168,347	$	1,213,009

Liabilities	Liabilities					Liabilities
Current liabilities	Current liabilities					Current liabilities
Accounts payable	Accounts payable	$	12,449	$	11,218	Accounts payable	$	9,340	$	11,163
Income taxes payable						Income taxes payable	438		32,956
Accrued liabilities	Accrued liabilities	23,905		26,069		Accrued liabilities	16,573		22,268
Current portion of lease obligation	Current portion of lease obligation	2,267		2,711		Current portion of lease obligation	1,174		1,330
Derivative liabilities	Derivative liabilities	574		14,375		Derivative liabilities	37		15
Current portion due to non-controlling interests						Current portion due to non-controlling interests	364		384
Total current liabilities	Total current liabilities	39,195		54,373		Total current liabilities	27,926		68,116
Due to non-controlling interests		1,356		1,913
Non-current portion due to non-controlling interests						Non-current portion due to non-controlling interests	1,023		1,383
Non-current portion of lease obligation	Non-current portion of lease obligation	6,653		7,095		Non-current portion of lease obligation	2,050		2,546
Deferred income tax liability		46		81
Deferred tax liability						Deferred tax liability	675		—
Total liabilities	Total liabilities	47,250		63,462		Total liabilities	31,674		72,045

Shareholders’ equity	Shareholders’ equity					Shareholders’ equity
Share capital (authorized for issue as of June 30, 2022 and December 31, 2021: unlimited; shares outstanding as of June 30, 2022 and December 31, 2021: 377,896,371 and 374,952,693, respectively)		604,626		595,497
Share capital (authorized for issue as of June 30, 2023 and December 31, 2022: unlimited; shares outstanding as of June 30, 2023 and December 31, 2022: 381,089,357 and 380,575,403, respectively)						Share capital (authorized for issue as of June 30, 2023 and December 31, 2022: unlimited; shares outstanding as of June 30, 2023 and December 31, 2022: 381,089,357 and 380,575,403, respectively)	613,152		611,318
Additional paid-in capital	Additional paid-in capital	35,198		32,465		Additional paid-in capital	45,317		42,682
Retained earnings	Retained earnings	606,557		659,416		Retained earnings	463,153		490,682
Accumulated other comprehensive income		41,688		49,865
Accumulated other comprehensive income (loss)						Accumulated other comprehensive income (loss)	18,067		(797)
Total equity attributable to shareholders of Cronos Group	Total equity attributable to shareholders of Cronos Group	1,288,069		1,337,243		Total equity attributable to shareholders of Cronos Group	1,139,689		1,143,885
Non-controlling interests	Non-controlling interests	(3,106)		(2,967)		Non-controlling interests	(3,016)		(2,921)
Total shareholders’ equity	Total shareholders’ equity	1,284,963		1,334,276		Total shareholders’ equity	1,136,673		1,140,964
Total liabilities and shareholders’ equity	Total liabilities and shareholders’ equity	$	1,332,213	$	1,397,738	Total liabilities and shareholders’ equity	$	1,168,347	$	1,213,009

See notes to condensed consolidated interim financial statements.


Cronos Group Inc.
Condensed Consolidated Statements of Net Loss and Comprehensive ~~Loss~~Income (Loss)

(In thousands of U.S dollars, except share and per share amounts, unaudited)			Table of Contents


		Three months ended June 30,				Six months ended June 30,					Three months ended June 30,				Six months ended June 30,
		2022		2021		2022		2021			2023		2022		2023		2022
Net revenue, before excise taxes	Net revenue, before excise taxes	$	28,554	$	18,848	$	57,960	$	33,502	Net revenue, before excise taxes	$	25,798	$	27,095	$	52,352	$	54,173
Excise taxes	Excise taxes	(5,493)		(3,226)		(9,866)		(5,269)		Excise taxes	(6,777)		(5,493)		(13,836)		(9,866)
Net revenue	Net revenue	23,061		15,622		48,094		28,233		Net revenue	19,021		21,602		38,516		44,307
Cost of sales	Cost of sales	18,941		19,445		37,048		35,019		Cost of sales	15,922		17,280		32,490		33,275
Inventory write-down		—		11,961		—		11,961

Gross profit	Gross profit	4,120		(15,784)		11,046		(18,747)		Gross profit	3,099		4,322		6,026		11,032
Operating expenses	Operating expenses									Operating expenses
Sales and marketing	Sales and marketing	5,582		13,209		10,594		23,463		Sales and marketing	5,297		4,185		11,038		7,195
Research and development	Research and development	4,302		5,199		8,341		10,301		Research and development	1,107		4,194		3,146		8,115
General and administrative	General and administrative	17,005		22,417		39,373		44,323		General and administrative	13,451		16,286		25,307		37,417
Restructuring costs	Restructuring costs	1,270		—		4,354		—		Restructuring costs	—		978		—		3,009
Share-based compensation	Share-based compensation	2,616		2,565		6,302		5,064		Share-based compensation	2,331		2,583		4,866		6,199
Depreciation and amortization	Depreciation and amortization	1,411		1,043		2,704		1,778		Depreciation and amortization	1,533		1,398		3,058		2,666
Impairment loss on goodwill and indefinite-lived intangible assets		—		234,914		—		234,914

Impairment loss on long-lived assets	Impairment loss on long-lived assets	—		1,214		3,493		2,955		Impairment loss on long-lived assets	—		—		—		3,493
Total operating expenses	Total operating expenses	32,186		280,561		75,161		322,798		Total operating expenses	23,719		29,624		47,415		68,094
Operating loss	Operating loss	(28,066)		(296,345)		(64,115)		(341,545)		Operating loss	(20,620)		(25,302)		(41,389)		(57,062)
Other income	Other income									Other income
Interest income, net	Interest income, net	3,775		2,293		5,821		4,622		Interest income, net	12,471		3,775		23,646		5,820
Gain (loss) on revaluation of derivative liabilities	Gain (loss) on revaluation of derivative liabilities	3,410		115,248		13,829		(1,626)		Gain (loss) on revaluation of derivative liabilities	43		3,410		(22)		13,829
Share of income (loss) from equity method investments	Share of income (loss) from equity method investments	5,197		(1,115)		5,197		(2,758)		Share of income (loss) from equity method investments	270		5,197		(226)		5,197
Gain (loss) on revaluation of financial instruments	Gain (loss) on revaluation of financial instruments	(2,112)		77		2,156		(123)		Gain (loss) on revaluation of financial instruments	5,193		(2,112)		(2,565)		2,156
Impairment loss on other investments	Impairment loss on other investments	—		—		(11,238)		—		Impairment loss on other investments	—		—		—		(11,238)
Foreign currency transaction loss	Foreign currency transaction loss	(2,852)		—		(4,724)		—		Foreign currency transaction loss	(3,174)		(2,852)		(4,817)		(4,724)
Other, net	Other, net	2		1,050		137		1,034		Other, net	(26)		49		59		184
Total other income	Total other income	7,420		117,553		11,178		1,149		Total other income	14,777		7,467		16,075		11,224
Loss before income taxes	Loss before income taxes	(20,646)		(178,792)		(52,937)		(340,396)		Loss before income taxes	(5,843)		(17,835)		(25,314)		(45,838)
Income tax expense (benefit)	Income tax expense (benefit)	(308)		—		54		—		Income tax expense (benefit)	(180)		(308)		(1,616)		54
Loss from continuing operations	Loss from continuing operations	(20,338)		(178,792)		(52,991)		(340,396)		Loss from continuing operations	(5,663)		(17,527)		(23,698)		(45,892)
Loss from discontinued operations	Loss from discontinued operations	—		(561)		—		(582)		Loss from discontinued operations	(2,834)		(2,811)		(4,056)		(7,099)
Net loss	Net loss	(20,338)		(179,353)		(52,991)		(340,978)		Net loss	(8,497)		(20,338)		(27,754)		(52,991)
Net loss attributable to non-controlling interest	Net loss attributable to non-controlling interest	(117)		(279)		(132)		(592)		Net loss attributable to non-controlling interest	(137)		(117)		(225)		(132)
Net loss attributable to Cronos Group	Net loss attributable to Cronos Group	$	(20,221)	$	(179,074)	$	(52,859)	$	(340,386)	Net loss attributable to Cronos Group	$	(8,360)	$	(20,221)	$	(27,529)	$	(52,859)

Comprehensive loss
Comprehensive income (loss)										Comprehensive income (loss)
Net loss	Net loss	$	(20,338)	$	(179,353)	$	(52,991)	$	(340,978)	Net loss	$	(8,497)	$	(20,338)	$	(27,754)	$	(52,991)
Other comprehensive income (loss)	Other comprehensive income (loss)									Other comprehensive income (loss)
Foreign exchange gain (loss) on translation	Foreign exchange gain (loss) on translation	(24,161)		13,470		(8,184)		29,754		Foreign exchange gain (loss) on translation	16,580		(24,161)		18,994		(8,184)
Comprehensive loss		(44,499)		(165,883)		(61,175)		(311,224)
Comprehensive income (loss)										Comprehensive income (loss)	8,083		(44,499)		(8,760)		(61,175)
Comprehensive income (loss) attributable to non-controlling interests	Comprehensive income (loss) attributable to non-controlling interests	122		(394)		(139)		432		Comprehensive income (loss) attributable to non-controlling interests	(87)		122		(95)		(139)
Comprehensive loss attributable to Cronos Group		$	(44,621)	$	(165,489)	$	(61,036)	$	(311,656)
Comprehensive income (loss) attributable to Cronos Group										Comprehensive income (loss) attributable to Cronos Group	$	8,170	$	(44,621)	$	(8,665)	$	(61,036)

Net loss from continuing operations per share
Basic - continuing operations		$	(0.05)	$	(0.48)	$	(0.14)	$	(0.92)
Diluted - continuing operations		$	(0.05)	$	(0.48)	$	(0.14)	$	(0.92)

Net loss per share										Net loss per share
Basic and diluted - continuing operations										Basic and diluted - continuing operations	$	(0.01)	$	(0.05)	$	(0.06)	$	(0.12)
Basic and diluted - discontinued operations										Basic and diluted - discontinued operations	(0.01)		—		(0.01)		(0.02)
Basic and diluted										Basic and diluted	$	(0.02)	$	(0.05)	$	(0.07)	$	(0.14)

See notes to condensed consolidated interim financial statements.


Cronos Group Inc.
Condensed Consolidated Statements of Changes in Equity
For the ~~three and~~ six months ended June 30, ~~2022~~2023 and ~~2021~~2022
(In thousands of U.S. dollars, except share amounts, unaudited)

Number of shares Share capital Additional paid-in capital Retained earnings Accumulated other comprehensive income (loss) Non-controlling interests Total shareholders’ equity
Balance as of January 1, 2022 374,952,693 $ 595,497 $ 32,465 $ 659,416 $ 49,865 $ (2,967) $ 1,334,276
Activities relating to share-based compensation 347,287 871 2,900 — — — 3,771
Net loss — — — (32,638) — (15) (32,653)
Foreign exchange gain (loss) on translation — — — — 16,223 (246) 15,977
Balance as of March 31, 2022 375,299,980 $ 596,368 $ 35,365 $ 626,778 $ 66,088 $ (3,228) $ 1,321,371
Activities relating to share-based compensation 395,156 2,251 (167) — — — 2,084
Share issuance pursuant to research and development milestones 2,201,235 6,007 — — — — 6,007
Net loss — — — (20,221) — (117) (20,338)
Foreign exchange gain (loss) on translation — — — — (24,400) 239 (24,161)
Balance as of June 30, 2022 377,896,371 $ 604,626 $ 35,198 $ 606,557 $ 41,688 $ (3,106) $ 1,284,963


	Number of shares	Share capital		Additional paid-in capital		Retained earnings		Accumulated other comprehensive income (loss)		Non-controlling interests		Total shareholders’ equity
Balance as of January 1, 2023	380,575,403	$	611,318	$	42,682	$	490,682	$	(797)	$	(2,921)	$	1,140,964


Activities relating to share-based compensation	240,518	917		1,362		—		—		—		2,279
Net loss	—	—		—		(19,169)		—		(88)		(19,257)
Foreign exchange gain on translation	—	—		—		—		2,334		80		2,414
Balance as of March 31, 2023	380,815,921	$	612,235	$	44,044	$	471,513	$	1,537	$	(2,929)	$	1,126,400
Activities relating to share-based compensation	273,436	917		1,273		—		—		—		2,190
Net loss	—	—		—		(8,360)		—		(137)		(8,497)
Foreign exchange gain on translation	—	—		—		—		16,530		50		16,580
Balance as of June 30, 2023	381,089,357	$	613,152	$	45,317	$	463,153	$	18,067	$	(3,016)	$	1,136,673


		Number of shares	Share capital		Additional paid-in capital		Retained earnings		Accumulated other comprehensive income (loss)		Non-controlling interests		Total shareholders’ equity					Number of shares		Share capital		Additional paid-in capital		Retained earnings		Accumulated other comprehensive income (loss)		Non-controlling interests		Total shareholders’ equity
Balance as of January 1, 2021		360,253,332	$	569,260	$	34,596	$	1,064,509	$	42,999	$	(3,196)	$	1,708,168
Balance as of January 1, 2022															Balance as of January 1, 2022		374,952,693		$	595,497	$	32,465	$	659,416	$	49,865	$	(2,967)	$	1,334,276

Activities relating to share-based compensation	Activities relating to share-based compensation	11,403,258	15,652		(2,506)		(7,694)		—		—		5,452			Activities relating to share-based compensation		347,287		871		2,900		—		—		—		3,771
Net loss	Net loss	—	—		—		(161,312)		—		(313)		(161,625)			Net loss		—		—		—		(32,638)		—		(15)		(32,653)
Foreign exchange gain on translation		—	—		—		—		15,145		1,139		16,284
Balance as of March 31, 2021		371,656,590	$	584,912	$	32,090	$	895,503	$	58,144	$	(2,370)	$	1,568,279
Foreign exchange gain (loss) on translation															Foreign exchange gain (loss) on translation		—		—		—		—		16,223		(246)		15,977
Balance as of March 31, 2022															Balance as of March 31, 2022		375,299,980		$	596,368	$	35,365	$	626,778	$	66,088	$	(3,228)	$	1,321,371
Activities relating to share-based compensation															Activities relating to share-based compensation		395,156		2,251		(167)		—		—		—		2,084
Share issuance pursuant to research and development milestones															Share issuance pursuant to research and development milestones		2,201,235		6,007		—		—		—		—		6,007
Net loss															Net loss		—		—		—		(20,221)		—		(117)		(20,338)
Foreign exchange gain (loss) on translation															Foreign exchange gain (loss) on translation		—		—		—		—		(24,400)		239		(24,161)
Balance as of June 30, 2022															Balance as of June 30, 2022		377,896,371		$	604,626	$	35,198	$	606,557	$	41,688	$	(3,106)	$	1,284,963

Activities relating to share-based compensation		148,957	2,451		278		(63)		—		—		2,666
Top-up rights out-of-period adjustment		—	(14,505)		—		3,227		—		—		(11,278)
Net loss		—	—		—		(179,074)		—		(279)		(179,353)
Foreign exchange gain (loss) on translation		—	—		—		—		13,585		(115)		13,470
Balance as of June 30, 2021		371,805,547	$	572,858	$	32,368	$	719,593	$	71,729	$	(2,764)	$	1,393,784

See notes to condensed consolidated interim financial statements.


Cronos Group Inc.
Condensed Consolidated Statements of Cash Flows

(In thousands of U.S. dollars, except share amounts, unaudited)			Table of Contents


		Six months ended June 30,					Six months ended June 30,
		2022		2021			2023		2022
Operating activities	Operating activities					Operating activities
Net loss	Net loss	$	(52,991)	$	(340,978)	Net loss	$	(27,754)	$	(52,991)
Adjustments to reconcile net loss to cash used in operating activities:	Adjustments to reconcile net loss to cash used in operating activities:					Adjustments to reconcile net loss to cash used in operating activities:
Share-based compensation	Share-based compensation	6,302		5,064		Share-based compensation	4,887		6,302
Depreciation and amortization	Depreciation and amortization	7,051		5,083		Depreciation and amortization	4,785		7,051
Impairment loss on goodwill and indefinite-lived intangible assets		—		234,914

Impairment loss on long-lived assets	Impairment loss on long-lived assets	3,493		2,955		Impairment loss on long-lived assets	205		3,493
Impairment loss on other investments	Impairment loss on other investments	11,238		—		Impairment loss on other investments	—		11,238
(Income) loss from investments		(7,193)		2,758
(Gain) loss on revaluation of derivative liabilities		(13,829)		1,626
Loss (gain) from investments						Loss (gain) from investments	2,955		(7,193)
Loss (gain) on revaluation of derivative liabilities						Loss (gain) on revaluation of derivative liabilities	22		(13,829)

Changes in expected credit losses on long-term financial assets	Changes in expected credit losses on long-term financial assets	(655)		—		Changes in expected credit losses on long-term financial assets	(1,146)		(655)
Foreign currency transaction loss	Foreign currency transaction loss	4,724		—		Foreign currency transaction loss	4,817		4,724
Other non-cash operating activities, net	Other non-cash operating activities, net	(1,956)		(1,192)		Other non-cash operating activities, net	(4,012)		(1,956)
Changes in operating assets and liabilities:	Changes in operating assets and liabilities:					Changes in operating assets and liabilities:
Accounts receivable, net	Accounts receivable, net	1,981		(2,194)		Accounts receivable, net	10,623		1,981
Interest receivable						Interest receivable	(6,807)		(383)
Other receivables	Other receivables	3,590		6,960		Other receivables	(200)		3,973
Prepaids and other current assets	Prepaids and other current assets	(3,759)		1,268		Prepaids and other current assets	480		(3,759)
Inventory	Inventory	(8,145)		10,951		Inventory	(7,259)		(8,145)
Accounts payable and accrued liabilities		(1,042)		(13,412)

Accounts payable						Accounts payable	(2,478)		481
Income taxes payable						Income taxes payable	(32,801)		—
Accrued liabilities						Accrued liabilities	(5,784)		(1,523)
Cash flows used in operating activities	Cash flows used in operating activities	(51,191)		(86,197)		Cash flows used in operating activities	(59,467)		(51,191)
Investing activities	Investing activities					Investing activities
Purchase of short-term investments	Purchase of short-term investments	(157,300)		(120,180)		Purchase of short-term investments	(479,763)		(157,300)
Proceeds from short-term investments	Proceeds from short-term investments	117,975		136,204		Proceeds from short-term investments	169,418		117,975
Purchase of other investments		—		(110,392)

(Advances) repayments on loan receivables		1,573		(5,064)

Dividends received from equity method investment						Dividends received from equity method investment	1,299		—
Proceeds from repayment on loan receivables						Proceeds from repayment on loan receivables	11,388		1,573
Purchase of property, plant and equipment	Purchase of property, plant and equipment	(2,218)		(8,347)		Purchase of property, plant and equipment	(1,298)		(2,218)
Purchase of intangible assets	Purchase of intangible assets	(421)		(843)		Purchase of intangible assets	(8)		(421)
Other investing activities	Other investing activities	70		2,059		Other investing activities	—		70
Cash flows used in investing activities	Cash flows used in investing activities	(40,321)		(106,563)		Cash flows used in investing activities	(298,964)		(40,321)
Financing activities	Financing activities					Financing activities
Withholding taxes paid on share-based awards	Withholding taxes paid on share-based awards	(2,080)		(8,919)		Withholding taxes paid on share-based awards	(782)		(2,080)
Other financing activities, net	Other financing activities, net	46		12		Other financing activities, net	—		46
Cash flows used in financing activities	Cash flows used in financing activities	(2,034)		(8,907)		Cash flows used in financing activities	(782)		(2,034)
Effect of foreign currency translation on cash and cash equivalents	Effect of foreign currency translation on cash and cash equivalents	(3,884)		18,825		Effect of foreign currency translation on cash and cash equivalents	3,997		(3,884)
Net change in cash and cash equivalents	Net change in cash and cash equivalents	(97,430)		(182,842)		Net change in cash and cash equivalents	(355,216)		(97,430)
Cash and cash equivalents, beginning of period	Cash and cash equivalents, beginning of period	886,973		1,078,023		Cash and cash equivalents, beginning of period	764,644		886,973
Cash and cash equivalents, end of period	Cash and cash equivalents, end of period	$	789,543	$	895,181	Cash and cash equivalents, end of period	$	409,428	$	789,543
Supplemental cash flow information	Supplemental cash flow information					Supplemental cash flow information
Interest paid	Interest paid	$	—	$	—	Interest paid	$	—	$	—
Interest received	Interest received	3,490		2,961		Interest received	$	13,385	$	3,490
Income taxes paid	Income taxes paid	140		858		Income taxes paid	$	32,995	$	140

See notes to condensed consolidated interim financial statements.


Cronos Group Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands of U.S. dollars, except share amounts)			Table of Contents

1. Background, Basis of Presentation, and Summary of Significant Accounting Policies

(a)Background

Cronos Group Inc. (“~~Cronos Group”~~Cronos” or the “Company”) is incorporated in the province of British Columbia ~~and~~ under the Business Corporations Act ~~(British~~(British Columbia) with principal executive offices at 111 Peter St., Suite 300, Toronto, Ontario, M5V 2H1. The Company’s common shares are currently listed on the Toronto Stock Exchange (“TSX”) and Nasdaq Global Market (“Nasdaq”) under the ticker symbol “CRON.”

Cronos ~~Group~~ is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product ~~development and~~development. With a passion to responsibly elevate the consumer experience, Cronos is ~~seeking to build~~building an iconic brand portfolio. ~~Cronos Group’s~~Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS®, and Lord Jones®~~, Happy Dance~~® ~~and PEACE+~~®.

(b)Basis of presentation

~~The~~These condensed consolidated interim financial statements of Cronos Group are unaudited. They have been prepared in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) for interim financial information and with applicable rules and regulations of the U.S. Securities and Exchange Commission relating to interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, ~~2022~~2023 are not necessarily indicative of the results that may be expected for any other reporting period.

These condensed consolidated interim financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in its Annual Report on Form 10-K for the year ended December 31, ~~2021~~2022 (the “Annual Report”).

Certain prior ~~year~~period amounts have been reclassified to conform to the current year presentation of our condensed consolidated interim financial statements. These reclassifications had no effect on the reported results of operations and ending shareholders’ equity.

(c)Discontinued Operations

In the second quarter of 2023, the Company exited its U.S. hemp-derived cannabinoid product operations. The exit of the U.S. operations represented a strategic shift that has a major effect on the Company’s operations and financial results, and as such, qualifies for reporting as discontinued operations in our condensed consolidated statements of net loss and comprehensive income (loss). Prior period amounts have been reclassified to reflect the discontinued operations classification of the U.S. operations.

(d)Segment information

Segment reporting is prepared on the same basis that the Company’s chief operating decision maker (the “CODM”) manages the business, makes operating decisions and assesses the Company’s performance. ~~The~~Historically, the Company has reported results for two reportable segments, the U.S. and Rest of World. In the second quarter of 2023, as a result of the Company’s exit of its then-existing U.S. operations, the Company determined that it has ~~the following 2 reportable segments: U.S. (the “U.S. segment”) and ROW (the “ROW segment”).~~ ~~The U.S.~~one operating segment ~~consists~~and therefore one reportable segment, which is comprised of ~~the~~operations ~~manufacture~~in Canada and ~~distribution of U.S. hemp-derived cannabinoid infused products.~~ ~~The ROW operating segment~~Israel and is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. All prior period segment disclosure information has been reclassified to conform to the current reporting structure in this Form 10-Q. These ~~2 segments represent~~reclassifications had no effect on our consolidated financial statements in any period presented.

(e)Revenue recognition

The following tables present the Company's revenue by major product category for continuing operations:


	Three months ended June 30,
	2023		2022
Cannabis flower	$	14,014	$	15,739
Cannabis extracts	4,926		5,582
Other	81		281
Net revenue	$	19,021	$	21,602


Cronos Group Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands of U.S. dollars, except share amounts)			Table of Contents


	Six months ended June 30,
	2023		2022
Cannabis flower	$	27,142	$	34,364
Cannabis extracts	11,227		9,570
Other	147		373
Net revenue	$	38,516	$	44,307

Net revenue attributed to a geographic ~~regions in which~~region based on the ~~Company operates and the different product offerings within each geographic region. The results of each segment are regularly reviewed by the CODM to assess the performance~~location of the ~~segment and make decisions regarding the allocation of resources using Adjusted EBITDA (as defined below)~~customer were as the measure of segment profit or loss. Adjusted EBITDA is defined as earnings before interest, tax, depreciation, non-cash items and items that do not reflect management’s assessment of ongoing business performance.follows for continuing operations:


	Three months ended June 30,
	2023		2022
Canada	$	13,595	$	14,389
Israel	5,426		7,213


Net revenue	$	19,021	$	21,602


	Six months ended June 30,
	2023		2022
Canada	$	28,029	$	27,965
Israel	10,487		16,342


Net revenue	$	38,516	$	44,307

~~(d)~~(f)Concentration of risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk from its operating activities, primarily accounts receivable and other receivables, and its investing activities, including cash held with banks and financial institutions, short-term investments and loans ~~receivable, and advances to joint ventures.~~receivable. The Company’s maximum exposure to this risk is equal to the carrying amount of these financial assets, which amounted to ~~$1,052,494~~$943,884 and ~~$1,118,684~~$987,836 as of June 30, ~~2022~~2023 and December 31, ~~2021,~~2022, respectively.

An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on the days past due for groupings of various customer segments with similar loss patterns. The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Accounts receivable are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan and a failure to make contractual payments for a period of greater than 120 days past due. As of June 30, ~~2022~~2023 and December 31, ~~2021,~~2022, the Company had $2$69 and ~~$8,~~$219, respectively, in expected credit losses that have been recognized on receivables from contracts with ~~customers in the ROW segment.~~ customers.

As of June 30, ~~2022 and~~2023, the Company assessed that there is a concentration of credit risk, as 41% of the Company’s accounts receivable were due from two customers with an established credit history with the Company. As of December 31, ~~2021,~~2022, 55% of the Company’s accounts receivable were due from three customers with an established credit history with the Company.

The Company sells products to a limited number of major customers. Major customers are defined as customers that each individually accounted for greater than 10% of the Company’s revenue. During the three months ended June 30, 2023, the Company ~~had $165 and $104, respectively, in expected credit losses that have been recognized on receivables~~earned a total net revenue before excise taxes of $16,839 from ~~contracts with~~three major customers, intogether accounting for 67% of the ~~U.S. segment.~~Company’s total net revenues before excise taxes. During the three months ended June 30, 2022, the Company earned a total net revenue before excise taxes of $12,767 from three major customers, together accounting for 59% of the Company’s total net revenues before excise taxes. During the six months ended June 30, 2023, the Company earned a total net revenue before excise taxes of $34,732 from three major customers, together accounting for 67% of the Company’s total net revenues before excise taxes. During the six months ended June 30, 2022, the Company earned a total net revenue before excise taxes of $24,690 from three major customers, together accounting for 56% of the Company’s total net revenues before excise taxes.


Cronos Group Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands of U.S. dollars, except share amounts)			Table of Contents

As of June 30, 2022, the Company assessed that there is a concentration of credit risk, as 70% of the Company’s accounts receivable were due from three customers with an established credit history with the Company. As of December 31, 2021, 88% of the Company’s accounts receivable were due from four customers with an established credit history with the Company.

The Company sells products to a limited number of major customers. Major customers are defined as customers that each individually accounted for greater than 10% of the Company’s revenue. During the three months ended June 30, 2022, the Company earned a total net revenue before excise taxes of $12,767 from three major customers in the ROW segment, together accounting for 56% of the Company’s total net revenues before excise taxes. During the three months ended June 30, 2021, the ROW segment earned a total net revenue before excise taxes of $8,497 from three major customers, together accounting for 45% of the Company’s total net revenues before excise taxes. During the six months ended June 30, 2022, the Company earned a total net revenue before excise taxes of $24,690 from three major customers in the ROW segment, together accounting for 51% of the Company’s total net revenue before excise taxes. During the six months ended June 30, 2021, the ROW segment earned a total net revenue before excise taxes of $18,250 from four major customers, together accounting for 54% of the Company’s total net revenues before excise taxes. During the three and six months ended June 30, 2022 and 2021, the U.S. segment had no major customers.

~~(e)~~(g)Adoption of new accounting pronouncements

On January 1, ~~2022,~~2023, the Company adopted ASU No. 2020-06, Debt –Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815–40) (“ASU No. 2020-06”). ASU No. 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. ASU No. 2020-06 is part of the Financial Accounting Standards Board’s (“FASB”) simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The adoption of ASU No. 2020-06 did not have an impact on the Company’s condensed consolidated interim financial statements.

~~(f)New accounting pronouncements not yet adopted~~

~~In March 2022, the FASB issued~~ ASU 2022-02, Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures (“ASU No. 2022-02”). ASU No. 2022-02 eliminates the existing troubled debt restructuring recognition and measurement guidance, and instead aligns the accounting treatment to that of other loan modifications. The amendments enhance existing disclosure requirements and introduce new requirements related to certain modifications of receivables made to borrowers experiencing financial difficulty. ASU No. 2022-02 also requires that entities disclose current-period gross write-offs by year of origination for financing receivables and net investments in leases. ~~ASU No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, and is to be adopted prospectively.~~ The ~~Company does not expect the~~ adoption of ASU No. 2022-02 todid not have a material impact on ~~its~~the Company’s condensed consolidated interim financial statements.

(h)New accounting pronouncements not yet adopted

In June 2022, the ~~FASB~~Financial Accounting Standards Board (“FASB”) issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU No. 2022-03”). ASU No. 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered in measuring fair value. The amendments also require additional disclosures for equity securities subject to contractual sale restrictions. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, and iswe expect to ~~be adopted~~adopt ASU 2022-03 prospectively. The Company does not expect the adoption of ASU No. 2022-03 to have a material impact on its condensed consolidated interim financial statements.

2. Discontinued Operations

In the second quarter of 2023, the Company exited its then-existing U.S. hemp-derived cannabinoid product operations. Accordingly, the net loss of the U.S. operations for the three and six months ended June 30, 2023 and 2022 are reported separately as loss from discontinued operations on the condensed consolidated statements of net loss and comprehensive income (loss).

The following table presents the major components comprising loss from discontinued operations in the condensed consolidated statements of operations for the three and six months ended June 30, 2023 and 2022:


	Three months ended June 30,			Six months ended June 30,
		2023		2022		2023		2022
Net revenue		$	380	$	1,459	$	1,029	$	3,787
Cost of sales		848		1,661		2,044		3,773
Inventory write-down		839		—		839		—
Gross profit		(1,307)		(202)		(1,854)		14
Operating expenses
Sales and marketing		387		1,397		518		3,399
Research and development		18		108		20		226
General and administrative		213		719		736		1,956
Restructuring costs		534		292		534		1,345
Share-based compensation		5		33		21		103
Depreciation and amortization		5		13		13		38

Impairment loss on long-lived assets(ii)		205		—		205		—
Total operating expenses		1,367		2,562		2,047		7,067
Interest income		3		—		8		1
Other, net(i)		(163)		(47)		(163)		(47)
Total other loss		(160)		(47)		(155)		(46)
Loss before income taxes		(2,834)		(2,811)		(4,056)		(7,099)
Income tax expense (benefit)		—		—		—		—
Net loss from discontinued operations		$	(2,834)	$	(2,811)	$	(4,056)	$	(7,099)

(i)For the three and six months ended June 30, 2023 and June 30, 2022, Other, net related to loss on disposal of assets that were part of the U.S. operations.

(ii)During the three and six months ended June 30, 2023, as a result of the exit of the U.S. operations, the Company recognized an impairment charge of $205 related to the right-of-use lease assets associated with the Company’s former U.S. manufacturing facility in Los Angeles, California.

The following tables present the Company's discontinued operations revenue by major product category:


Cronos Group Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands of U.S. dollars, except share amounts)			Table of Contents


	Three months ended June 30, 2023
	2023		2022
Cannabis extracts	$	380	$	1,459
Net revenue	$	380	$	1,459


	Six months ended June 30,
	2023		2022
Cannabis extracts	$	1,029	$	3,787
Net revenue	$	1,029	$	3,787

The following tables summarize the Company’s discontinued operations restructuring activity for the three and six months ended June 30, 2023 and 2022:


	Accrual as of April 1, 2023		Expenses		Payments/Write-offs		Accrual as of June 30, 2023
Employee Termination Benefits	$	—	$	442	$	(223)	$	219

Other Restructuring Costs	—		92		—		92
Total	$	—	$	534	$	(223)	$	311


	Accrual as of January 1, 2023		Expenses		Payments/Write-offs		Accrual as of June 30, 2023
Employee Termination Benefits	$	—	$	442	$	(223)	$	219

Other Restructuring Costs	—		92		—		92
Total	$	—	$	534	$	(223)	$	311


	Accrual as of April 1, 2022		Expenses		Payments/Write-offs		Accrual as of June 30, 2022
Employee Termination Benefits	$	102	$	292	$	(328)	$	66


Total	$	102	$	292	$	(328)	$	66


	Accrual as of January 1, 2022		Expenses		Payments/Write-offs		Accrual as of June 30, 2022
Employee Termination Benefits	$	—	$	1,345	$	(1,279)	$	66


Total	$	—	$	1,345	$	(1,279)	$	66


Cronos Group Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands of U.S. dollars, except share amounts)			Table of Contents

The following table presents a reconciliation of assets and liabilities of the discontinued operations presented in the condensed consolidated balance sheets:


	As of June 30, 2023		As of December 31, 2022
Assets
Current assets
Cash and cash equivalents	$	1,918	$	2,300

Accounts receivable, net	7		253
Other receivables	—		775

Prepaids and other current assets	53		464
Inventory, net	—		934
Current assets of discontinued operations	1,978		4,726

Non-current assets



Property, plant and equipment, net	—		254
Right-of-use assets	—		430

Intangible assets, net	—		1,594

Non-current assets of discontinued operations	—		2,278

Liabilities
Current liabilities
Accounts payable	131		166

Accrued liabilities	621		807
Current portion of lease obligation	216		415


Current liabilities of discontinued operations	$	968	$	1,388

For the six months ended June 30, 2023, purchases of property plant and equipment related to discontinued operations were $67. For the six months ended June 30, 2022 purchases of property plant and equipment related to discontinued operations were $133.

3. Inventory, net

Inventory, net is comprised of the following items:

As of June 30, 2022 As of December 31, 2021
Raw materials $ 7,435 $ 9,211
Work-in-progress 14,548 12,405
Finished goods 16,926 10,778
Supplies and consumables 933 408
Total $ 39,842 $ 32,802


	As of June 30, 2023		As of December 31, 2022
Raw materials	$	7,419	$	7,421
Work-in-progress	15,926		15,646
Finished goods	20,730		13,503
Supplies and consumables	1,115		989
Total	$	45,190	$	37,559

912


Cronos Group Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands of U.S. dollars, except share amounts)			Table of Contents

3.4. Investments

(a)~~Variable interest entities and equity~~Equity method investments, net

A reconciliation of the carrying amount of the investments in equity method investees, net is as follows:

Ownership interest As of June 30, 2022 As of December 31, 2021
Cronos Growing Company Inc. (“Cronos GrowCo”) 50% $ 21,731 $ 16,764
NatuEra S.à.r.l. (“Natuera”) 50% — —
$ 21,731 $ 16,764


	Ownership interest	As of June 30, 2023		As of December 31, 2022

Cronos Growing Company Inc. (“Cronos GrowCo”)	50%	$	17,646	$	18,755

		$	17,646	$	18,755

On June 30, 2023, the Company received a dividend of C$1,750 ($1,322) from Cronos GrowCo, which reduced the Company’s carrying amount in the investment.

The following is a summary of the Company’s share of net ~~income~~gain (loss) from equity method investments:

For the three months ended June 30, For the six months ended June 30,
2022 2021 2022 2021
Cronos GrowCo 5,197 (459) $ 5,197 $ (758)
Natuera — (656) — (2,000)
$ 5,197 $ (1,115) $ 5,197 $ (2,758)


	For the three months ended June 30,				For the six months ended June 30,
	2023		2022		2023		2022
Cronos GrowCo	$	270	$	5,197	$	(226)	$	5,197

	$	270	$	5,197	$	(226)	$	5,197

(b)Other investments

Other investments consist of investments in common shares and options of two companies in the cannabis industry.

PharmaCann, Inc.

In 2021, the Company purchased an option (the “PharmaCann Option”) to acquire 473,787 shares of Class A Common Stock of PharmaCann, Inc. (“PharmaCann”), a vertically integrated cannabis company in the United States, which represented an ownership interest of approximately 10.5% as of ~~December 31, 2021.~~the purchase date of the PharmaCann Option, for an aggregate purchase price of approximately $110,392. The PharmaCann Option is classified as an equity security without a readily determinable fair value. The Company has elected to measure the fair value of the PharmaCann Option at cost less impairment, if any, and subsequently adjusted for observable price changes in orderly transactions for the identical or a similar investment of the same issuer. ~~On February 28, 2022, PharmaCann closed~~As of June 30, 2023, the previously announced transaction with LivWell Holdings, Inc. (“LivWell”) pursuant to which PharmaCann acquired LivWell (the “LivWell Transaction”). LivWell is a multi-state cannabis cultivation and retail leader based in Colorado. As a result of the LivWell Transaction, the Company’s proforma ownership percentage in PharmaCann on a fully-diluted basis ~~decreased to~~was approximately ~~6.4%~~6.3%. The decrease in the Company’s ownership percentage since acquisition does not materially affect the Company’s rights under the PharmaCann Option.

Vitura Health Limited (formerly known as Cronos ~~Australia Limited~~Australia)

The Company owns approximately 10% of the outstanding common shares of ~~Cronos Australia~~Vitura Health Limited (“~~Cronos Australia”~~Vitura”). The investment is considered an equity security with a readily determinable fair value. Changes in the fair value of the investment are recorded as gain (loss) on revaluation of financial instruments on the condensed consolidated statements of net loss and comprehensive ~~loss.~~income (loss). The PharmaCann Option is measured at fair value on a non-recurring basis and is a level 3 asset. See Note 11 “Fair Value Measurements” for more information on the fair value hierarchy.

1013


Cronos Group Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands of U.S. dollars, except share amounts)			Table of Contents

The following table summarizes the Company’s other investments activity:


		As of April 1, 2022		Unrealized loss		Impairment charges		Foreign exchange effect		As of June 30, 2022			As of April 1, 2023		Unrealized gain		Impairment charges		Foreign exchange effect		As of June 30, 2023
PharmaCann	PharmaCann	$	99,154	$	—	$	—	$	—	$	99,154	PharmaCann	$	49,000	$	—	$	—	$	—	$	49,000
Cronos Australia		12,607		(2,200)		—		(892)		9,515
Vitura												Vitura	13,833		5,194		—		(102)		18,925
		$	111,761	$	(2,200)	$	—	$	(892)	$	108,669		$	62,833	$	5,194	$	—	$	(102)	$	67,925


		As of January 1, 2022		Unrealized gain		Impairment charges		Foreign exchange effect		As of June 30, 2022			As of January 1, 2023		Unrealized loss		Impairment charges		Foreign exchange effect		As of June 30, 2023
PharmaCann	PharmaCann	$	110,392	$	—	$	(11,238)	$	—	$	99,154	PharmaCann	$	49,000	$	—	$	—	$	—	$	49,000
Cronos Australia		8,000		1,996		—		(481)		9,515
Vitura												Vitura	21,993		(2,729)		—		(339)		18,925
		$	118,392	$	1,996	$	(11,238)	$	(481)	$	108,669		$	70,993	$	(2,729)	$	—	$	(339)	$	67,925


	As of April 1, 2022		Unrealized loss		Impairment charges		Foreign exchange effect		As of June 30, 2022
PharmaCann	$	99,154	$	—	$	—	$	—	$	99,154
Vitura	12,607		(2,200)		—		(892)		9,515
	$	111,761	$	(2,200)	$	—	$	(892)	$	108,669


	As of January 1, 2022		Unrealized gain		Impairment charges		Foreign exchange effect		As of June 30, 2022
PharmaCann	$	110,392	$	—	$	(11,238)	$	—	$	99,154
Vitura	8,000		1,996		—		(481)		9,515
	$	118,392	$	1,996	$	(11,238)	$	(481)	$	108,669

During the ~~three~~six months ended ~~March 31,~~June 30, 2022, the Company identified adverse forecast changes in the financial performance of PharmaCann as indicators of impairment related to the PharmaCann Option and conducted ~~an analysis~~analyses comparing the PharmaCann Option’s carrying amount to its estimated fair value. The fair value was estimated using a combination of the market and income approaches. Under the income approach, significant inputs used in the discounted cash flow method ~~include~~were the discount rate, growth rates, ~~and~~ cash flow ~~projections.~~projections, and the timing of federal legalization of cannabis in the U.S. Under the market valuation approach, the key assumptions that require judgment under the Guideline Public Companies method are cash flow projections, selected multiples and the discount for lack of marketability. As a result of this analysis, the Company recorded a non-cash impairment charge of $11,238 during the six months ended June 30, 2022, as the difference between the carrying amount of the PharmaCann Option and its estimated fair value in the condensed consolidated statements of net loss and comprehensive ~~loss.~~income (loss).

During the three and six months ended June 30, 2021, the Company had no gain or loss on revaluation of other investments. As of June 30, 2022 and December 31, 2021, the Company did not hold any additional other investments.


Cronos Group Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands of U.S. dollars, except share amounts)			Table of Contents

5. Loans Receivable, net

Loans receivable, net consists of the following:


		As of June 30, 2022		As of December 31, 2021			As of June 30, 2023		As of December 31, 2022

GrowCo Facility(i)		$	3,625	$	3,138
GrowCo Credit Facility						GrowCo Credit Facility	$	5,035	$	4,427
Add: Current portion of accrued interest	Add: Current portion of accrued interest	3,988		2,322		Add: Current portion of accrued interest	—		4,463
Total current portion of loans receivable	Total current portion of loans receivable	7,613		5,460		Total current portion of loans receivable	5,035		8,890
GrowCo Facility(i)		62,310		64,367
GrowCo Credit Facility						GrowCo Credit Facility	55,757		56,898
Mucci Promissory Note	Mucci Promissory Note	14,127		14,019		Mucci Promissory Note	13,383		13,438
Cannasoul Collaboration Loan(ii)		1,999		2,249

Cannasoul Collaboration Loan						Cannasoul Collaboration Loan	1,736		1,837
Add: Long-term portion of accrued interest						Add: Long-term portion of accrued interest	204		172
Total long-term portion of loans receivable	Total long-term portion of loans receivable	78,436		80,635		Total long-term portion of loans receivable	71,080		72,345
Total loans receivable, net	Total loans receivable, net	$	86,049	$	86,095	Total loans receivable, net	$	76,115	$	81,235

~~(i)~~Cronos GrowCo Credit Facility

On August 23, 2019, the Company, as lender, and Cronos GrowCo, as borrower, entered into a senior secured credit agreement for an aggregate principal amount of C$100,000 (the “GrowCo Credit Facility”). In August 2021, the GrowCo Credit Facility was amended to increase the aggregate principal amount available to C$105,000. As of both June 30, ~~2022~~2023 and December 31, ~~2021,~~2022, Cronos GrowCo had ~~outstanding borrowings of C$102,000 ($79,228) and~~drawn C$104,000 ($~~81,598), respectively,~~78,538 and $76,730, respectively) from the GrowCo Credit Facility. The interest rate on the outstanding borrowings is the Canadian Prime Rate plus 1.25%, with interest payments due on December 2021, December 2022, and quarterly thereafter. Principal payments of C$1,000 commenced in March 2022 and are due quarterly thereafter. As of June 30, ~~2022,~~2023, Cronos GrowCo had repaid C$~~2,000~~8,167 ($~~1,554)~~6,167) and C$16,486 ($12,450) in principal and interest, respectively, under the terms of the GrowCo Credit Facility.

Mucci Promissory Note

On June 28, 2019, the Company entered into a promissory note receivable agreement (the “Mucci Promissory Note”) for C$16,350 (approximately $12,347) with the Cronos GrowCo joint venture partner (“Mucci”). The ~~available borrowing capacity~~Mucci Promissory Note is secured by a general security agreement covering all the assets of Mucci. On September 30, 2022, the Mucci Promissory Note was amended and restated to increase the interest rate from 3.95% to the Canadian Prime Rate plus 1.25%, change the interest payments from quarterly to annual, and defer Mucci’s initial cash interest payment from September 30, 2022 to July 1, 2023.

Prior to July 1, 2022, interest accrued on the Mucci Promissory Note was capitalized as part of the principal balance. As of July 1, 2022, interest was accrued and to be paid in cash beginning on July 1, 2023. On June 30, 2023, Mucci made a payment of C$1,750 (approximately $1,322) under the ~~GrowCo Facility was~~Mucci Promissory Note, with C$~~1,000~~1,187 ($~~777) at~~897) related to accrued interest and C$563 ($425) related to outstanding principal.

Cannasoul Collaboration Loan

As of both June 30, ~~2022~~2023 and December 31, ~~2021.~~

~~(ii)As of June 30,~~ 2022, ~~and December 31, 2021,~~ Cannasoul Lab Services Ltd. has received ILS 8,297 ~~($2,376)~~(approximately $2,239 and ~~ILS 8,297 ($2,664)~~$2,359, respectively), ~~respectively,~~ from the Cannasoul Collaboration Loan.

1115


Cronos Group Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands of U.S. dollars, except share amounts)			Table of Contents

Expected credit loss allowances on the Company’s long-term financial assets for the three and six months ended June 30, ~~2022~~2023 and ~~2021~~2022 were comprised of the following items:


		As of April 1, 2022		Increase (decrease)(i)		Foreign exchange effect		As of June 30, 2022			As of April 1, 2023		Increase (decrease)(i)		Foreign exchange effect		As of June 30, 2023
GrowCo Facility		$	14,354	$	(660)	$	(401)	$	13,293
GrowCo Credit Facility										GrowCo Credit Facility	$	11,719	$	(379)	$	239	$	11,579

Mucci Promissory Note	Mucci Promissory Note	93		1		(3)		91		Mucci Promissory Note	91		(7)		2		86
Cannasoul Collaboration Loan	Cannasoul Collaboration Loan	409		4		(36)		377		Cannasoul Collaboration Loan	514		4		(15)		503
		$	14,856	$	(655)	$	(440)	$	13,761		$	12,324	$	(382)	$	226	$	12,168


		As of April 1, 2021		Increase (decrease)		Foreign exchange effect		As of June 30, 2021			As of April 1, 2022		Increase (decrease)(i)		Foreign exchange effect		As of June 30, 2022
GrowCo Facility		$	1,569	$	—	$	21	$	1,590
Natuera Series A Loan(ii)		1,151		(1,153)		2		—
GrowCo Credit Facility										GrowCo Credit Facility	$	14,354	$	(660)	$	(401)	$	13,293

Mucci Promissory Note	Mucci Promissory Note	274		—		4		278		Mucci Promissory Note	93		1		(3)		91
Cannasoul Collaboration Loan	Cannasoul Collaboration Loan	26		—		13		39		Cannasoul Collaboration Loan	409		4		(36)		377
		$	3,020	$	(1,153)	$	40	$	1,907		$	14,856	$	(655)	$	(440)	$	13,761


		As of January 1, 2022		Increase (decrease)(i)		Foreign exchange effect		As of June 30, 2022			As of January 1, 2023		Increase (decrease)(i)		Foreign exchange effect		As of June 30, 2023
GrowCo Facility		$	14,089	$	(664)	$	(132)	$	13,293
GrowCo Credit Facility										GrowCo Credit Facility	$	12,455	$	(1,149)	$	273	$	11,579

Mucci Promissory Note	Mucci Promissory Note	90		2		(1)		91		Mucci Promissory Note	89		(5)		2		86
Cannasoul Collaboration Loan	Cannasoul Collaboration Loan	415		7		(45)		377		Cannasoul Collaboration Loan	522		8		(27)		503
		$	14,594	$	(655)	$	(178)	$	13,761		$	13,066	$	(1,146)	$	248	$	12,168


		As of January 1, 2021		Increase (decrease)		Foreign exchange effect		As of June 30, 2021			As of January 1, 2022		Increase (decrease)		Foreign exchange effect		As of June 30, 2022
GrowCo Facility		$	1,546	$	—	$	44	$	1,590
Natuera Series A Loan(ii)		721		(737)		16		—
GrowCo Credit Facility										GrowCo Credit Facility	$	14,089	$	(664)	$	(132)	$	13,293

Mucci Promissory Note	Mucci Promissory Note	270		—		8		278		Mucci Promissory Note	90		2		(1)		91
Cannasoul Collaboration Loan	Cannasoul Collaboration Loan	26		—		13		39		Cannasoul Collaboration Loan	415		7		(45)		377
		$	2,563	$	(737)	$	81	$	1,907		$	14,594	$	(655)	$	(178)	$	13,761

(i)During the three and six months ended June 30, 2023, $382 and $1,146, respectively, were recorded as decreases to general and administrative expenses on the condensed consolidated statements of net loss and comprehensive income (loss) as a result of principal and interest payments made by Cronos GrowCo reducing our expected credit losses on loans receivable. During both the three and six months ended June 30, 2022, $655 was recorded as a decrease to general and administrative expenses on the condensed consolidated statements of net loss and comprehensive ~~loss~~income (loss) as a result of adjustments to our expected credit losses. ~~There were no such adjustments during the three and six months ended June 30, 2021.~~

~~(ii)~~On April 1, 2021, the Company and an affiliate of Agroidea, the other joint venture partner of Natuera, converted all advances made to Natuera under the master loan agreement entered into with Natuera on September 27, 2019, plus accrued interest, into equity of Natuera. As a result, the Company decreased its credit loss allowances by $1,153 and $737 for the three and six months ended June 30, 2021, respectively. As of June 30, 2022 and December 31, 2021, loans receivable, net for the Natuera Series A Loan was $nil.

~~5. Intangible Assets, net~~

~~Intangible assets, net are comprised of the following items as of June 30, 2022 and December 31, 2021:~~

Useful life (in years) As of June 30, 2022
Cost Accumulated amortization Accumulated impairment charges Net
Software 5 $ 6,065 $ (2,137) $ (80) $ 3,848
Health Canada licenses 17 8,706 (1,865) (6,841) —
Ginkgo exclusive licenses(i)
10 23,655 (865) (4,668) 18,122
Israeli codes(ii)
20 294 (42) — 252
Total definite-lived intangible assets 38,720 (4,909) (11,589) 22,222
Lord Jones® brand
N/A 64,000 — (62,500) 1,500
Total intangible assets $ 102,720 $ (4,909) $ (74,089) $ 23,722


~~Cronos Group Inc.~~
~~Notes to Condensed Consolidated Financial Statements (Unaudited)~~

~~(In thousands of U.S. dollars, except share amounts)~~			~~Table of Contents~~

Useful life (in years) As of December 31, 2021
Cost Accumulated amortization Accumulated impairment charges Net
Software 5 $ 5,644 $ (1,595) $ (4) $ 4,045
Health Canada licenses 17 8,793 (1,883) (6,910) —
Ginkgo exclusive licenses 10 17,330 (335) (4,752) 12,243
Israeli codes(ii)
20 330 (39) — 291
Total definite-lived intangible assets 32,097 (3,852) (11,666) 16,579
Lord Jones® brand
N/A 64,000 — (62,500) 1,500
Trademarks N/A 142 — (142) —
Total intangible assets $ 96,239 $ (3,852) $ (74,308) $ 18,079

~~(i)~~In June 2022, the Company announced the achievement of the final productivity target in respect of tetrahydrocannabivarin (“THCV”) under its collaboration and license agreement (the “Ginkgo Collaboration Agreement”) with Ginkgo Bioworks Holdings, Inc. (“Ginkgo”). As a result of the achievement of the final productivity target for THCV, the Company issued 2,201,236 common shares at a share price of C$3.47, and made a cash payment of $600, for total consideration of C$8,412 ($6,522) to Ginkgo through the Ginkgo Collaboration Agreement. The definite-lived intangible asset is being amortized using the straight-line method over its estimated useful life of ten years.

~~(ii)The Israeli codes were transferred by non-controlling interests to Cronos Israel in exchange for their equity interests in the Cronos Israel entities.~~

~~Amortization expense~~ ~~was $606 and $274 for thethree months ended June 30, 2022 and 2021, respectively and $1,121 and $443 for the six months ended June 30, 2022 and 2021, respectively~~.

~~As of June 30, 2022, the estimated future amortization of definite-lived intangible assets is as follows:~~

As of June 30, 2022
Remainder of 2022 (6 months) $ 1,539
2023 3,034
2024 3,016
2025 2,716
2026 2,109
2027 1,924
Thereafter 7,884
$ 22,222

For the three and six months ended June 30, 2021, the Company recorded an impairment charge of $56,500 on its Lord Jones® brand intangible asset. There were no impairment charges on intangible assets for the three and six months ended June 30, 2022.

6. Derivative Liabilities

As of June 30, 2022, Altria Group Inc. (“Altria”) beneficially held 156,573,537 of the Company’s common shares, an approximate 41% ownership interest in the Company (calculated on a non-diluted basis) and 1 warrant of the Company (the “Altria Warrant”). As summarized in this note, if exercised in full on such date, the exercise of the Altria Warrant would have resulted in Altria holding a total ownership interest in the Company of approximately 52% (calculated on a non-diluted basis). Pursuant to the investor rights agreement (the “Investor Rights Agreement”) between the Company and Altria ~~(the “Investor Rights Agreement”~~Group Inc. (“Altria”), ~~entered into in connection with the closing of Altria’s investment in the Company (the “Altria Investment”) pursuant to a subscription agreement dated December 7, 2018,~~ the Company granted Altria certain rights, among others, summarized in this ~~note.~~


~~Cronos Group Inc.~~note.
~~Notes to Condensed Consolidated Financial Statements (Unaudited)~~

~~(In thousands of U.S. dollars, except share amounts)~~			~~Table of Contents~~

The summaries below are qualified entirely by the terms and conditions fully set out in the Investor Rights ~~Agreement and the Altria Warrant, as applicable.~~Agreement.

a.The Altria Warrant entitles the holder, subject to certain qualifications and limitations, to subscribe for and purchase up to an additional 10% of the common shares of Cronos (83,976,971 common shares as of June 30, 2022) at a per share exercise price of C$19.00, which expires on March 8, 2023.

b.The Company granted to Altria, subject to certain qualifications and limitations, upon the occurrence of certain issuances of common shares of the Company executed by the Company (including issuances pursuant to the research and development (“R&D”) partnership ~~(the “Ginkgo Strategic Partnership”)~~ with ~~Ginkgo)~~Ginkgo Bioworks Holdings, Inc. (“Ginkgo”), the right to purchase up to such number of common shares of the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any issuance of shares by the Company (“Pre-emptive Rights”), at the same price per common share of the Company at which the common shares are sold in the relevant issuance; provided that if the consideration paid in connection with any such issuance is non-cash, the price per common share of the Company that would have been received had such common shares been issued for cash consideration will be determined by an independent committee (acting reasonably and in good faith); provided further that the price per common share of the Company to be paid by Altria pursuant to its exercise of its Pre-emptive Rights related to the Ginkgo ~~Strategic Partnership~~Collaboration Agreement will be C$16.25 per common share. These rights may not be exercised if Altria’s ownership percentage of the issued and outstanding shares of the Company falls below 20%.


Cronos Group Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands of U.S. dollars, except share amounts)			Table of Contents

c.b.In addition to (and without duplication of) the Pre-emptive Rights, the Company granted to Altria, subject to certain qualifications and limitations, the right to subscribe for common shares of the Company issuable in connection with the exercise, conversion or exchange of convertible securities of the Company issued prior to March 8, 2019 or thereafter (excluding any convertible securities of the Company owned by Altria or any of its subsidiaries), a share incentive plan of the Company, the exercise of any right granted by the Company pro rata to all shareholders of the Company to purchase additional common shares and/or securities of the Company, bona fide bank debt, equipment financing or non-equity interim financing transactions that contemplate an equity component or bona fide acquisitions (including acquisitions of assets or rights under a license or otherwise), mergers or similar business combination transactions or joint ventures involving the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any such transactions (“Top-up Rights”).

The price per common share to be paid by Altria pursuant to the exercise of its Top-up Rights will be, subject to certain limited exceptions, the 10-day volume-weighted average price of the common shares of the Company on the TSX for the 10 full days preceding such exercise by Altria; provided that the price per common share of the Company to be paid by Altria pursuant to the exercise of its Top-up Rights in connection with the issuance of common shares of the Company pursuant to the exercise of options or warrants that were outstanding as of March 8, 2019 will be C$16.25 per common share without any set off, counterclaim, deduction, or withholding. These rights may not be exercised if Altria’s ownership percentage of the issued and outstanding shares of the Company falls below 20%. The Pre-emptive Rights, and fixed price Top-up Rights have been classified as derivative liabilities on the Company’s consolidated balance sheet.

As of June 30, 2023, Altria beneficially held 156,573,537 of the Company’s common shares, an approximate 41% ownership interest in the Company (calculated on a non-diluted basis).

Reconciliation of the Company’s derivative liabilities activity are as follows:

As of April 1, 2022 Revaluation gain Exercise of rights Foreign exchange effect As of June 30, 2022
(a) Altria Warrant $ 3,845 $ (3,245) $ — $ (109) $ 491
(b) Pre-emptive Rights 67 (49) — (2) 16
(c) Top-up Rights 187 (116) — (4) 67
$ 4,099 $ (3,410) $ — $ (115) $ 574


	As of April 1, 2023		Revaluation (gain) loss		Foreign exchange effect		As of June 30, 2023

Pre-emptive Rights	$	79	$	(43)	$	1	$	37
Top-up Rights	1		—		(1)		—
	$	80	$	(43)	$	—	$	37

As of April 1, 2021 Revaluation gain Out-of-period adjustment Foreign exchange effect As of June 30, 2021
(a) Altria Warrant $ 234,656 $ (85,778) $ — $ 1,205 $ 150,083
(b) Pre-emptive Rights 20,173 (6,360) — 113 13,926
(c) Top-up Rights 17,471 (23,110) 11,278 (85) 5,554
$ 272,300 $ (115,248) $ 11,278 $ 1,233 $ 169,563


	As of April 1, 2022		Revaluation gain		Foreign exchange effect		As of June 30, 2022
Altria Warrant	$	3,845	$	(3,245)	$	(109)	$	491
Pre-emptive Rights	67		(49)		(2)		16
Top-up Rights	187		(116)		(4)		67
	$	4,099	$	(3,410)	$	(115)	$	574

As of January 1, 2022 Revaluation gain Exercise of rights Foreign exchange effect As of June 30, 2022
(a) Altria Warrant $ 13,720 $ (13,256) $ — $ 27 $ 491
(b) Pre-emptive Rights 180 (164) — — 16
(c) Top-up Rights 475 (409) — 1 67
$ 14,375 $ (13,829) $ — $ 28 $ 574


	As of January 1, 2023		Revaluation (gain) loss		Foreign exchange effect		As of June 30, 2023

Pre-emptive Rights	$	—	$	36	1		$	37
Top-up Rights	15		(14)		(1)		—
	$	15	$	22	$	—	$	37


	As of January 1, 2022		Revaluation gain		Foreign exchange effect		As of June 30, 2022
Altria Warrant	$	13,720	$	(13,256)	$	27	$	491
Pre-emptive Rights	180		(164)		—		16
Top-up Rights	475		(409)		1		67
	$	14,375	$	(13,829)	$	28	$	574

Fluctuations in the expected life of the derivative instruments and the Company’s share price are primary drivers for the changes in the derivative valuations during each reporting period. As the period of time that the derivative liability is expected to be outstanding decreases and the share price decreases, the fair value typically decreases for each related derivative instrument. Weighted-average expected life and share price are two of the significant observable inputs used in the fair value measurement of each of the Company’s derivative instruments.

1417


Cronos Group Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands of U.S. dollars, except share amounts)			Table of Contents

As of January 1, 2021 Revaluation (gain)/loss Exercise of rights Foreign exchange effect As of June 30, 2021
(a) Altria Warrant $ 138,858 $ 7,186 $ — $ 4,039 $ 150,083
(b) Pre-emptive Rights 12,095 1,473 — 358 13,926
(c) Top-up Rights 12,457 (7,033) — 130 5,554
$ 163,410 $ 1,626 $ — $ 4,527 $ 169,563

Fluctuations in the Company’s share price and the expected life of the derivative instruments are primary drivers for the changes in the derivative valuations during each reporting period. As the share price decreases and the expected period of time the derivative liability is expected to be outstanding decreases, the fair value typically decreases for each related derivative instrument. Share price and weighted-average expected life are two of the significant observable inputs used in the fair value measurement of each of the Company’s derivative instruments.

The fair values of the derivative liabilities were determined using the Black-Scholes pricing model using the following inputs:


		As of June 30, 2022				As of June 30, 2023
		Altria Warrant	Pre-emptive Rights	Top-up Rights		Pre-emptive Rights	Top-up Rights
Share price at valuation date (per share in C$)	Share price at valuation date (per share in C$)	$3.60	$3.60	$3.60	Share price at valuation date (per share in C$)	$2.61	$2.61
Subscription price (per share in C$)	Subscription price (per share in C$)	$19.00	$16.25	$16.25	Subscription price (per share in C$)	$16.25	$16.25
Weighted-average risk-free interest rate(i)	Weighted-average risk-free interest rate(i)	2.74%	2.47%	2.51%	Weighted-average risk-free interest rate(i)	4.72%	4.86%
Weighted-average expected life (in years)(ii)	Weighted-average expected life (in years)(ii)	0.69	0.45	0.63	Weighted-average expected life (in years)(ii)	1.50	1.10
Expected annualized volatility(iii)	Expected annualized volatility(iii)	77%	77%	77%	Expected annualized volatility(iii)	59%	59%
Expected dividend yield	Expected dividend yield	—%	—%	—%	Expected dividend yield	—%	—%


		As of December 31, 2021				As of December 31, 2022
		Altria Warrant	Pre-emptive Rights	Top-up Rights		Pre-emptive Rights	Top-up Rights
Share price at valuation date (per share in C$)	Share price at valuation date (per share in C$)	$4.98	$4.98	$4.98	Share price at valuation date (per share in C$)	$3.44	$3.44
Subscription price (per share in C$)	Subscription price (per share in C$)	$19.00	$16.25	$16.25	Subscription price (per share in C$)	$16.25	$16.25
Weighted-average risk-free interest rate(i)	Weighted-average risk-free interest rate(i)	0.79%	0.39%	0.50%	Weighted-average risk-free interest rate(i)	4.14%	4.28%
Weighted-average expected life (in years)(ii)	Weighted-average expected life (in years)(ii)	1.18	0.50	0.80	Weighted-average expected life (in years)(ii)	0.25	0.59
Expected annualized volatility(iii)	Expected annualized volatility(iii)	80%	80%	80%	Expected annualized volatility(iii)	73%	73%
Expected dividend yield	Expected dividend yield	—%	—%	—%	Expected dividend yield	—%	—%

(i)The risk-free interest rate was based on Bank of Canada government treasury bills and bonds with a remaining term equal to the expected life of the derivative liabilities. As of June 30, ~~2022~~2023 and December 31, ~~2021,~~2022, the risk-free interest rate uses a range of approximately ~~2.06%~~4.46% to ~~3.09%~~4.89% and ~~0.16%~~3.81% to ~~1.10%~~4.37%, respectively, for the Pre-emptive Rights and Top-up Rights.

(ii)The expected life represents the period of time, in years, that the derivative liabilities are expected to be outstanding. The expected life of the Pre-emptive Rights and Top-up Rights is determined based on the expected term of the underlying options, warrants, and shares, to which the Pre-emptive Rights and Top-up Rights are linked. As of June 30, ~~2022~~2023 and December 31, ~~2021,~~2022, the expected life uses a range of approximately ~~0.25~~1.00 years to ~~3.25~~2.25 years and 0.25 years to ~~3.75~~2.75 years, respectively, for the Pre-emptive Rights and Top-up Rights.

(iii)Volatility was based on an equally weighted blended historical and implied volatility level of the underlying equity securities of the Company.

~~The following table quantifies each~~

7. Restructuring

In the first quarter of 2022, the Company initiated a strategic plan to realign the business around its brands, centralize functions and evaluate the Company’s supply chain (the “Realignment”). As part of the ~~significant inputs described above~~Realignment, on February 28, 2022, the Board approved plans to leverage the Company’s strategic partnerships to improve supply chain efficiencies and ~~provides a sensitivity analysis~~reduce manufacturing overhead by exiting its production facility in Stayner, Ontario, Canada (the “Peace Naturals Campus”). On February 27, 2023, the Board approved revisions to the Realignment, which are expected to result in the Company maintaining select components of its operations at the Peace Naturals Campus, namely distribution warehousing, certain research and development activities and manufacturing of certain of the ~~impact on the reported values~~Company’s products, while seeking to sell and lease back all or some of the ~~derivative liabilities.~~Peace Naturals Campus or to lease certain portions of the Peace Naturals Campus to third parties. The ~~sensitivity analysis for each significant input is performed by assuming a 10% decrease~~Realignment initiatives were intended to position the Company to drive profitable and sustainable growth over time.

During the three and six months ended June 30, 2022, the Company recognized $978 and $3,009, respectively, of restructuring costs in connection with the Realignment, including the change in the ~~input while~~nature of operations at the Peace Naturals Campus. Charges related thereto include employee-related costs such as severance, relocation and other ~~significant inputs remain constant at management’s best estimate~~termination benefits, as ofwell as contract termination and other related costs. During the ~~respective dates. While a decrease~~three and six months ended June 30, 2023, the Company incurred no restructuring costs in its continuing operations. Restructuring costs incurred in the ~~inputs noted below would cause a decrease~~Company’s discontinued operations during the three and six months ended June 30, 2023 and 2022 is presented in ~~the carrying amount of the derivative liability, there would also be an equal and opposite impact on net income (loss)~~Note 2 “Discontinued Operations.

10% decrease as of June 30, 2022
Altria Warrant Pre-emptive Rights Top-up Rights
Share price $ 219 $ 8 $ 19
Weighted-average expected life 196 16 24
Expected annualized volatility 318 11 27
”

1518


Cronos Group Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands of U.S. dollars, except share amounts)			Table of Contents

10% decrease as of December 31, 2021
Altria Warrant Pre-emptive Rights Top-up Rights
Share price $ 3,970 $ 80 $ 123
Weighted-average expected life 2,971 171 133
Expected annualized volatility 5,402 96 155

These inputs are classified as Level 3 on the fair value hierarchy and are subject to volatility and several factors outside the Company’s control, which could significantly affect the fair value of these derivative liabilities in future periods.

7. ~~Restructuring~~

The Company expects to incur approximately $6,400 in connection with the Realignment, including the planned exit of the Stayner Facility, of which $4,354 has been incurred as of June 30, 2022. Estimated charges related to the exit of the Stayner Facility include employee-related costs such as severance, relocation and other termination benefits, as well as contract termination and other related costs. The Company expects to incur approximately $2,000 in additional charges related to the Realignment, including the planned exit of the Stayner Facility.

~~The Company incurred the following restructuring costs by reportable segment:~~

Three months ended June 30, Six months ended June 30,
2022 2021 2022 2021
Rest of World $ 978 $ — $ 3,009 $ —
United States 292 — 1,345 —
Total $ 1,270 $ — $ 4,354 $ —

The following table summarizes the Company’s restructuring activity for the three and six months ended June 30, 2022:

Accrual as of April 1, 2022 Expenses Payments/Write-offs Accrual as of June 30, 2022
Employee termination benefits $ 1,254 $ 432 $ (798) $ 888
Other restructuring costs 144 838 (961) 21
Total $ 1,398 $ 1,270 $ (1,759) $ 909


	Accrual as of April 1, 2022		Expenses		Payments/Write-offs		Accrual as of June 30, 2022
Employee Termination Benefits	$	1,152	$	140	$	(470)	$	822

Other Restructuring Costs	144		838		(961)		21
Total	$	1,296	$	978	$	(1,431)	$	843

Accrual as of January 1, 2022 Expenses Payments/Write-offs Accrual as of June 30, 2022
Employee termination benefits $ — $ 2,935 $ (2,047) $ 888
Other restructuring costs — 1,419 (1,398) 21
Total $ — $ 4,354 $ (3,445) $ 909


	Accrual as of January 1, 2022		Expenses		Payments/Write-offs		Accrual as of June 30, 2022
Employee Termination Benefits	$	—	$	1,590	$	(768)	$	822

Other Restructuring Costs	—		1,419		(1,398)		21
Total	$	—	$	3,009	$	(2,166)	$	843


~~Cronos Group Inc.~~
~~Notes to Condensed Consolidated Financial Statements (Unaudited)~~

~~(In thousands of U.S. dollars, except share amounts)~~			~~Table of Contents~~

8. Share-based Compensation

(a)Share-based award plans

The Company has granted stock options, restricted share units (“RSUs”) and deferred share units (“DSUs”) to employees and non-employee directors under the Stock Option Plan dated May 26, 2015 (the “2015 Stock Option Plan”), the 2018 Stock Option Plan dated June 28, 2018 (the “2018 Stock Option Plan” and, together with the 2015 Stock Option Plan, the “Prior Option Plans”), the Employment Inducement Award Plan #1 (the “Employment Inducement Award Plan”), the 2020 Omnibus Equity Incentive Plan dated March 29, 2020 (the “2020 Omnibus Plan”) and the DSU Plan dated August 10, 2019 (the “DSU Plan”). The Company can no longer make grants under the Prior Option Plans or the Employment Inducement Award Plan.

The following table summarizes the total share-based compensation expense associated with the Company’s stock options, RSUs and ~~RSUs~~liability-classified awards for the three and six months ended June 30, 2023 and 2022:

Three months ended June 30, Six months ended June 30,
2022 2021 2022 2021
Stock options $ 1,141 $ 1,864 $ 2,870 $ 3,928
RSUs 1,475 701 3,432 1,136
Total share-based compensation $ 2,616 $ 2,565 $ 6,302 $ 5,064


	Three months ended June 30,				For the six months ended June 30,
	2023		2022		2023		2022
Stock options	$	372	$	1,141	$	1,106	$	2,870
RSUs	1,959		1,442		3,760		3,329

Total share-based compensation	$	2,331	$	2,583	$	4,866	$	6,199

(b)Stock options

Vesting conditions for grants of options are determined by the Compensation ~~Committee of the Board.~~Committee. The typical vesting for stock option grants made under the 2020 Omnibus Plan is annual vesting over three to five years with a maximum term of ten years. The typical vesting for stock option grants made under the Prior Option Plans is quarterly vesting over three to five years with a maximum term of seven years. The Prior Option Plans did not, and the 2020 Omnibus Plan does not, authorize grants of options with an exercise price below fair market value.


Cronos Group Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands of U.S. dollars, except share amounts)			Table of Contents

The following is a summary of the changes in stock options for the six months ended June 30, ~~2022~~2023 and ~~2021:~~2022:

Weighted-average exercise price (C$) (i)
Number of options Weighted-average remaining contractual term (years)
Balance as of January 1, 2022 $ 7.75 8,939,330 2.70
Exercise of options 3.11 (1,481,004)
Cancellation, forfeiture and expiry of options 13.56 (89,251)
Balance as of June 30, 2022 $ 8.61 7,369,075 1.53
Exercisable as of June 30, 2022 $ 8.28 4,686,991 1.04


	Weighted-average exercise price (C$) (i)		Number of options	Weighted-average remaining contractual term (years)
Balance as of January 1, 2023	$	10.57	5,350,600	0.73
Issuance of options	2.96		188,317

Cancellation, forfeiture and expiry of options	7.75		(3,435,716)
Balance as of June 30, 2023	$	14.50	2,103,201	2.34
Exercisable as of June 30, 2023	$	18.72	1,426,612	1.00

Weighted-average exercise price (C$) (i)
Number of options Weighted-average remaining contractual term (years)
Balance as of January 1, 2021 $ 5.40 13,755,148 2.30
Exercise of options 2.14 (5,349,818)
Cancellation, forfeiture and expiry of options 14.86 (33,699)
Balance as of June 30, 2021 $ 7.45 8,371,631 2.66
Exercisable as of June 30, 2021 $ 6.49 4,679,240 1.43


	Weighted-average exercise price (C$) (i)		Number of options	Weighted-average remaining contractual term (years)
Balance as of January 1, 2022	$	7.75	8,939,330	2.70

Exercise of options	3.11		(1,481,004)
Cancellation, forfeiture and expiry of options	13.56		(89,251)
Balance as of June 30, 2022	$	8.61	7,369,075	1.53
Exercisable as of June 30, 2022	$	8.28	4,686,991	1.04

(i)The weighted-average exercise price reflects the conversion of foreign currency-denominated stock options translated into C$ using the average foreign exchange rate as of the date of issuance.

For the six months ended June 30, 2023, the weighted-average fair value per option at grant date was C$2.07. The fair value of the options issued during the period was determined using the Black-Scholes option pricing model, using the following inputs:


			2023
Share price at grant date (per share)			$2.96
Exercise price (per option)			$2.96
Risk-free interest rate			3.22%
Expected life of options (in years)			7
Expected annualized volatility			72.68%
Expected dividend yield			—
Weighted average Black-Scholes value at grant date (per option)			$2.07
Forfeiture rate			—

The following table summarizes stock options outstanding:


		As of June 30, 2022	As of December 31, 2021		As of June 30, 2023	As of December 31, 2022
2020 Omnibus Plan	2020 Omnibus Plan	2,900,000	2,900,000	2020 Omnibus Plan	702,264	2,788,947
2018 Stock Option Plan	2018 Stock Option Plan	1,492,010	1,550,074	2018 Stock Option Plan	1,400,937	1,422,069
2015 Stock Option Plan	2015 Stock Option Plan	2,977,065	4,489,256	2015 Stock Option Plan	—	1,139,584
Total stock options outstanding	Total stock options outstanding	7,369,075	8,939,330	Total stock options outstanding	2,103,201	5,350,600

1720


Cronos Group Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands of U.S. dollars, except share amounts)			Table of Contents

(c)Restricted share units

The following is a summary of the changes in RSUs for the six months ended June 30, ~~2022~~2023 and ~~2021:~~2022:


		Weighted-average grant date fair value (C$)(ii)		Number of RSUs		Weighted-average grant date fair value (C$)(ii)		Number of RSUs
Balance as of January 1, 2022		$	9.22	1,225,870
Balance as of January 1, 2023					Balance as of January 1, 2023	$	4.63	5,725,470
Granted(i)	Granted(i)	4.32		4,513,992	Granted(i)	2.66		2,819,174
Vested and issued	Vested and issued	8.58		(722,721)	Vested and issued	5.04		(735,523)
Cancellation and forfeitures	Cancellation and forfeitures	8.32		(101,561)	Cancellation and forfeitures	3.93		(254,382)
Balance as of June 30, 2022		$	4.84	4,915,580
Balance as of June 30, 2023					Balance as of June 30, 2023	$	3.87	7,554,739


		Weighted-average grant date fair value (C$)(ii)		Number of RSUs		Weighted-average grant date fair value (C$)(ii)		Number of RSUs
Balance as of January 1, 2021		$	7.66	948,357
Balance as of January 1, 2022					Balance as of January 1, 2022	$	9.22	1,225,870
Granted(i)	Granted(i)	11.29		515,433	Granted(i)	4.32		4,513,992

Vested and issued	Vested and issued	$	7.52	(89,912)	Vested and issued	8.58		(722,721)
Balance as of June 30, 2021		$	9.03	1,373,878

Cancellation and forfeitures					Cancellation and forfeitures	8.32		(101,561)
Balance as of June 30, 2022					Balance as of June 30, 2022	$	4.84	4,915,580

(i)RSUs granted in the period vest annually in equal installments over a three-year period from either the grant date or ~~vest~~ after a three or five year “cliff-period.” All RSUs are subject to such holder’s continued employment through each vesting date. The vesting of such RSUs is not subject to the achievement of any performance criteria.

(ii)The weighted-average grant date fair value reflects the conversion of foreign currency-denominated RSUs translated into C$ using the foreign exchange rate as of the date of issuance.

(d)Deferred share units

The following is a summary of the changes in DSUs for the six months ended June 30, ~~2022~~2023 and ~~2021:~~2022:

Financial liability Number of DSUs
Balance as of January 1, 2022 $ 408 104,442
Gain on revaluation (161) —
Balance as of June 30, 2022 $ 247 104,442


	Financial liability		Number of DSUs
Balance as of January 1, 2023	$	674	265,732


Gain on revaluation	(150)		—
Balance as of June 30, 2023	$	524	265,732

Financial liability Number of DSUs
Balance as of January 1, 2021 $ 577 83,293
Loss on revaluation 141 —
Balance as of June 30, 2021 $ 718 83,293

~~(e)Warrants~~

~~The following is a summary of the changes in warrants for the six months ended June 30, 2021:~~

Weighted-average exercise price (C$) Number of warrants
Balance as of January 1, 2021 $ 0.25 7,987,349
Exercise of warrants 0.25 (7,987,349)
Balance as of June 30, 2021 $ — —

~~As of June 30, 2022, there are no warrants outstanding other than the Altria Warrant. See Note 6 “Derivative Liabilities” for further description of the Altria Warrant.~~


	Financial liability		Number of DSUs
Balance as of January 1, 2022	$	408	104,442


Gain on revaluation	(161)		—
Balance as of June 30, 2022	$	247	104,442

1821


Cronos Group Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands of U.S. dollars, except share amounts)			Table of Contents

9. ~~Earnings (Loss)~~Loss per Share

Basic and diluted ~~earnings (loss)~~loss per share from continuing and discontinued operations are calculated as follows (in thousands, except share and per share amounts):

Three months ended June 30, Six months ended June 30,
2022 2021 2022 2021
Basic and diluted earnings (loss) per share computation
Net loss from continuing operations attributable to the shareholders of Cronos Group $ (20,221) $ (178,513) $ (52,859) $ (339,804)
Weighted-average number of common shares outstanding for computation for basic and diluted earnings per share(i)
376,031,860 371,721,382 375,530,077 367,391,118
Basic loss from continuing operations per share $ (0.05) $ (0.48) $ (0.14) $ (0.92)
Diluted loss per share from continuing operations $ (0.05) $ (0.48) $ (0.14) $ (0.92)
Loss from discontinued operations attributable to the shareholders of Cronos Group $ — $ (561) $ — $ (582)
Weighted-average number of common shares outstanding from computation for basic and diluted earnings per share 376,031,860 371,721,382 375,530,077 367,391,118
Basic earnings (loss) from discontinued operations per share $ 0.00 $ 0.00 $ 0.00 $ 0.00
Diluted earnings (loss) from discontinued operations per share $ 0.00 $ 0.00 $ 0.00 $ 0.00


	Three months ended June 30,				Six months ended June 30,
	2023		2022		2023		2022
Basic and diluted loss per share computation
Net loss from continuing operations attributable to the shareholders of Cronos Group	$	(5,526)	$	(17,410)	$	(23,473)	$	(45,760)
Weighted-average number of common shares outstanding for computation for basic and diluted loss per share(i)	380,961,682		376,031,860		380,792,802		375,530,077
Basic loss from continuing operations per share	$	(0.01)	$	(0.05)	$	(0.06)	$	(0.12)
Diluted loss per share from continuing operations	$	(0.01)	$	(0.05)	$	(0.06)	$	(0.12)

Loss from discontinued operations attributable to the shareholders of Cronos Group	$	(2,834)	$	(2,811)	$	(4,056)	$	(7,099)
Weighted-average number of common shares outstanding for computation for basic and diluted loss per share(i)	380,961,682		376,031,860		380,792,802		375,530,077
Basic loss from discontinued operations per share	$	(0.01)	$	0.00	$	(0.01)	$	(0.02)
Diluted loss from discontinued operations per share	$	(0.01)	$	0.00	$	(0.01)	$	(0.02)

(i)In computing diluted ~~earnings~~loss per share, incremental common shares are not considered in periods in which a net loss is reported as the inclusion of the common share equivalents would be anti-dilutive.

For the three months ended June 30, ~~2022~~2023 and ~~2021,~~2022, total securities of ~~119,589,123~~28,769,758 and ~~120,491,183, respectively, and for the six months ended June 30, 2022 and 2021, total securities of 118,906,603 and 128,373,444,~~119,589,123, respectively, were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive.

~~10. Segment Information~~

The tables below set forth our condensed consolidated results of operations by segment. The Company’s condensed consolidated financial results for these periods are not necessarily indicative of the consolidated financial results that the Company will achieve in future periods~~. Segment data was as follows for the three and six months ended June 30, 2022 and 2021:~~

Three months ended June 30, 2022
United States Rest of World Corporate Total
Cannabis flower $ — $ 15,739 $ — $ 15,739
Cannabis extracts 1,459 5,582 — 7,041
Other — 281 — 281
Net revenue $ 1,459 $ 21,602 $ — $ 23,061
Share of income from equity method investments $ — $ 5,197 $ — $ 5,197
Total assets $ 430,455 $ 285,902 $ 615,856 $ 1,332,213
Depreciation and amortization $ 87 $ 1,324 $ — $ 1,411
Adjusted EBITDA (3,877) (8,995) (5,927) (18,799)


~~Cronos Group Inc.~~
~~Notes to Condensed Consolidated Financial Statements (Unaudited)~~

~~(In thousands of U.S. dollars, except share amounts)~~			~~Table of Contents~~

Three months ended June 30, 2021
United States Rest of World Corporate Total
Cannabis flower $ — $ 11,597 $ — $ 11,597
Cannabis extracts 2,227 1,531 — 3,758
Other — 267 — 267
Net revenue $ 2,227 $ 13,395 $ — $ 15,622
Share of loss from equity method investments $ — $ (1,115) $ — $ (1,115)
Total assets $ 473,828 $ 386,805 $ 741,850 $ 1,602,483
Depreciation and amortization 68 975 — 1,043
Adjusted EBITDA (10,711) (32,605) (6,443) (49,759)

Six months ended June 30, 2022
United States Rest of World Corporate Total
Cannabis flower $ — $ 34,364 $ — $ 34,364
Cannabis extracts 3,787 9,570 — 13,357
Other — 373 — 373
Net revenue $ 3,787 $ 44,307 $ — $ 48,094
Share of income from equity method investments $ — $ 5,197 $ — $ 5,197
Total assets $ 430,455 $ 285,902 $ 615,856 $ 1,332,213
Depreciation and amortization 183 2,521 — 2,704
Adjusted EBITDA (10,963) (12,420) (14,316) (37,699)

Six months ended June 30, 2021
United States Rest of World Corporate Total
Cannabis flower $ — $ 21,031 $ — $ 21,031
Cannabis extracts 4,668 2,234 — 6,902
Other — 300 — 300
Net revenue $ 4,668 $ 23,565 $ — $ 28,233
Share of loss from equity method investments $ — $ (2,758) $ — $ (2,758)
Total assets $ 473,828 $ 386,805 $ 741,850 $ 1,602,483
Depreciation and amortization 139 1,639 — 1,778
Adjusted EBITDA (20,221) (54,789) (11,323) (86,333)


~~Cronos Group Inc.~~
~~Notes to Condensed Consolidated Financial Statements (Unaudited)~~

~~(In thousands of U.S. dollars, except share amounts)~~			~~Table of Contents~~

~~The following tables set forth a reconciliation of net income (loss) as determined in accordance with U.S. GAAP to Adjusted EBITDA for the periods indicated:~~

Three months ended June 30, 2022
United States Rest of World Corporate Total
Net loss $ (4,498) $ (8,759) $ (7,081) $ (20,338)
Interest income, net (426) (3,349) — (3,775)
Income tax benefit — (308) — (308)
Share of income from equity method investments — (5,197) — (5,197)
Gain on revaluation of derivative liabilities(iii)
— (3,410) — (3,410)
Loss on revaluation of financial instruments(v)
— 2,112 — 2,112
Foreign currency transaction loss — 2,852 — 2,852
Other, net(vii)
— (2) — (2)
Restructuring costs(ix)
292 978 — 1,270
Share-based compensation(x)
473 2,143 — 2,616
Financial statement review costs(xi)
— — 1,154 1,154
Depreciation and amortization 282 3,945 — 4,227
Adjusted EBITDA $ (3,877) $ (8,995) $ (5,927) $ (18,799)

Three months ended June 30, 2021
United States Rest of World Corporate Total
Net income (loss) $ (247,847) $ 79,627 $ (11,133) $ (179,353)
Interest income, net (20) (2,273) — (2,293)
Share of loss from equity method investments — 1,115 — 1,115
Impairment loss on goodwill and indefinite-lived intangible assets(i)
234,914 — — 234,914
Impairment loss on long-lived assets(ii)
1,214 — — 1,214
Gain on revaluation of derivative liabilities(iii)
— (115,248) — (115,248)
Transaction costs(iv)
— — 2,758 2,758
Gain on revaluation of financial instruments(v)
— (77) — (77)
Other, net(vii)
— (1,050) — (1,050)
Loss from discontinued operations(viii)
— 561 — 561
Share-based compensation(x)
822 1,743 — 2,565
Financial statement review costs(xi)
— — 1,932 1,932
Depreciation and amortization 206 2,997 — 3,203
Adjusted EBITDA $ (10,711) $ (32,605) $ (6,443) $ (49,759)


~~Cronos Group Inc.~~
~~Notes to Condensed Consolidated Financial Statements (Unaudited)~~

~~(In thousands of U.S. dollars, except share amounts)~~			~~Table of Contents~~

Six months ended June 30, 2022
United States Rest of World Corporate Total
Net loss $ (26,714) $ (6,745) $ (19,532) $ (52,991)
Interest income, net (455) (5,366) — (5,821)
Income tax expense — 54 — 54
Share of income from equity method investments — (5,197) — (5,197)
Impairment loss on long-lived assets(ii)
— 3,493 — 3,493
Gain on revaluation of derivative liabilities(iii)
— (13,829) — (13,829)
Gain on revaluation of financial instruments(v)
— (2,156) — (2,156)
Impairment loss on other investment(vi)
11,238 — — 11,238
Foreign currency transaction loss — 4,724 — 4,724
Other, net(vii)
— (137) — (137)
Restructuring costs(ix)
1,345 3,009 — 4,354
Share-based compensation(x)
2,909 3,393 — 6,302
Financial statement review costs(xi)
— — 5,216 5,216
Depreciation and amortization 714 6,337 — 7,051
Adjusted EBITDA $ (10,963) $ (12,420) $ (14,316) $ (37,699)

Six months ended June 30, 2021
United States Rest of World Corporate Total
Net loss $ (259,939) $ (62,520) $ (18,519) $ (340,978)
Interest income, net (23) (4,599) — (4,622)
Share of loss from equity method investments — 2,758 — 2,758
Impairment loss on goodwill and indefinite-lived intangible assets(i)
234,914 — — 234,914
Impairment loss on long-lived assets(ii)
2,955 — — 2,955
Loss on revaluation of derivative liabilities(iii)
— 1,626 — 1,626
Transaction costs(iv)
— — 3,259 3,259
Loss on revaluation of financial instruments(v)
— 123 — 123
Other, net(vii)
— (1,034) — (1,034)
Loss from discontinued operations(viii)
— 582 — 582
Share-based compensation(x)
1,567 3,497 — 5,064
Financial statement review costs(xi)
— — 3,937 3,937
Depreciation and amortization 305 4,778 — 5,083
Adjusted EBITDA $ (20,221) $ (54,789) $ (11,323) $ (86,333)

~~(i)~~For the three and six months ended June 30, 2021, impairment on goodwill and indefinite-lived intangible assets relates to impairment on goodwill and indefinite-lived intangible assets related to the Company’s U.S. segment.

~~(ii)~~For the six months ended June 30, 2023 and 2022, ~~impairment loss on long-lived assets related to the Company’s decision to seek a sublease for leased office space in Toronto, Ontario, Canada during the first quarter~~total securities of ~~2022. For the three months ended June 30, 2021, impairment loss on long-lived assets relates to an impairment on property, plant~~29,428,093 and ~~equipment~~118,906,603, respectively, were not included in the ~~U.S. segment. For~~computation of diluted shares outstanding because the six months ended June 30, 2021, impairment loss on long-lived assets relates to the aforementioned impairment loss on property, plant and equipment as well as an impairment loss on leased premises in the U.S. segment from the first quarter of 2021. See Note 13 “~~Impairment Loss on Long-lived Assets~~.”

~~(iii)For the three and six months ended June 30, 2022 and 2021, (gain) loss on revaluation of derivative liabilities represents the fair value changes on the derivative liabilities. See Note 6 “Derivative Liabilities~~.”

~~(iv)~~For the three and six months ended June 30, 2021, transaction costs represent legal, financial and other advisory fees and expenses incurred in connection with various strategic investments. These costs are included in general and administrative expenses on the condensed consolidated statements of net income (loss) and comprehensive income (loss).

~~(v)~~For the three and six months ended June 30, 2022, (gain) loss on revaluation of financial instruments related primarily to the Company’s equity securities in Cronos Australia. For three and six months ended June 30, 2021, (gain) loss on revaluation of financial instruments related primarily to revaluations of financial liabilities resulting from DSUs.

~~(vi)For the six months ended June 30, 2022, impairment loss on other investments related to the PharmaCann Option for the difference between its fair value and carrying amount. See Note 3 “Investments.~~”


~~Cronos Group Inc.~~
~~Notes to Condensed Consolidated Financial Statements (Unaudited)~~

~~(In thousands of U.S. dollars, except share amounts)~~			~~Table of Contents~~

~~(vii)~~For the three and six months ended June 30, 2022, other, net related to (gain) loss on disposal of assets. For the three and six months ended June 30, 2021, other, net primarily related to gain recorded on sale of the Company’s Winnipeg facility previously designated as held-for-sale in the first quarter of 2021.

~~(viii)For the three and six months ended June 30, 2021, loss from discontinued operations related to the discontinuance of Original B.C. Ltd. (“OGBC”).~~

~~(ix)~~For the three and six months ended June 30, 2022, restructuring costs related to the employee-related severance costs and other restructuring costs associated with the Realignment, including the planned exit of the Stayner Facility. See Note 7 “~~Restructuring.~~”

~~(x)~~For the three and six months ended June 30, 2022 and 2021, share-based compensation related to the vesting expenses of share-based compensation awarded to employees under the Company’s share-based award plans as described in Note 8 “~~Share-based Compensation~~.”

~~(xi)~~For the three and six months ended June 30, 2022 and 2021, financial statement review costs include costs and reserves taken related to the restatements of the Company’s 2019 and second quarter 2021 interim financial statements, costs related to the Company’s responses to requests for information from various regulatory authorities relating to such restatements and legal costs defending shareholder class action complaints brought against the Company as a result of the 2019 restatement.

~~Net revenue attributed to a geographic region based on the location of the customer were as follows:~~

Three months ended June 30, Six months ended June 30,
2022 2021 2022 2021
Canada $ 14,388 $ 10,664 $ 27,965 $ 18,246
Israel 7,214 2,310 16,342 4,828
United States 1,459 2,227 3,787 4,668
Other countries — 421 — 491
Net revenue $ 23,061 $ 15,622 $ 48,094 $ 28,233

effect would be anti-dilutive.

~~11.~~10. Commitments and Contingencies

(a)Commitments

There have been no material changes in the information regarding commitments as disclosed in the Company’s Annual Report.

(b)Contingencies

The Company is subject to various legal proceedings in the ordinary course of its business and in connection with its marketing, distribution and sale of its products. Many of these legal proceedings are in the early stages of litigation and seek damages that are unspecified or not quantified. Although the outcome of these matters cannot be predicted with certainty, the Company does not believe these legal proceedings, individually or in the aggregate, will have a material adverse effect on its financial condition but could be material to its results of operations for a quarterly period depending, in part, on its results for that quarter.

(i)Class action complaints relating to restatement of 2019 interim financial statements

On March 11 and 12, 2020, 2two alleged shareholders of the Company separately filed 2two putative class action complaints in the U.S. District Court for the Eastern District of New York against the Company and its Chief Executive Officer and now former Chief Financial Officer. The court has consolidated the cases, and the consolidated amended complaint alleges violations of Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder against all defendants, and Section 20(a) of the Exchange Act against the individual defendants. The consolidated amended complaint generally alleges that certain of the Company’s prior public statements about revenues and internal control were incorrect based on the Company’s disclosures relating to the Audit Committee of the Board’s review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel. The consolidated amended complaint does not quantify a damage request. Defendants moved to dismiss on February 8, 2021.

2322


Cronos Group Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands of U.S. dollars, except share amounts)			Table of Contents

On June 3, 2020, an alleged shareholder filed a Statement of Claim, as amended on August 12, 2020, in the Ontario Superior Court of Justice in Toronto, Ontario, Canada, seeking, among other things, an order certifying the action as a class action on behalf of a putative class of shareholders and damages of an unspecified amount. The Amended Statement of Claim names (i) the Company, (ii) its Chief Executive Officer, (iii) now former Chief Financial Officer, (iv) former Chief Financial Officer and Chief Commercial Officer, and (v) current and former members of the Board as defendants and alleges breaches of the Ontario Securities Act, oppression under the Ontario Business Corporations Act and common law misrepresentation. The Amended Statement of Claim generally alleges that certain of the Company’s prior public statements about revenues and internal control were misrepresentations based on the Company’s March 2, 2020 disclosure that the Audit Committee of the Board was conducting a review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel, and the Company’s subsequent restatement. The Amended Statement of Claim does not quantify a damage request. On June 28, 2021, the Court dismissed motions brought by the plaintiff for leave to commence a claim for misrepresentation under the Ontario Securities Act and for certification of the action as a class action. The plaintiff ~~has~~ appealed the Court’s dismissal of the motions only with respect to the Company, the Chief Executive Officer, and the now former Chief Financial Officer; the remaining defendants were dismissed from the matter with prejudice, and the Company and all individual defendants agreed not to seek costs from plaintiff in connection with the dismissal of the motions. On September 26, 2022, the Court of Appeal for Ontario reversed the Superior Court’s dismissal of the leave and certification motions, granted the plaintiff leave to proceed to bring a claim for misrepresentation under the Ontario Securities Act, and remitted the certification motion back to the Superior Court.

(ii)Regulatory reviews relating to restatements

The Company has been responding to requests for information from various regulatory authorities relating to its previously disclosed restatement of its financial statements for the first three quarters of 2019 as well as the previously disclosed restatement of the second quarter of 2021 interim financial ~~statements.~~statements (collectively, the “Restatements”). The Company ishas been responding to all such requests for information and cooperating with all regulatory authorities. The Company cannot predict the outcome of any such regulatory review or investigation and it is possible that additional investigations or one or more formal proceedings may be commenced against the Company and its current and former officers and directors in connection with these regulatory reviews and investigations.

~~(iii)Litigation relating to marketing, distribution and sale of products~~SEC Settlement

On ~~June 16, 2020,~~October 24, 2022, the SEC issued an ~~alleged consumer filed~~Order Instituting Cease-and-Desist Proceedings Pursuant to Section 8(a) of the Securities Act of 1933 (the “Securities Act”) and Section 21(c) of the Exchange Act, Making Findings, and Imposing a ~~Statement of Claim on behalf of a class in~~Cease-and-Desist Order (the “Settlement Order”) resolving the Court of Queen’s Bench of Alberta in Alberta, Canada, against the Company and other Canadian cannabis manufacturers and/or distributors. On December 4, 2020, a Third Amended Statement of Claim was filed, which added a second alleged consumer. The Third Amended Statement of Claim alleges claims related to the defendants’ advertised content of cannabinoids in cannabis products for medicinal use on or after June 16, 2010 and cannabis products for adult use on or after October 17, 2018. The Third Amended Statement of Claim seeks a total of C$500 million for breach of contract, compensatory damages, and unjust enrichment or such other amount as may be proven in trial and C$5 million in punitive damages against each defendant, including the Company. The Third Amended Statement of Claim also seeks interest and costs associated with the action. Restatements.

The Company has ~~not responded~~agreed to settle with the ~~Third Amended Statement~~SEC, without admitting or denying the allegations described in the Settlement Order. The Settlement Order fully and finally disposes of ~~Claim.~~ the investigation of the Company by the SEC into the Restatements without the payment of any civil penalty or other amount.

The Settlement Order required the Company to cease and desist from committing or causing any violations and any future violations of Section 17(a) of the Securities Act, Sections 10(b), 13(a), 13(b)(2)(B) of the Exchange Act and Rules 10b-5, 13a-13, 13a-15(a), 13a-16 and 12b-20 thereunder. Additionally, the Company agreed to certain undertakings, which include, among other things, retaining a qualified independent consultant (the “Consultant”) to engage in a review of, and make recommendations with respect to, certain of the Company’s internal accounting controls and internal control over financing reporting. The Consultant’s review has been completed.

As a result of the Settlement Order, the Company (i) lost its status as a well-known seasoned issuer for a period of three years, (ii) is unable to rely on the private offering exemptions provided by Regulations A and D under the Securities Act for a period of five years and (iii) is unable to rely on the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 for a period of three years.

OSC Settlement

On ~~January 31,~~October 24, 2022, ~~upon consent of~~the Ontario Capital Markets Tribunal approved a settlement agreement (the “Settlement Agreement”) between the Company and the ~~plaintiffs,~~staff of the ~~court dismissed~~OSC, resolving the ~~case in its entirety as~~Restatements.

Pursuant to the ~~Company.~~

~~A number~~terms of ~~claims, including purported class actions, have been brought~~the Settlement Agreement, which fully and finally disposed the investigation of the Company by the OSC, Cronos agreed to pay a total of C$1.34 million to fully settle the matter, and acknowledged that it had failed to comply with the requirement under Section 77 of the Securities Act (Ontario) to file interim financial reports in the ~~U.S. against companies engaged~~manner set out therein and had acted in a manner contrary to the ~~U.S. hemp business alleging, among other things, violations~~public interest. Additionally, the Company agreed to retain the Consultant to engage in a review of, ~~state consumer protection, health~~ and advertising laws. On April 8, 2020, a putative class action complaint was filed in the U.S. District Court for the Central District of California against Redwood Holding Group, LLC (“Redwood”), alleging violations of California’s Unfair Competition Law, False Advertising Law, Consumers Legal Remedies Act, and breaches of the California Commercial Code for breach of express warranties and implied warranty of merchantabilitymake recommendations with respect to, ~~Redwood’s marketing and sale of U.S. hemp products. The complaint did not quantify a damage request. On April 10, 2020, the class action complaint was dismissed for~~ certain pleading deficiencies and the plaintiff was granted leave until April 24, 2020 to amend the complaint to establish federal subject matter jurisdiction. On April 28, 2020, the action was dismissed without prejudice for failure to prosecute and for failure to comply with a court order. As of the ~~date of this Quarterly Report,~~Company’s internal accounting controls and internal control over financing reporting, on substantially the ~~plaintiff~~same terms as were required by the SEC pursuant the Settlement Agreement. The Consultant’s review has ~~not refiled the complaint.~~

~~The Company expects litigation and regulatory proceedings relating to the marketing, distribution and sale of its products to increase.~~

been completed.

2423


Cronos Group Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands of U.S. dollars, except share amounts)			Table of Contents

~~12.~~(iii)Litigation relating to marketing, distribution and sale of products

On April 17, 2023, a group of plaintiffs led by the Green Leaf (Ale Yarok) political party filed a Statement of Claim and Request for Approval of a Class Action on behalf of a purported class of Israeli cannabis consumers in the District Court of Tel Aviv, Israel, against 26 cannabis-related parties, including three Cronos Israel entities. The Statement of Claim alleges that the defendants violated certain laws relating to the marketing of medical cannabis products, including marketing to unlicensed cannabis consumers. The lawsuit seeks a total of ILS 420 million.

11. Fair Value Measurements

The Company complies with ASC 820 Fair Value Measurements for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In general, fair values are determined by:

•Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities.

•Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves.

•Level 3 inputs are unobservable data points for the asset or liability, and ~~includes~~include situations where there is little, if any, market activity for the asset or liability.

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis:


		June 30, 2022									June 30, 2023
		Level 1		Level 2		Level 3		Total			Level 1		Level 2		Level 3		Total
Cash and cash equivalents	Cash and cash equivalents	$	789,543	$	—	$	—	$	789,543	Cash and cash equivalents	$	409,428	$	—	$	—	$	409,428
Short-term investments	Short-term investments	155,352		—		—		155,352		Short-term investments	431,510		—		—		431,510
Other investments(i)	Other investments(i)	9,515		—		—		9,515		Other investments(i)	18,925		—		—		18,925
Derivative liabilities	Derivative liabilities	—		—		574		574		Derivative liabilities	—		—		37		37

December 31, 2021
Level 1 Level 2 Level 3 Total
Cash and cash equivalents $ 886,973 $ — $ — $ 886,973
Short-term investments 117,684 — — 117,684
Other investments(i)
8,000 — — 8,000
Derivative liabilities — — 14,375 14,375


Cronos Group Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands of U.S. dollars, except share amounts)			Table of Contents


	December 31, 2022
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	764,644	$	—	$	—	$	764,644
Short-term investments	113,077		—		—		113,077
Other investments(i)	21,993		—		—		21,993
Derivative liabilities	—		—		15		15

(i)As of June 30, ~~2022~~2023 and December 31, ~~2021,~~2022, the Company’s influence on ~~Cronos Australia~~Vitura is deemed non-significant and the investment is considered an equity security with a readily determinable fair value. See Note ~~3 “Investments~~”4 “Investments” for additional information.

There were no transfers between fair value categories during the periods presented.

The following tables present information about the Company’s assets that are measured at fair value on a non-recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:


	As of June 30, 2023
	Level 1	Level 2	Level 3	Total
Other investments(i)	—	—	49,000	49,000


	As of December 31, 2022
	Level 1	Level 2	Level 3	Total
Other investments(i)	—	—	49,000	49,000

(i)On June 14, 2021, the Company purchased an option to acquire 473,787 shares of Class A Common Stock of PharmaCann, a vertically integrated cannabis company in the United States, at an exercise price of $0.0001 per share, representing approximately 10.5% of PharmaCann’s issued and outstanding capital stock on a fully diluted basis as of the date of the PharmaCann Option, for an aggregate purchase price of approximately $110,392. On February 28, 2022, PharmaCann closed its previously announced transaction with LivWell Holdings Inc. (“LivWell”) pursuant to which PharmaCann acquired LivWell (“the LivWell Transaction”). LivWell is a multi-state cannabis cultivation and retail leader based in Colorado. As a result of the LivWell Transaction, the Company’s ownership percentage in PharmaCann on a fully diluted basis decreased to approximately 6.4%. As of both June 30, 2023 and December 31, 2022, the Company’s ownership percentage in PharmaCann on a fully diluted basis was approximately 6.3%. See Note 4 “Investments.”

There were no transfers between fair value categories during the periods presented.

~~13.~~12. Impairment Loss on Long-lived Assets

(a)Right-of-use assets and property, plant, and equipment, net

During the six months ended June 30, 2022, the Company recognized an impairment charge of $1,986 related to the right-of-use lease asset associated with the Company’s corporate headquarters, encompassing approximately 29,000 square feet, in Toronto, Ontario, Canada, for which the Company determined it would seek a sublease. In addition, the Company recognized an impairment charge of $1,507 during the six months ended June 30, 2022 related to leasehold improvements and other office equipment that it plans to include in any potential sublease agreement. The determination to seek a sublease of the property and include leasehold improvements and other office equipment in any potential sublease agreement triggered the impairment charges. Both of the impairment charges are recognized as impairment loss on long-lived assets on the condensed consolidated statements of net loss and comprehensive ~~loss.~~income (loss).

~~During~~

13. Related Party Transactions

(a)Cronos GrowCo

The Company holds a variable interest in Cronos GrowCo through its ownership of 50% of Cronos GrowCo’s common shares and senior secured debt in Cronos GrowCo. See Note 4 “Investments” for additional information.

The Company made the three months ended June 30, 2021, the Company concluded that there were impairment indicators on property, plant and equipment associated with sales channels in the U.S. segment. As a result, a quantitative impairment analysis was required asfollowing purchases of June 30, 2021. As such, the Company reassessed its estimates and forecasts as of June 30, 2021, to determine the fair values of the property, plant and equipment using an undiscounted cash flow methodology. Significant inputs include growth rates and cash flow projections. As a result of the analysis, as of June 30, 2021, the Company concluded the carrying amount of the property, plant and equipment associated with sales channels in the U.S. segment exceeded its fair value, which resulted in impairment charges of $1,214 on the condensed consolidated statements of net loss and comprehensive loss for the three and six months ended June 30, 2021.cannabis products from Cronos GrowCo:


	Three months ended June 30,				Six months ended June 30,
	2023		2022		2023		2022
Cronos GrowCo - purchases	$	6,549	$	5,597	$	14,015	$	8,815


Cronos Group Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)

(In thousands of U.S. dollars, except share amounts)			Table of Contents

During the six months ended June 30, 2021, the Company recognized an impairment charge of $1,039 related to leasehold improvements located within leased premises, encompassing approximately 6,000 square feet, in Los Angeles, California, which the Company determined it no longer had plans to use. The significant change in the extent and manner in which the leasehold improvements are being used and the expectation that, more likely than not, the leasehold improvements will be disposed of before the end of their useful life triggered an impairment. The right-of-use lease asset associated with the leasehold improvements was also written down as a result of the Company’s decision to no longer use the leased premises. The Company recognized an impairment charge on the de-recognition of the right-of-use asset of $702 during the six months ended June 30, 2021. Both of the impairment charges are recognized as impairment loss on long-lived assets on the condensed consolidated statements of net loss and comprehensive loss.

~~No impairment charges were recorded during the three months ended June 30, 2022 on property, plant and equipment and right-of-use assets, other than as noted above.~~

~~14. Related Party Transactions~~

~~(a)Altria~~

~~On March 8, 2019, in connection with the Altria Investment, Altria, through certain of its wholly owned subsidiaries, purchased a 45% equity interest in the Company.~~ As of June 30, ~~2022, Altria beneficially held an approximately 41% ownership interest in the Company (calculated on a non-diluted basis).~~

~~The Company incurred the following expenses for consulting services from Altria Pinnacle LLC, a subsidiary of Altria (“Altria Pinnacle”):~~

Three months ended June 30, Six months ended June 30,
2022 2021 2022 2021
Altria Pinnacle - expense $ — $ 2 $ 28 $ 12

~~As of both June 30, 2022~~2023, and December 31, ~~2021, the Company had no payables outstanding to Altria Pinnacle.~~

~~(b)Cronos GrowCo~~

~~The Company holds a variable interest in Cronos GrowCo through its ownership of 50% of Cronos GrowCo’s common shares and senior secured debt in Cronos GrowCo. See Note 3 “Investments” for additional information.~~

~~The Company made the following purchases of cannabis products from Cronos GrowCo:~~

Three months ended June 30, Six months ended June 30,
2022 2021 2022 2021
Cronos GrowCo - purchases $ 5,597 $ 534 $ 8,815 $ 534

~~As of June 30,~~ 2022, ~~and December 31, 2021,~~ the Company had payables outstanding to Cronos GrowCo of ~~$2,103~~$2,682 and ~~$82,~~$2,519, respectively.

Additionally, on August 23, 2019, the Company, as lender, and Cronos GrowCo, as borrower, entered into the GrowCo Facility. See Note 45 “Loans Receivable, net” for additional information.

(b)Vendor Agreement

In November 2022, the Company entered into an agreement with an external vendor whereby the vendor would provide certain manufacturing services to the Company. The vendor then subcontracted out a portion of those services to another company whose chief executive officer is an immediate family member of an executive of the Company. The Company has no direct contractual relationship with the related party.

During the three and six months ended June 30, 2023, the Company purchased $603 and $1,436, respectively, of products and services under this agreement and had outstanding accounts payable related to the agreement of $45 and $nil as of June 30, 2023 and December 31, 2022, respectively.

14. Subsequent Events

(a) Planned Exit of the Fermentation Facility

On August 4, 2023, the Board approved plans to wind-down operations at its Winnipeg, Manitoba facility (“Cronos Fermentation”) and list the Cronos Fermentation facility for sale. The Company expects to incur approximately $1,200 in restructuring costs associated with the exit of Cronos Fermentation facility. These charges include employee-related costs such as severance, relocation and other termination benefits, as well as contract termination and other related costs, which are expected to be incurred primarily in the second half of 2023, but do not include any impairment charges to property, plant or equipment. These anticipated charges are subject to a number of assumptions, including the ability to wind down Cronos Fermentation efficiently and effectively, the length of the sales process, the bids received in the sale process, market factors and others. As a result of these assumptions, actual results may differ materially. The Company cannot, at this time, quantify the impairment charges, if any, to long-lived assets associated with the wind-down.

(b) Cost Reductions

Also on August 4, 2023, the Board approved additional organization-wide cost reductions. Expected restructuring costs of approximately $2,000, with the majority expected to be incurred in the second half of 2023, include mostly one-time employee-related severance charges. These anticipated costs are subject to a number of assumptions, including the ability of the Company to effectively and efficiently further streamline operations, the number of employee reductions, the timing of employee reductions, the level of the Company’s operations, market factors and others. As a result of these assumptions, actual results may differ materially.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read together with other information, including Cronos Group’s condensed consolidated interim financial statements and the related notes to those statements, included in Part I, Item 1 of this Quarterly Report on Form 10-Q for the quarterly period ended June 30, ~~2022~~2023 (this “Quarterly Report”), consolidated financial statements appearing in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2021~~2022 (the “Annual Report”), Part I, Item 1A, Risk Factors, of the Annual Report and Part II, Item 1A, Risk Factors, of this Quarterly Report.

Forward-Looking Statements

This Quarterly Report, the documents incorporated into this Quarterly Report by reference, other reports we file with, or furnish to, the U.S. Securities and Exchange Commission (“SEC”) and other regulatory agencies, and statements by our directors, officers, other employees and other persons authorized to speak on our behalf contain information that may constitute forward-looking information and forward-looking statements within the meaning of applicable U.S. and Canadian securities laws and court decisions (collectively, “Forward-Looking Statements”), which are based upon our current internal expectations, estimates, projections, assumptions and beliefs. All information that is not clearly historical in nature may constitute Forward-Looking Statements. In some cases, Forward-Looking Statements can be identified by the use of forward-looking terminology, such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, expressions and phrases, including negative and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussion of strategy. Forward-Looking Statements include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of historical fact.

Forward-Looking Statements include, but are not limited to, statements with respect to:

•expectations related to our announcement of additional cost-cutting measures, including our decision to wind-down operations at our Winnipeg, Manitoba facility and list the ~~impact~~facility for sale, the expected costs and benefits from the wind-down of production activities at the ~~ongoing military conflict between Russia~~facility, challenges and ~~Ukraine (and resulting sanctions) on our business, financial condition~~effects related thereto as well as changes in strategy, metrics, investments, costs, operating expenses, employee turnover and ~~results of operations or cash flows;~~other changes with respect thereto;

•expectations related to the ~~uncertainties associated with the COVID-19 pandemic, including our ability, and the abilities~~impact of our ~~joint ventures~~decision to exit our U.S. hemp-derived cannabinoid product operations, including the costs, expenses and write-offs associated therewith, the impact on our operations and our suppliers and distributors, to effectively deal with the restrictions, limitations and health issues presented by the COVID-19 pandemic, the ability to continue our production, distribution and sale of our products, and demand for and the use of our products by consumers;

•~~laws and regulations~~financial statements and any ~~amendments thereto applicable~~future plans to our business and the impact thereof, including uncertainty regarding the application of United States (“U.S.”) state and federal law to U.S. hemp (including CBD and other U.S. hemp-derived cannabinoids) products and the scope of any regulations byre-enter the U.S. Food and Drug Administration (the “FDA”), the U.S. Drug Enforcement Administration (the “DEA”), the U.S. Federal Trade Commission (the “FTC”), the U.S. Patent and Trademark Office (the “PTO”) and any state equivalent regulatory agencies over U.S. hemp (including CBD and other U.S. hemp-derived cannabinoids) products;

•the laws and regulations and any amendments thereto relating to the U.S. hemp industry in the U.S., including the promulgation of regulations for the U.S. hemp industry by the U.S. Department of Agriculture (the “USDA”) and relevant state regulatory authorities;market;

•expectations related to our announced realignment (the “Realignment”) and any progress, challenges and effects related thereto as well as changes in strategy, metrics, investments, reporting structure, costs, operating expenses, employee turnover and other changes with respect thereto;

•the timing of ~~our exit from~~the change in the nature of operations at our facility in Stayner, Ontario (the ~~“Stayner Facility”~~“Peace Naturals Campus”) and the expected costs and benefits from the wind-down of cultivation and certain production activities at the ~~Stayner Facility;~~Peace Naturals Campus;

•our ability to effectively wind-down cultivation and certain production activities at the ~~Stayner Facility~~Peace Naturals Campus in an organized fashion and acquire raw materials from other suppliers, including Cronos Growing Company Inc. (“Cronos GrowCo”), and the costs and timing associated therewith;

•~~the grant, renewal and impact of any license or supplemental license to conduct activities with cannabis or any amendments thereof;~~

•~~our international activities and joint venture interests, including required regulatory approvals and licensing, anticipated costs and timing, and expected impact;~~

•~~our ability to successfully create and launch brands and further create, launch and scale U.S. hemp-derived cannabinoid consumer products and cannabis products;~~

•~~the benefits, viability, safety, efficacy, dosing and social acceptance of cannabis, including CBD and other cannabinoids;~~

•~~expectations regarding the implementation and effectiveness of key personnel changes;~~

•~~the anticipated benefits and impact of Altria Group Inc.’s investment in the Company (the “Altria Investment”), pursuant to a subscription agreement dated December 7, 2018;~~

•the potential exercise of one warrant of the Company included as part of the Altria Investment (the “Altria Warrant”), pre-emptive rights and/or top-up rights in connection with the Altria Investment, including proceeds to us that may result therefrom;

~~Table of Contents~~

•~~expectations regarding the use of proceeds of equity financings, including the proceeds from the Altria Investment;~~

•the legalization of the use of cannabis for medical or adult-use in jurisdictions outside of Canada, the related timing and impact thereof and our intentions to participate in such markets, if and when such use is legalized;

•expectations regarding the potential success of, and the costs and benefits associated with, our joint ventures, strategic alliances and equity investments, including the strategic partnership (the “Ginkgo Strategic Partnership”) with Ginkgo Bioworks Holdings, Inc. (“Ginkgo”);

•our ability or plans to ~~execute on~~identify, develop, commercialize or expand our ~~strategy~~technology and research and development (“R&D”) initiatives in cannabinoids, or the ~~anticipated benefits of such strategy;~~success thereof;

•expectations regarding revenues, expenses, gross margins and capital expenditures;

•expectations regarding our future production and manufacturing strategy and operations, the costs and timing associated therewith and the receipt of ~~the amount or frequency of impairment losses, including as a result of the write-down of intangible assets, including goodwill;~~applicable production and sale licenses;

•the ongoing impact of the legalization of additional cannabis product types and forms for adult-use in Canada, including federal, provincial, territorial and municipal regulations pertaining thereto, the related timing and impact thereof and our intentions to participate in such markets;

•the ~~future performance~~legalization of the use of cannabis for medical or adult-use in jurisdictions outside of Canada, including the United States, the related timing and impact thereof and our ~~business~~intentions to participate in such markets, if and ~~operations;~~

•~~our competitive advantages and business strategies;~~when such use is legalized;

•the ~~competitive conditions~~grant, renewal, withdrawal, suspension, delay and impact of ~~the industry;~~

•~~the expected growth in the number of customers using our products;~~any license or supplemental license to conduct activities with cannabis or any amendments thereof;

•our ability ~~or plans~~ to ~~identify, develop, commercialize or expand our technology~~successfully create and ~~research~~launch brands and ~~development (“R&D”) initiatives in cannabinoids, or the success thereof;~~cannabis products;

•~~expectations~~the benefits, viability, safety, efficacy, dosing and social acceptance of cannabis, including CBD and other cannabinoids;

Table of Contents

•laws and regulations and any amendments thereto applicable to our business and the impact thereof, including uncertainty regarding ~~acquisitions~~the application of United States (“U.S.”) state and ~~dispositions~~federal law and the scope of any regulations by the U.S. Food and Drug Administration (the “FDA”), the U.S. Drug Enforcement Administration (the “DEA”), the U.S. Federal Trade Commission (the “FTC”), the U.S. Patent and Trademark Office (the “PTO”) and any state equivalent regulatory agencies;

•the anticipated benefits ~~therefrom;~~and impact of Altria Group Inc.’s investment in the Company (the “Altria Investment”), pursuant to a subscription agreement dated December 7, 2018;

•uncertainties as to our ability to exercise our option (the “PharmaCann Option”) in PharmaCann Inc. (“PharmaCann”), in the near term or the future, in full or in part, including the uncertainties as to the status and future development of federal legalization of cannabis in the U.S. and our ability to realize the anticipated benefits of the transaction with PharmaCann;

•expectations regarding ~~revenues, expenses~~the implementation and ~~anticipated cash needs;~~effectiveness of key personnel changes;

•expectations regarding ~~cash flow, liquidity~~acquisitions and ~~sources of funding;~~

•~~expectations regarding capital expenditures;~~

•~~expectations regarding our future production and manufacturing strategy and operations, the costs and timing associated therewith~~dispositions and the ~~receipt of applicable production and sale licenses;~~

•~~expectations regarding our growing, production and supply chain capacities;~~

•~~expectations regarding the resolution of litigation and other legal and regulatory proceedings, reviews and investigations;~~

•~~expectations with respect to future production costs;~~

•~~expectations with respect to future sales and distribution channels and networks;~~

•~~the expected methods to be used to distribute and sell our products;~~

•~~the~~ anticipated ~~future gross margins of our operations;~~

•~~accounting standards and estimates;~~benefits therefrom;

•our ability to timely and effectively remediate any material weaknesses in our internal control over financial reporting;

•expectations of the amount or frequency of impairment losses, including as a result of the write-down of intangible assets, including goodwill;

•the uncertainties associated with the COVID-19 pandemic, including our ability, and the abilities of our joint ventures and our suppliers and distributors, to effectively deal with the restrictions, limitations and health issues presented by the COVID-19 pandemic, the ability to continue our production, distribution and sale of our products, and demand for and the use of our products by consumers;

•the impact of the ongoing military conflict between Russia and Ukraine (and resulting sanctions) on our business, financial condition and results of operations or cash flows;

•our compliance with the terms of the settlement with the SEC (the “Settlement Order”) and the settlement agreement with the Ontario Securities Commission (“Settlement Agreement”), including complying with any recommendations made by the independent consultant appointed pursuant to the Settlement Order and Settlement Agreement; and

•~~expectations regarding~~ the ~~costs~~impact of the loss of our ability to rely on private offering exemptions under Regulation D of the Securities Act of 1933, as amended (the “Securities Act”), and ~~benefits associated with~~the loss of our ~~contracts and agreements with third parties, including under our third party supply and manufacturing agreements.~~status as a well-known seasoned issuer, each as a result of the Settlement Order.

Certain of the Forward-Looking Statements contained herein concerning the industries in which we conduct our business are based on estimates prepared by us using data from publicly available governmental sources, market research, industry analysis and on assumptions based on data and knowledge of these industries, which we believe to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. The industries in which we conduct our business involve risks and uncertainties that are subject to change based on various factors, which are described further below.

~~Table of Contents~~

The Forward-Looking Statements contained herein are based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including: (i) our ability to efficiently and effectively ~~exit~~wind-down our operations at our Winnipeg, Manitoba facility and realize the ~~Stayner Facility,~~expected cost-savings and other benefits related thereto, (ii) our ability to efficiently and effectively wind-down our operations in the U.S. and realize the expected cost-savings and other benefits related thereto, (iii) our ability to realize the expected cost-savings, efficiencies and other benefits of our Realignment and other announced cost-cutting measures and employee turnover related thereto; (iv) our ability to efficiently and effectively wind-down our cultivation and certain production activities at the Peace Naturals Campus, receive the benefits of the ~~Stayner Facility wind down~~change in the nature of our operations at our Peace Naturals Campus and acquire raw materials on a timely and cost-effective basis from third parties, including Cronos GrowCo; ~~(ii)~~(v) our ability to realize anticipated benefits, synergies or generate revenue, profits or value from our acquisitions and strategic investments; (vi) the production and manufacturing capabilities and output from our facilities and our joint ventures, strategic alliances and equity investments; (vii) government regulation of our activities and products including, but not limited to, the areas of cannabis taxation and environmental protection; (viii) the timely receipt of any required regulatory authorizations, approvals, consents, permits and/or licenses; (ix) consumer interest in our products; (x) competition; (xi) anticipated and unanticipated costs; (xii) our ability to generate cash flow from operations; (xiii) our ability to conduct operations in a safe, efficient and effective manner; (xiv) our ability to hire and retain qualified staff, and acquire equipment and services in a timely and cost-efficient manner; (xv) our ability to exercise the PharmaCann Option and realize the anticipated benefits of the transaction with PharmaCann; (xvi) our ability to complete planned dispositions, and, if completed, obtain our anticipated sales price; (xvii) our ability, and the abilities of our joint ventures and our suppliers and distributors, to effectively deal with the restrictions, limitations and health issues presented by the COVID-19 pandemic and the ability to continue our production, distribution and sale of our products and customer demand for and use of our products; ~~(iii) management’s perceptions of historical trends, current conditions and expected future developments; (iv) our ability to generate cash flow from operations; (v)~~(xviii) general economic, financial market, regulatory and political conditions in which we operate; ~~(vi) the production~~(xix) management’s perceptions of historical trends, current conditions and ~~manufacturing capabilities~~expected future developments; and output from our facilities and our joint ventures, strategic alliances and equity investments; (vii) consumer interest in our products; (viii) competition; (ix) anticipated and unanticipated costs; (x) government regulation of our activities and products including, but not limited to, the areas of taxation and environmental protection; (xi) the timely receipt of any required regulatory authorizations, approvals, consents, permits and/or licenses; (xii) our ability to obtain qualified staff, equipment and services in a timely and cost-efficient manner; (xiii) our ability to conduct operations in a safe, efficient and effective manner; (xiv) our ability to realize anticipated benefits, synergies or generate revenue, profits or value from our recent acquisitions into our existing operations; (xv) our ability to realize the expected cost-savings, efficiencies and other benefits of our Realignment and employee turnover related thereto; (xvi) our ability to complete planned dispositions, and, if completed, obtain our anticipated sales price; (xvii) our ability to exercise the PharmaCann Option and realize the anticipated benefits of the transaction with PharmaCann; and (xviii)(xx) other considerations that management believes to be appropriate in the circumstances. While our management considers these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct.

Table of Contents

By their nature, Forward-Looking Statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the Forward-Looking Statements in this Quarterly Report and other reports we file with, or furnish to, the SEC and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf. Such factors include, without limitation, that we may not be able to ~~exit the Stayner Facility~~wind-down our operations at our Winnipeg, Manitoba facility in ~~an organized fashion~~a disciplined and cost-effective manner or achieve the anticipated benefits ~~of the exit~~thereof or be able to access raw materials on a timely and cost-effective basis from ~~third parties,~~third-parties; that we may be unable to further streamline our operations and reduce expenses; that we may not be able to wind-down our U.S. operations in a disciplined and cost-effective manner or achieve the anticipated benefits thereof or be able to effectively and efficiently re-enter the U.S. market in the future; that we may not able to wind-down cultivation and certain production activities at the Peace Naturals Campus in a disciplined manner or achieve the anticipated benefits of the change in the nature of our operations or be able to access raw materials on a timely and cost-effective basis from third-parties, including Cronos GrowCo; the risk that the COVID-19 pandemic and the military conflict between Russia and Ukraine may disrupt our operations and those of our suppliers and distribution channels and negatively impact the demand for and use of our products; the risk that cost savings and any other synergies from the Altria Investment may not be fully realized or may take longer to realize than expected; ~~the risk that we will not complete planned dispositions, or, if completed, obtain our anticipated sales price; the implementation and effectiveness of~~failure to execute key personnel changes; the risks that our Realignment, the ~~closure~~change in the nature of our operations at the ~~Stayner Facility~~Peace Naturals Campus and our further leveraging of our strategic partnerships will not result in the expected cost-savings, efficiencies and other benefits or will result in greater than anticipated turnover in personnel; ~~future~~lower levels of revenues; the lack of consumer demand for our cannabis ~~and U.S. hemp~~ products; our ~~ability~~inability to reduce expenses at the level needed to meet our projected net change in cash and cash equivalents; our inability to manage disruptions in credit markets or changes to our credit ratings; unanticipated future levels of capital, environmental or maintenance expenditures, general and administrative and other expenses; ~~the success or timing of completion of ongoing or anticipated capital or maintenance projects; business strategies,~~ growth opportunities ~~and expected investment;~~not turning out as expected; the ~~adequacy~~lack of ~~our capital resources and liquidity, including but not limited to, availability of sufficient~~ cash flow necessary to execute our business plan (either within the expected timeframe or at all); difficulty raising capital; the potential adverse effects of judicial, regulatory or other proceedings, or threatened litigation or proceedings, on our business, financial condition, results of operations and cash flows; volatility in and/or degradation of general economic, market, industry or business conditions; compliance with applicable environmental, economic, health and safety, energy and other policies and regulations and in particular health concerns with respect to vaping and the use of cannabis ~~and U.S. hemp products~~ in vaping devices; the ~~anticipated~~unexpected effects of actions of third parties such as competitors, activist investors or federal (including U.S. federal), state, provincial, territorial or local regulatory authorities or self-regulatory organizations; adverse changes in regulatory requirements in relation to our business and products; legal or regulatory obstacles that could prevent us from being able to exercise the PharmaCann Option and thereby realizing the anticipated benefits of the transaction with PharmaCann; dilution of our ~~fully-diluted~~fully diluted ownership of PharmaCann and the loss of our rights as a result of that dilution; a delay in our remediation of a material ~~weaknesses~~weakness in our internal control over financial reporting and the improvement of our control environment and our systems, processes and procedures; and the factors discussed under Part I, Item 1A “Risk Factors” of the Annual ~~Report.~~Report and under Part II, Item 1A “Risk Factors” in our Quarterly Reports. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on Forward-Looking Statements.

Forward-Looking Statements are provided for the purposes of assisting the reader in understanding our financial performance, financial position and cash flows as of and for periods ended on certain dates and to present information about management’s current expectations and plans relating to the future, and the reader is cautioned not to place undue reliance on these Forward-Looking Statements because of their inherent uncertainty and to appreciate the limited purposes for which they are being used by management. While we believe that the assumptions and expectations reflected in the Forward-Looking Statements are reasonable based on information currently available to management, there is no assurance that such assumptions and expectations will prove to have been correct. Forward-Looking Statements are made as of the date they are made and are based on the beliefs, estimates, expectations and opinions of management on that date. We undertake no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such Forward-Looking Statements. The Forward-Looking Statements contained in this Quarterly Report

~~Table of Contents~~

and other reports we file with, or furnish to, the SEC and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf are expressly qualified in their entirety by these cautionary statements.

Foreign currency exchange rates

All currency amounts in this Quarterly Report are stated in U.S. dollars, which is our reporting currency, unless otherwise noted. All references to “dollars” or “$” are to U.S. dollars. The assets and liabilities of our foreign operations are translated into dollars at the exchange rate in effect as of June 30, ~~2022,~~2023, June 30, ~~2021~~2022, and December 31, ~~2021.~~2022. Transactions affecting the shareholders’ equity (deficit) are translated at historical foreign exchange rates. The condensed consolidated statements of net ~~income (loss)~~loss and comprehensive income (loss) and condensed consolidated statements of cash flows of our foreign operations are translated into dollars by applying the average foreign exchange rate in effect for the reporting period as reported on Bloomberg.

The exchange rates used to translate from Canadian dollars (“C$”) to dollars is shown below:

(Exchange rates are shown as C$ per $) As of
June 30, 2022 June 30, 2021 December 31, 2021
Quarter-to-date average rate 1.2765 1.2293 N/A
Spot rate 1.2874 1.2395 1.2746
Year-to-date average rate 1.2715 1.2481 1.2541

Table of Contents

(Exchange rates are shown as C$ per $)

As of

June 30, 2023

June 30, 2022

December 31, 2022

Spot rate

1.3242

1.2874

1.3554

Year-to-date average rate

1.3474

1.2715

N/A

The exchange rates used to translate from Israeli Shekels (“ILS”) to dollars is shown below:

(Exchange rates are shown as ILS per $)

As of

June 30, 2023

June 30, 2022

December 31, 2022

Spot rate

3.7051

3.4936

3.5178

Year-to-date average rate

3.5892

3.2670

N/A

Business Overview

Cronos ~~Group~~ is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product ~~development and are seeking~~development. With a passion to ~~build~~responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. ~~Cronos Group’s~~Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS®,and Lord Jones®~~, Happy Dance~~® ~~and PEACE+~~®.

Strategy

Cronos ~~Group~~ seeks to create value for shareholders by focusing on four core strategic priorities:

•growing a portfolio of iconic brands that responsibly elevate the consumer experience;

•developing a diversified global sales and distribution network;

•establishing an efficient global supply chain; and

•creating and monetizing disruptive intellectual property.

Discontinued Operations

In the second quarter of 2023, Cronos exited its U.S. hemp-derived cannabinoid product operations. The exit of the U.S. operations represented a strategic shift that has a major effect on Cronos’ operations and financial results, and as such, qualifies for reporting as discontinued operations in our condensed consolidated statements of net loss and comprehensive income (loss). Prior period amounts have been reclassified to reflect the discontinued operations classification of the U.S. operations. For further detail on the discontinuation of the U.S. operations, see Note 2 “Discontinued Operations” to the condensed consolidated interim financial statements under Item 1 of this Quarterly Report.

Business segments

We report through two segments: “United States” (the “U.S. segment”) and “Rest of World” (the “ROW segment”). These two segments represent the geographic regions in which we operate and the different product offerings within each geographic region.

~~The U.S. segment manufactures, markets and distributes U.S. hemp-derived supplements and cosmetic products through e-commerce, retail and hospitality partner channels~~Beginning in the ~~United States under~~second quarter of 2023, following the ~~brands Lord Jones~~®~~, Happy Dance~~®exit of our U.S. operations, Cronos is reporting through one consolidated segment, which includes operations in both Canada and ~~PEACE+~~®.

~~The ROW segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets.~~Israel. In Canada, Cronos ~~Group~~ operates two wholly owned license holders under the Cannabis Act (Canada) (the “Cannabis Act”), Peace Naturals Project Inc. (“Peace Naturals”), which has production facilities near Stayner, Ontario (the ~~“Stayner Facility”~~“Peace Naturals Campus”), and Thanos Holdings Ltd., known as Cronos Fermentation (“Cronos Fermentation”), which has a production facility in Winnipeg, Manitoba. In Israel, the Company operates under the IMC-GAP, IMC-GMP and IMC-GDP certifications required for the cultivation, production and marketing of dried flower, pre-rolls and ~~cannabis~~ oils in the Israeli medical market. Cronos Group has established three strategic joint ventures in Canada, Israel and Colombia. Additionally, as of June 30, 2022, Cronos Group held approximately 10% of the issued capital of Cronos Australia Limited (“Cronos Australia”), which is listed on the Australian Securities Exchange under the trading symbol “CAU.” Cronos Group currently exports cannabis products to two of the countries that permit the import of such products: Germany and Israel.

Table of Contents

Recent Developments

~~COVID-19 update~~Brand and Product Portfolio

In December 2019, an outbreak of a novel strain of coronavirus, COVID-19, was identified in Wuhan, China. Since then, COVID-19 has spread across the globe, including the U.S., Canada and Israel, and other countries in which Cronos Group or its affiliates operate (including Australia and Colombia) and was recognized as a pandemic by the World Health Organization. The COVID-19 pandemic resulted in a sharp contraction in many areas of the global economy and increased volatility and uncertainty in the capital markets. In response to the pandemic, the governments of many countries, provinces, states, municipalities, and other geographic regions took preventative or protective actions, including closures of certain businesses, mandatory quarantines, limits on individuals’ time outside of their homes, travel restrictions and social distancing or other preventative measures. Such measures were eased or lifted in varying degrees by different governments of various countries, states and municipalities since implementation in 2020, but the continued spread of COVID-19 and increased infection rates has caused, and may continue to cause, some jurisdictions to roll back reopening plans that had been underway and re-impose quarantines, border closures, closure of certain businesses and stay-at-home orders.

The COVID-19 pandemic continues to impact the global economy and, specifically, the U.S., Canada, Israel, and the other countries in which Cronos Group or its affiliates operate (including Australia and Colombia). We continue to closely monitor and respond, where possible, to the ongoing COVID-19 pandemic. As the global situation continues to change rapidly, ensuring the health and safety of our employees remains one of our top priorities.

In the ~~U.S., numerous states have~~second quarter of 2023, the Company expanded its number-one-ranking gummy portfolio with two new flavors, Pink Lemonade and Strawberry Kiwi, under the SOURZ by Spinach® brand.

In July 2023, the Company expanded its vape offering under the Spinach® brand by launching 1.2 gram vapes, featuring 1,000mg of THC per cartridge. The initial flavor offerings under this new size format are Peach Punch, Pink Lemonade and Strawberry Slurricane.

Cronos continued to ~~remove their COVID-19 related restrictions. This has resulted in~~elevate its pre-roll offering under the ~~re-opening~~Spinach® brand by launching three new infused pre-rolls during the second quarter of 2023. The Spinach® Fully Charged infused pre-roll line extension includes Peach Punch, Pink Lemonade and increased occupancy capacities in, retail outlets, including those that sell our products. Any reinstatement of restrictions on the operations of retail outlets could negatively impact our short-term results of operations in the U.S. Recently in the U.S., there have been a number of supply chain challenges, such as container ships facing delays due to congestion in ports, impacting many industries, including the industries in which we operate. Although we have not yet seen a significant impact from supply chain disruptions, we continue to monitor our supply chain closely.Strawberry Slurricane.

In Canada, COVID-19 restrictions began gradually easing at the end of June 2021 as the vaccination rate increased. The lockdown measures taken in the first six months of 2021 to slow infection rates negatively impacted our short-term revenue growth in Canada in 2021. The increase in cases related to the Omicron variant of COVID-19 beginning in December 2021 caused the reinstatement of some restrictions on non-essential retail stores in some provinces, including Quebec, in early 2022; however, those restrictions have eased in most other provinces. Each province is responsible for implementing re-opening plans and certain provinces, including Ontario, are progressing through phases of re-opening which may permit continued increases to the allowance of in-person shopping, typically in the form of percentage of store capacity. All provinces have some form of cannabis retail open to consumers, whether it be restricted in-person shopping, curb-side pickup or delivery. Most provinces have lifted the requirement that retail shoppers show proof of vaccination before entering retail stores. The potential for recurring retail restrictions is ongoing, which could negatively impact our results of operations.

In Israel, ~~most COVID-19 restrictions have been removed as vaccination rates have increased. Occupancy limitations~~Cronos launched two new pre-roll offerings under the Peace Naturals® brand, Wedding Rolls and Cocoa Bomba, in ~~retail outlets have been removed, including those that sell~~addition to a new flower offering with our ~~products. We do not expect the remaining COVID-19 restrictions to have a material impact on our short-term revenue growth in Israel.~~

Collectively, the effects of the COVID-19 pandemic have adversely affected our results of operations and, if the effects continue unabated, could continue to do so as long as measures to combat the COVID-19 pandemic remain in effect or supply chains continue to be challenged. At this time, neither the duration nor scope of the disruption can be predicted; therefore, the ultimate impact to our business cannot be reasonably estimated, but such impact could materially adversely affect our business, financial condition and results of operations.

Despite the impacts of the COVID-19 pandemic, we believe that our significant cash on hand and short-term investments will be adequate to meet liquidity and capital requirements for at least the next twelve months.

~~Table of Contents~~successful Space Cake genetic.

Strategic and Organizational Update

In May 2023, Cronos simultaneously announced the ~~second~~discontinuation of the U.S. segment and the planned repurposing of the Lord Jones® brand, by bringing the brand back to its adult-use roots in Canada in the fourth quarter of ~~2022,~~2023.

In August 2023, following ana careful evaluation of the ~~U.S. business as part of the~~ Company’s ~~Realignment,~~global supply chain, the Company ~~began a phased exit~~announced the planned wind-down of Cronos Fermentation, with intentions to list the ~~wholesale beauty category to focus the portfolio on adult-use product formats within the direct-to-consumer channel. As a result, the~~facility for sale. The Company reduced sales and marketing headcount in the U.S. to better align the business structure with the new strategy. Due to the restructuring of the U.S. business and other newly identified cost savings opportunities, the Company now expects to incur charges of approximately ~~$6.4~~$1.2 million ~~in expenses~~ in connection with the ~~Realignment, an increase from the previously stated $5.8 million.~~

~~In addition, the Company anticipates capital expenditures~~planned exit. These charges include employee-related costs, such as ~~a result of the Realignment of approximately $2.2 million~~severance, relocation and other termination benefits, as well as contract termination and other related costs, which are expected to ~~modernize information technology systems and build distribution capabilities. As of June 30, 2022, related capital expenditures were $0.3 million. As the Company continues its transition through~~be incurred primarily in the second half of ~~2022, it anticipates that it will begin~~2023. Cronos expects to ~~incur~~continue to operate the Cronos Fermentation facility with a phased reduction and planned exit by the end of 2023.

Also in August 2023, the Company announced organization-wide cost reductions. Expected restructuring costs of approximately $2.0 million, with the majority expected to be incurred in the second half of 2023, include mostly one-time employee-related severance charges.

Global Supply Chain

In July 2023, Cronos signed an agreement with one of the ~~expected capital expenditures as part~~leading distributors of ~~the Realignment.~~

~~Brand and Product Portfolio~~

~~Subsequent~~medical cannabis in Germany. Cronos anticipates commencing shipments of cannabis to the second quarter, in July and August 2022, the Company launched two rare cannabinoid products featuring cannabinol (“CBN”) across select markets in Canada with intentions to expand across Canada over time. The first was a gummy featuring CBN under the Spinach FEELZ™ brand, Deep Dreamz Blueberry Pomegranate (2:1 THC|CBN), featuring 2 gummies per pack with 10mg tetrahydrocannabinol (“THC”) and 5mg CBN per pack. The addition of a CBN-focused gummy further builds on our rare cannabinoid portfolio. Additionally, the Company complemented the CBN gummy launch with an offeringGermany in the ~~vape category,~~third quarter of 2023. Cronos intends to launch the ~~Spinach FEELZ™ Deep Dreamz Blackberry Kush (7:1 THC|CBN) 1-gram vape.~~

~~Intellectual property initiatives~~

~~In June 2022, Cronos announced the achievement of the final productivity target for tetrahydrocannabivarin (“THCV”) under its strategic partnership (the “Ginkgo Strategic Partnership”)~~Peace Naturals® medical-focused brand in Germany with ~~Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) (“Ginkgo”). THCV is hypothesized~~a goal to ~~reduce the appetite-enhancing property of THC.~~

~~Appointments~~

~~In August 2022, the Company appointed Arye Weigensberg as Senior Vice President, Head of Research & Development, after serving~~make it a top brand similar to our success in an interim capacity since November 2021. Prior to serving as interim Head of Research and Development, Mr. Weigensberg was the General Manager and Vice President of Research and Technology at Cronos Research Labs. Before joining the Company, Mr. Weigensberg was the CEO of Altria Israel Ltd (an Altria research and development hub). Since joining Cronos, Mr. Weigensberg has played a foundational role developing the scope of our rare cannabinoid work, while advancing our research capabilities to forge new strategies for differentiated cannabis products.

Israel.

3231

Table of Contents

Consolidated Results of Operations

The tables below ~~sets~~set forth our condensed consolidated results of operations, expressed in thousands of U.S. dollars for the periods presented. Our condensed consolidated financial results for these periods are not necessarily indicative of the consolidated financial results that we will achieve in future periods.


(in thousands of USD)													(in thousands of USD)	Three months ended June 30,					Six months ended June 30,
		Three months ended June 30,				Six months ended June 30,			2023			2022				2023			2022
		2022		2021			2022			2021
Net revenue before excise taxes		$	28,554	$	18,848		$	57,960		$	33,502
Net revenue, before excise taxes													Net revenue, before excise taxes	$	25,798		$	27,095		$	52,352	$	54,173
Excise taxes	Excise taxes	(5,493)		(3,226)			(9,866)			(5,269)			Excise taxes	(6,777)			(5,493)			(13,836)		(9,866)
Net revenue	Net revenue	23,061		15,622			48,094			28,233			Net revenue	19,021			21,602			38,516		44,307
Cost of sales	Cost of sales	18,941		19,445			37,048			35,019			Cost of sales	15,922			17,280			32,490		33,275
Inventory write-down		—		11,961			—			11,961

Gross profit	Gross profit	4,120		(15,784)			11,046			(18,747)			Gross profit	3,099			4,322			6,026		11,032
Operating expenses:
Operating expenses													Operating expenses
Sales and marketing	Sales and marketing	5,582		13,209			10,594			23,463			Sales and marketing	5,297			4,185			11,038		7,195
Research and development	Research and development	4,302		5,199			8,341			10,301			Research and development	1,107			4,194			3,146		8,115
General and administrative	General and administrative	17,005		22,417			39,373			44,323			General and administrative	13,451			16,286			25,307		37,417
Restructuring costs	Restructuring costs	1,270		—			4,354			—			Restructuring costs	—			978			—		3,009
Share-based compensation	Share-based compensation	2,616		2,565			6,302			5,064			Share-based compensation	2,331			2,583			4,866		6,199
Depreciation and amortization	Depreciation and amortization	1,411		1,043			2,704			1,778			Depreciation and amortization	1,533			1,398			3,058		2,666
Impairment loss on goodwill and indefinite-lived intangible assets		—		234,914			—			234,914

Impairment loss on long-lived assets	Impairment loss on long-lived assets	—		1,214			3,493			2,955			Impairment loss on long-lived assets	—			—			—		3,493
Total operating expenses	Total operating expenses	32,186		280,561			75,161			322,798			Total operating expenses	23,719			29,624			47,415		68,094
Operating loss	Operating loss	(28,066)		(296,345)			(64,115)			(341,545)			Operating loss	(20,620)			(25,302)			(41,389)		(57,062)
Other income	Other income	7,420		117,553			11,178			1,149			Other income	14,777			7,467			16,075		11,224
Income tax benefit (expense)		308		—			(54)			—
Income tax expense (benefit)													Income tax expense (benefit)	180			308			1,616		(54)
Loss from discontinued operations	Loss from discontinued operations	—		(561)			—			(582)			Loss from discontinued operations	(2,834)			(2,811)			(4,056)		(7,099)
Net loss	Net loss	(20,338)		(179,353)			(52,991)			(340,978)			Net loss	(8,497)			(20,338)			(27,754)		(52,991)
Net loss attributable to non-controlling interest	Net loss attributable to non-controlling interest	(117)		(279)			(132)			(592)			Net loss attributable to non-controlling interest	(137)			(117)			(225)		(132)
Net loss attributable to Cronos Group	Net loss attributable to Cronos Group	$	(20,221)	$	(179,074)		$	(52,859)		$	(340,386)		Net loss attributable to Cronos Group	$	(8,360)		$	(20,221)		$	(27,529)	$	(52,859)

Summary of select financial results


		Three months ended June 30,						Change				Six months ended June 30,						Change
(in thousands of USD)																						(in thousands of USD)	Three months ended June 30,						Change				Six months ended June 30,						Change
		2022			2021			$		%		2022			2021			$		%			2023			2022			$		%		2023			2022			$		%
Net revenue	Net revenue	$	23,061		$	15,622		$	7,439	48	%	$	48,094		$	28,233		$	19,861	70	%	Net revenue	$	19,021		$	21,602		$	(2,581)	(12)	%	$	38,516		$	44,307		$	(5,791)	(13)	%
Cost of sales	Cost of sales	18,941			19,445			(504)		(3)	%	37,048			35,019			2,029		6	%	Cost of sales	15,922			17,280			(1,358)		(8)	%	32,490			33,275			(785)		(2)	%
Inventory write-down		—			11,961			(11,961)		(100)	%	—			11,961			(11,961)		(100)	%

Gross profit	Gross profit	4,120			(15,784)			19,904		126	%	11,046			(18,747)			29,793		159	%	Gross profit	3,099			4,322			(1,223)		(28)	%	6,026			11,032			(5,006)		(45)	%
Gross margin(i)	Gross margin(i)	18		%	(101)		%	N/A		119	pp	23		%	(66)		%	N/A		89	pp	Gross margin(i)	16		%	20		%	N/A		(4)	pp	16		%	25		%	N/A		(9)	pp

(i)Gross margin is defined as gross profit divided by net revenue.

Net revenue

For the three months ended June 30, ~~2022,~~2023, we reported consolidated net revenue of ~~$23.1~~$19.0 million, representing ~~an increase~~a decrease of ~~$7.4~~$2.6 million from the three months ended June 30, ~~2021.~~2022. For the six months ended June 30, ~~2022,~~2023, we reported consolidated net revenue of ~~$48.1~~$38.5 million, representing ~~an increase~~a decrease of ~~$19.9~~$5.8 million from the six months ended June 30, ~~2021.~~2022. For both the three and six month comparative periods, the ~~increase~~decrease was primarily due to lower cannabis flower sales in Israel due to competitive activity, the slowdown in patient permit authorizations and geopolitical unrest, and an ~~increase~~adverse price/mix in ~~net revenue~~Canada in the ~~ROW segment driven by growth in~~cannabis flower category driving increased excise tax payments as a percentage of revenue. Furthermore, the weakened Canadian dollar and Israeli ~~medical market and~~Shekel against the ~~Canadian adult-use market.~~U.S. dollar during the current period adversely impacted results.

3332

Table of Contents

Cost of sales

For the three months ended June 30, ~~2022,~~2023, we reported consolidated cost of sales of ~~$18.9~~$15.9 million, representing a decrease of ~~$0.5~~$1.4 million from the three months ended June 30, ~~2021.~~2022. For the six months ended June 30, ~~2022,~~2023, we reported consolidated cost of sales of ~~$37.0~~$32.5 million, representing ~~an increase~~a decrease of ~~approximately $2.0~~$0.8 million from the six months ended June 30, 2021. For the three month comparative period, the decrease was due to lower cannabis biomass costs, partially offset by higher sales volumes and lower fixed cost absorption due to the timing of wind down activities associated with our planned exit of the Stayner Facility. For the six month comparative period, the increase was primarily due to higher sales volumes in the ROW segment and lower fixed cost absorption due to the timing of wind down activities associated with our exit of the Stayner facility, partially offset by lower cannabis biomass costs.

~~Inventory write-down~~

For the three and six months ended June 30, 2021, we reported inventory write-downs of $12.0 million primarily related to cannabis strains and potency levels that were no longer in-line with consumer preferences in the Canadian market and adjustments for obsolete inventory in Canada. We reported no such write-down for the three and six months ended June 30, 2022.

~~Gross profit~~

For the three months ended June 30, 2022, we reported gross profit of $4.1 million, representing an increase in gross profit of $19.9 million compared to the three months ended June 30, 2021. For the six months ended June 30, 2022, we reported gross profit of $11.0 million, representing an increase in gross profit of $29.8 million compared to the six months ended June 30, 2021. For both the three and six month comparative periods, the change was primarily due to the absence of inventory write-downs in the current periods, increased revenue in the ROW segment driven mainly by sales of cannabis flower and a favorable mix of cannabis extract products, which carry a higher gross profit and gross margin than other product categories, and lower cannabis biomass costs, partially offset by lower fixed cost absorption due to the timing of wind down activities associated with our exit of the Stayner Facility.

~~Operating expenses~~

Three months ended June 30, Change Six months ended June 30, Change
2022 2021 $ % 2022 2021 $ %
Sales and marketing $ 5,582 $ 13,209 $ (7,627) (58) % $ 10,594 $ 23,463 $ (12,869) (55) %
Research and development 4,302 5,199 (897) (17) % 8,341 10,301 (1,960) (19) %
General and administrative 17,005 22,417 (5,412) (24) % 39,373 44,323 (4,950) (11) %
Restructuring 1,270 — 1,270 N/A 4,354 — 4,354 N/A
Share-based compensation 2,616 2,565 51 2 % 6,302 5,064 1,238 24 %
Depreciation and amortization 1,411 1,043 368 35 % 2,704 1,778 926 52 %
Impairment loss on goodwill and indefinite-lived intangible assets — 234,914 (234,914) (100) % — 234,914 (234,914) (100) %
Impairment loss on long-lived assets — 1,214 (1,214) (100) % 3,493 2,955 538 18 %
Total operating expenses $ 32,186 $ 280,561 $ (248,375) (89) % $ 75,161 $ 322,798 $ (247,637) (77) %

~~Sales and marketing~~

For the three months ended June 30, 2022, sales and marketing expenses were $5.6 million, representing a decrease of $7.6 million from the three months ended June 30, 2021. For the six months ended June 30, 2022, sales and marketing expenses were $10.6 million, representing a decrease of $12.9 million from the six months ended June 30, 2021. For both the three and six month comparative periods, the decrease was primarily due to lower ~~advertising and marketing spend as well as lower payroll-related costs~~cannabis flower sales in the Israeli medical market, lower cannabis biomass costs and the impact of the weakened Canadian dollar and Israeli Shekel against the U.S. ~~segment associated with~~dollar during the ~~Realignment.~~current periods.

~~Research and development~~Gross profit

For the three months ended June 30, ~~2022, research and development expenses were $4.3~~2023, we reported gross profit of $3.1 million, representing a decrease of ~~$0.9~~$1.2 million from the three months ended June 30, ~~2021.~~2022. For the six months ended June 30, ~~2022, research and development expenses were $8.3~~2023, we reported gross profit of $6.0 million, representing a decrease of ~~$2.0~~$5.0 million from the six months ended June 30, ~~2021.~~2022. For both the three and six month comparative periods, the decrease was primarily due to lower ~~payroll costs associated with~~cannabis flower sales in the ~~Realignment~~Israeli medical market and ~~focused investment~~adverse price/mix on cannabis flower sales in ~~more margin-accretive innovation.~~Canada resulting in higher excise taxes as a percentage of revenue.

~~General~~Operating expenses


	Three months ended June 30,				Change				Six months ended June 30,				Change
	2023		2022		$		%		2023		2022		$		%
Sales and marketing	$	5,297	$	4,185	$	1,112	27	%	$	11,038	$	7,195	$	3,843	53	%
Research and development	1,107		4,194		(3,087)		(74)	%	3,146		8,115		(4,969)		(61)	%
General and administrative	13,451		16,286		(2,835)		(17)	%	25,307		37,417		(12,110)		(32)	%
Restructuring costs	—		978		(978)		N/A		—		3,009		(3,009)		N/A
Share-based payments	2,331		2,583		(252)		(10)	%	4,866		6,199		(1,333)		(22)	%
Depreciation and amortization	1,533		1,398		135		10	%	3,058		2,666		392		15	%

Impairment loss on long-lived assets	—		—		—		N/A		—		3,493		(3,493)		N/A
Total operating expenses	$	23,719	$	29,624	$	(5,905)	(20)	%	$	47,415	$	68,094	$	(20,679)	(30)	%

Sales and ~~administrative~~marketing

For the three months ended June 30, ~~2022, general~~2023, sales and ~~administrative~~marketing expenses were ~~$17.0~~$5.3 million, representing ~~a decrease~~an increase of ~~$5.4~~$1.1 million from the three months ended June 30, ~~2021.~~2022. For the six months ended June 30, ~~2022, general~~2023, sales and ~~administrative~~marketing expenses were $11.0 million, representing an increase of $3.8 million from the six months ended June 30, 2022. For both the three and six month comparative periods, the increase was primarily due to higher advertising and marketing spend and higher payroll-related costs.

Research and development

~~Table~~For the three months ended June 30, 2023, research and development expenses were $1.1 million, representing a decrease of ~~Contents~~

$3.1 million from the three months ended June 30, 2022. For the six months ended June 30, 2023, research and development expenses were ~~$39.4~~$3.1 million, representing a decrease of $5.0 million from the six months ended June 30, ~~2021.~~2022. For both the three and six month comparative periods, the decrease was primarily due to ~~advisory fees~~lower costs associated with ~~strategic initiatives, including~~ the ~~PharmaCann investment, that~~achievement of Ginkgo milestones.

General and administrative

For the three months ended June 30, 2023, general and administrative expenses were ~~incurred during~~$13.5 million, representing a decrease of $2.8 million from the three months ended June 30, 2022. For the six months ended June 30, 2023, general and administrative expenses were $25.3 million, representing a decrease of $12.1 million from the six months ended June 30, 2022. For both the three and six month comparative periods, the decrease was primarily due to lower professional fees, largely related to financial statement review costs, and lower bonus and insurance costs.

Restructuring costs

For both the three and six months ended June 30, ~~2021, partially offset by higher employee-related~~2023, there were no restructuring costs ~~during the three~~incurred, compared to $1.0 million and ~~six months ended June 30, 2022.~~

~~Restructuring costs~~

~~For~~$3.0 million for the three and six months ended June 30, 2022, ~~restructuring costs were $1.3 million and $4.4 million, respectively, compared to no restructuring costs for the three and six months ended June 30, 2021.~~ respectively. For further information, see Note 7 “Restructuring ~~costs for both the three and six months ended June 30, 2022, were related~~” to the ~~Realignment, including the planned exit~~condensed consolidated interim financial statements under Item 1 of ~~the Stayner Facility.~~this Quarterly Report.

Share-based compensation

For the three months ended June 30, ~~2022,~~2023, share-based compensation expense was ~~$2.6~~$2.3 million, ~~essentially unchanged~~representing a decrease of $0.3 million from the three months ended June 30, ~~2021.~~2022. For the six months ended June 30, ~~2022,~~2023, share-based compensation expense was ~~$6.3~~$4.9 million, representing ~~an increase~~a decrease of ~~$1.2~~$1.3 million from the six months ended June 30, ~~2021.~~2022. For the ~~six month comparative period,~~three months ended June 30, 2023, the ~~increase~~decrease was primarily due to lower option expense, partially offset by higher expense on restricted share units. For the six

Table of Contents

months ended June 30, 2023, the decrease was primarily due to the acceleration of ~~equity grants~~expense in the ~~first quarter of~~six months ended June 30, 2022, on equity awards granted to certain executive employees in connection with their separation from the Company.

Depreciation and amortization

For the three months ended June 30, ~~2022,~~2023, depreciation and amortization expenses were ~~$1.4~~$1.5 million, representing an increase of $0.1 million from the three months ended June 30, 2022. For the six months ended June 30, 2023, depreciation and amortization expenses were $3.1 million, representing an increase of $0.4 million from the ~~three months ended June 30, 2021. For the~~ six months ended June 30, ~~2022, depreciation~~2022. For the three and ~~amortization expenses were $2.7 million, representing an increase of $0.9 million from the~~ six months ended June 30, ~~2021. For both~~2023, the ~~three and six month comparative periods, the change~~increase was primarily due to ~~additional depreciation on assets placed into service in the second half of 2021, as well as~~higher amortization on ~~Ginkgo related intangibles placed in service in the second half of 2021.~~

~~Impairment loss on goodwill and indefinite-lived~~Ginkgo-related intangible ~~assets~~

~~For both the three and six month ended June 30, 2022, there was no impairment loss on goodwill and indefinite-lived intangible~~ assets. For both the three and six month ended June 30, 2021, impairment loss on goodwill and indefinite-lived intangible assets was $234.9 million, primarily due to impairment charges on the goodwill associated with our U.S. reporting unit and Lord Jones® ~~brand.~~

Impairment loss on long-lived assets

For the three months ended June 30, 2023 and for three months ended June 30, 2022, ~~there was~~we recorded no impairment loss on long-lived assets. For the six months ended June 30, ~~2022,~~2023, we recorded no impairment loss on long-lived assets, ~~was~~compared to $3.5 million ~~representing an increase of $0.5 million from~~in the six months ended June 30, ~~2021.~~2022. For the six month comparative period, the increase related to the impairment of our right-of-use lease asset and associated leasehold improvements associated with our corporate headquarters in Toronto, Ontario, Canada. Seefurther information, see Note ~~13 “Impairment~~12 “Impairment Loss on Long-lived ~~Assets~~”Assets” to the condensed consolidated interim financial statements under Item 1 of this Quarterly Report.

~~Table of Contents~~

Other income (loss), and income tax ~~expense and discontinued operations~~benefit (expense)


		Three months ended June 30,				Change				Six months ended June 30,				Change					Three months ended June 30,				Change				Six months ended June 30,				Change
		2022		2021		$		%		2022		2021		$		%			2023		2022		$		%		2023		2022		$		%
Interest income, net	Interest income, net	$	3,775	$	2,293	$	1,482	65	%	$	5,821	$	4,622	$	1,199	26	%	Interest income, net	$	12,471	$	3,775	$	8,696	230	%	$	23,646	$	5,820	$	17,826	306	%
Gain (loss) on revaluation of derivative liabilities	Gain (loss) on revaluation of derivative liabilities	3,410		115,248		(111,838)		(97)	%	13,829		(1,626)		15,455		N/M		Gain (loss) on revaluation of derivative liabilities	43		3,410		(3,367)		(99)	%	(22)		13,829		(13,851)		N/M
Share of income (loss) from equity method investments	Share of income (loss) from equity method investments	5,197		(1,115)		6,312		566	%	5,197		(2,758)		7,955		288	%	Share of income (loss) from equity method investments	270		5,197		(4,927)		(95)	%	(226)		5,197		(5,423)		N/M
Gain (loss) on revaluation of financial instruments	Gain (loss) on revaluation of financial instruments	(2,112)		77		(2,189)		N/M		2,156		(123)		2,279		N/M		Gain (loss) on revaluation of financial instruments	5,193		(2,112)		7,305		N/M		(2,565)		2,156		(4,721)		N/M
Impairment loss on other investments	Impairment loss on other investments	—		—		—		N/A		(11,238)		—		(11,238)		N/A		Impairment loss on other investments	—		—		—		N/M		—		(11,238)		11,238		N/M
Foreign currency transaction loss	Foreign currency transaction loss	(2,852)		—		(2,852)		N/A		(4,724)		—		(4,724)		N/A		Foreign currency transaction loss	(3,174)		(2,852)		(322)		(11)	%	(4,817)		(4,724)		(93)		(2)	%
Other, net	Other, net	2		1,050		(1,048)		(100)	%	137		1,034		(897)		(87)	%	Other, net	(26)		49		(75)		N/M		59		184		(125)		(68)	%
Total other income	Total other income	7,420		117,553		(110,133)		(94)	%	11,178		1,149		10,029		873	%	Total other income	14,777		7,467		7,310		98	%	16,075		11,224		4,851		43	%
Income tax benefit (expense)	Income tax benefit (expense)	308		—		308		N/A		(54)		—		(54)		N/A		Income tax benefit (expense)	180		308		(128)		N/M		1,616		(54)		1,670		N/M
Loss from continuing operations																		Loss from continuing operations	(5,663)		(17,527)		11,864		68	%	(23,698)		(45,892)		22,194		48	%
Loss from discontinued operations	Loss from discontinued operations	—		(561)		561		100	%	—		(582)		582		100	%	Loss from discontinued operations	(2,834)		(2,811)		(23)		(1)	%	(4,056)		(7,099)		3,043		43	%
Net loss	Net loss	$	(20,338)	$	(179,353)	$	159,015	89	%	$	(52,991)	$	(340,978)	$	287,987	84	%	Net loss	$	(8,497)	$	(20,338)	$	11,841	58	%	$	(27,754)	$	(52,991)	$	25,237	48	%

(i)“N/M” is defined as not meaningful.

Interest income, net

For the three months ended June 30, ~~2022,~~2023, interest income, net was ~~$3.8~~$12.5 million, representing an increase of ~~$1.5~~$8.7 million from the three months ended June 30, ~~2021.~~2022. For the six months ended June 30, ~~2022,~~2023, interest income, net was ~~$5.8~~$23.6 million, representing an increase of ~~$1.2~~$17.8 million from the six months ended June 30, ~~2021.~~2022. For both the three and six month comparative periods, the increase in net interest income was primarily due to higher short-term investment balances and higher interest rates during the comparative periods.

Gain (loss) on revaluation of derivative liabilities

For the three months ended June 30, ~~2022,~~2023, the gain on revaluation of derivative liabilities was ~~$3.4 million,~~$43 thousand, representing a decrease of ~~$111.8~~$3.4 million from the three months ended June 30, ~~2021.~~2022. For the six months ended June 30, ~~2022,~~2023, the ~~gain~~loss on revaluation of derivative liabilities was ~~$13.8 million,~~$22 thousand, representing ~~an increase~~a decrease of ~~$15.5~~$13.9 million from the six months ended June 30, ~~2021.~~2022. We expect continued changes in derivative valuations as our share price fluctuates period to period and the remaining expected terms of our derivative instruments ~~decrease.~~change over time. For further information, see Note 6 “~~Derivative Liabilities~~”“Derivative Liabilities” to the condensed consolidated interim financial statements under Item 1 ~~“Financial Statements”~~ of this Quarterly Report.

Table of Contents

Share of income (loss) from equity method investments

For the three months ended June 30, ~~2022,~~2023, our share of income from equity method investments was ~~$5.2~~$0.3 million, representing ~~an increase~~a decrease of ~~$6.3~~$4.9 million from the three months ended June 30, ~~2021.~~2022. For the six months ended June 30, ~~2022,~~2023, our share of ~~income~~loss from equity method investments was ~~$5.2~~$0.2 million, representing ~~an increase~~a decrease of ~~$8.0~~$5.4 million from the six months ended June 30, ~~2021.~~2022. For both the three and six month comparative periods, the change was primarily due to ~~improved results~~lower income pick-ups from our equity method investment in Cronos GrowCo.

Gain (loss) on revaluation of financial instruments

For the three months ended June 30, ~~2022,~~2023, the gain on revaluation of financial instruments was $5.2 million, representing an increased gain of $7.3 million from the three months ended June 30, 2022. For the six months ended June 30, 2023, the loss on revaluation of financial instruments was ~~$2.1~~$2.6 million, representing an increased loss of ~~$2.2~~$4.7 million ~~compared to the three months ended June 30, 2021. For~~from the six months ended June 30, ~~2022, the gain on revaluation of financial instruments was $2.2 million, representing an increased gain of $2.3 million compared to the six months ended June 30, 2021.~~2022. For both the three and six month comparative periods, the change was primarily related to the change in fair value of our investment in ~~Cronos Australia.~~Vitura Health Limited (“Vitura”). For further information, see Note 34 “Investments” to the condensed consolidated interim financial statements under Item 1 ~~“Financial Statements”~~ of this Quarterly Report.

~~Table of Contents~~

Impairment loss on other investments

There were no impairment losses on other investments during the three and six months ended June 30, 2023. For the six months ended June 30, 2022, ~~the~~ impairment loss on other investments ofwas $11.2 million, ~~was driven by an~~due to impairment ~~of the~~charges recorded on our PharmaCann Option for the difference between its estimated fair value and its carrying amount. There were no impairment losses on other investments ~~in either~~during the three months ended June 30, ~~2022 or the three and six months ended June 30, 2021. Refer to~~2022. For more information, see Note ~~3 “Investments”~~4 “Investments” in our condensed consolidated interim financial statements under Item 1 of this Quarterly Report.

Foreign currency transaction loss

For the three ~~and six~~ months ended June 30, ~~2022,~~2023, foreign currency ~~transaction~~translation loss was $2.9 million and $4.7 million, respectively, which related to certain foreign currency-denominated intercompany loans anticipated to be settled in the foreseeable future. There were no such foreign currency transaction losses during the three and six months ended, June 30, 2021.

~~Other, net~~

~~For the three months ended June 30, 2022, other, net was $0.01~~$3.2 million, representing ~~a decrease~~an increased loss of ~~$1.0~~$0.3 million from the three months ended June 30, ~~2021.~~2022. For the six months ended June 30, ~~2022, other, net~~2023, foreign currency translation loss was ~~$0.1~~$4.8 million, representing ~~a decrease~~an increased loss of ~~$0.9~~$0.1 million from the six months ended June 30, 2021. For both the three and six month comparative periods, the decrease was primarily related to the gain on held for sale assets sold during the periods. There were no such sales for the three and six months ended June 30, 2022.

~~Results of Operations by Business Segment:~~

The tables below set forth our condensed consolidated results of operations by our two business segments: the ROW segment and the U.S. segment, expressed in U.S. dollars and in thousands for the periods presented. Our condensed consolidated financial results for these periods are not necessarily indicative of the consolidated financial results that we will achieve in future periods. Certain totals in the tables below will not sum to exactly 100% due to rounding.

~~Summary of select financial results~~ – ~~ROW~~

Three months ended June 30, Change Six months ended June 30, Change
2022 2021 $ % 2022 2021 $ %
Net revenue $ 21,602 $ 13,395 $ 8,207 61 % $ 44,307 $ 23,565 $ 20,742 88 %
Cost of sales 17,280 17,862 (582) (3) % 33,275 32,171 1,104 3 %
Inventory write-down — 11,961 (11,961) (100) % — 11,961 (11,961) (100) %
Gross profit 4,322 (16,428) 20,750 126 % 11,032 (20,567) 31,599 154 %
Gross margin 20 % (123) % N/A 143 pp 25 % (87) % N/A 112 pp

~~Net revenue~~ – ~~ROW~~

Three months ended June 30, Change Six months ended June 30, Change
2022 2021 $ % 2022 2021 $ %
Cannabis flower $ 15,739 $ 11,597 $ 4,142 36 % $ 34,364 $ 21,031 $ 13,333 63 %
Cannabis extracts 5,582 1,531 4,051 265 % 9,570 2,234 7,336 328 %
Other 281 267 14 5 % 373 300 73 24 %
Net revenue $ 21,602 $ 13,395 $ 8,207 61 % $ 44,307 $ 23,565 $ 20,742 88 %

For the three months ended June 30, 2022, the ROW segment reported net revenue of $21.6 million, representing an increase of $8.2 million from the three months ended June 30, 2021. For the six months ended June 30, 2022, the ROW segment reported net revenue of $44.3 million, representing an increase of $20.7 million from the six months ended June 30, 2021. For both the three and six month comparative periods, the change was primarily due to ~~an increase in net revenue~~certain foreign currency-denominated intercompany loans anticipated to be settled in the ~~Israeli medical market largely attributable to~~foreseeable future.

Other, net

Other, net primarily includes gains and losses on the ~~cannabis flower category, and in the Canadian adult-use market driven primarily by cannabis extract products.~~disposal of assets.

~~Cost of sales~~ – ~~ROW~~Loss from discontinued operations

For the three months ended June 30, 2022, the ROW segment reported cost of sales of $17.3 million, representing a decrease of $0.6 million from the three months ended June 30, 2021. For the six months ended June 30, 2022, the ROW segment reported cost of sales of $33.3 million, representing an increase of $1.1 million from the six months ended June 30, 2021. For the three month comparative period, the decrease was primarily due to lower cannabis biomass costs, partially offset by higher sales volumes and lower fixed cost absorption due to the timing of wind down activities associated with our planned exit of the Stayner Facility. For the six month comparative period, the increase was primarily due to higher sales volumes and lower fixed cost absorption due to the timing of wind down activities associated with our exit of the Stayner facility, partially offset by lower cannabis biomass costs.


	Three months ended June 30,			Six months ended June 30,
		2023		2022		2023		2022
Net revenue		$	380	$	1,459	$	1,029	$	3,787
Cost of sales		848		1,661		2,044		3,773
Inventory write-down(i)		839		—		839		—
Gross profit		(1,307)		(202)		(1,854)		14
Operating expenses
Sales and marketing		387		1,397		518		3,399
Research and development		18		108		20		226
General and administrative		213		719		736		1,956
Restructuring costs		534		292		534		1,345
Share-based compensation		5		33		21		103
Depreciation and amortization		5		13		13		38

Impairment loss on long-lived assets(ii)		205		—		205		—
Total operating expenses		1,367		2,562		2,047		7,067
Interest income		3		—		8		1
Other, net(iii)		(163)		(47)		(163)		(47)
Total other loss		(160)		(47)		(155)		(46)
Loss before income taxes		(2,834)		(2,811)		(4,056)		(7,099)
Income tax expense (benefit)		—		—		—		—
Net loss from discontinued operations		$	(2,834)	$	(2,811)	$	(4,056)	$	(7,099)

3735

Table of Contents

~~Inventory~~(i)As of June 30, 2023, all inventory associated with our U.S. operations was $nil as a result of the $0.8 million inventory write-down – ~~ROW~~of obsolete product in the second quarter of 2023.

(iii)For the three and six months ended June 30, ~~2021, the ROW segment reported consolidated inventory write-down of $12.0 million primarily~~2023 and June 30, 2022, Other, net related to ~~cannabis strains and potency levels~~loss on disposal of assets that were ~~no longer in-line with consumer preferences in~~part of the ~~Canadian market and adjustments for obsolete inventory in Canada. The ROW segment reported no such write-down for the three and six months ended June 30, 2022.~~U.S. operations.

~~Gross profit~~ – ~~ROW~~

For the three months ended June 30, ~~2022, the ROW segment reported gross profit of $4.3~~2023, loss from discontinued operations was $2.8 million, ~~representing an increase in gross profit of $20.8 million from~~consistent with the three months ended June 30, ~~2021.~~2022. For the six months ended June 30, ~~2022, the ROW segment reported gross profit of $11.0~~2023, loss from discontinued operations was $4.1 million, representing ~~an increase in gross profit~~a decreased loss of ~~$31.6~~$3.0 million from the six months ended June 30, ~~2021. For both~~2022. In each of the ~~three and six month~~ comparative periods, ~~the change was primarily~~lower gross profit due to ~~the absence of~~increased inventory write-downs in the current periods, increased cannabis flower revenue, the introduction of additional cannabis extract products that carry a higher gross margin than other product categories and lower cannabis biomass costs, partiallywas offset by lower ~~fixed cost absorption due to the timing of wind down activities associated with our exit of the Stayner Facility.~~

~~Summary of select financial results~~ – ~~U.S.~~

Three months ended June 30, Change Six months ended June 30, Change
2022 2021 $ % 2022 2021 $ %
Net revenue $ 1,459 $ 2,227 $ (768) (34) % $ 3,787 $ 4,668 $ (881) (19) %
Cost of sales 1,661 1,583 78 5 % 3,773 2,848 925 32 %
Gross profit (202) 644 (846) (131) % 14 1,820 (1,806) (99) %
Gross margin (14) % 29 % N/A (43) pp — % 39 % N/A (39) pp

~~Net revenue~~ – ~~U.S.~~

For the three months ended June 30, 2022, the U.S. segment reported net revenue of $1.5 million, representing a decrease of $0.8 million from the three months ended June 30, 2021. For the six months ended June 30, 2022, the U.S. segment reported net revenue of $3.8 million, representing a decrease of $0.9 million from the six months ended June 30, 2021. For both the three and six month comparative periods, the decrease was primarilyoperating expenses driven ~~by a reduction in sales as a result of a decrease in promotional spending and SKU rationalization efforts as the Company implements the Realignment with respect to the U.S. segment.~~

~~Cost of sales~~ – ~~U.S.~~

For the three months ended June 30, 2022, the U.S. segment reported cost of sales of $1.7 million, essentially unchanged from the three months ended June 30, 2021. For the six months ended June 30, 2022, the U.S. segment reported cost of sales of $3.8 million, representing an increase of $0.9 million from the six months ended June 30, 2021. For the six month comparative period, the increase was primarily due to higher inventory reserves.

~~Gross profit~~ – ~~U.S.~~

For the three months ended June 30, 2022, the U.S. segment reported negative gross profit of $0.2 million, representing a decrease of $0.8 million from the three months ended June 30, 2021. For the six months ended June 30, 2022, the U.S. segment reported gross profit of $0.01 million, representing a decrease of $1.8 million from the six months ended June 30, 2021. For both the three and six month comparative periods, gross profit was negatively impacted by lower sales ~~volumes~~ and ~~higher inventory reserves.~~

marketing expenses. For more information, see Note 2 “
Discontinued Operations” in our condensed consolidated interim financial statements under Item 1 of this Quarterly Report.

Non-GAAP Measures

Cronos Group reports its financial results in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”). This Quarterly Report refers to measures not recognized under U.S. GAAP (“non-GAAP measures”). These non-GAAP measures do not have a standardized meaning prescribed by U.S. GAAP and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these non-GAAP measures are provided as a supplement to corresponding U.S. GAAP measures to provide additional information regarding the results of operations from management’s perspective. Accordingly, non-GAAP measures should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with U.S. GAAP. All non-GAAP measures presented in this Quarterly Report are reconciled to their closest reported U.S. GAAP measure. Reconciliations of historical adjusted financial measures to corresponding U.S. GAAP measures are provided below.

~~Table of Contents~~

Adjusted EBITDA

Management reviews Adjusted EBITDA, a non-GAAP measure, which excludes non-cash items and items that do not reflect management’s assessment of ongoing business ~~performance of our operating segments.~~performance. Management defines Adjusted EBITDA as net income (loss) before interest, tax expense (benefit), depreciation and amortization adjusted for: share of ~~income (loss)~~(income) loss from equity method investments; impairment loss on goodwill and intangible assets; impairment loss on long-lived assets; (gain) loss on revaluation of derivative liabilities; (gain) loss on revaluation of financial instruments; transaction costs related to strategic projects; impairment loss on other investments; foreign currency transaction loss; other, net; loss from discontinued operations; restructuring costs; share-based compensation; and financial statement review costs and reserves related to the restatements of our 2019 and 2021 interim financial statements (the “Restatements”), including the costs related to ~~our responses to~~ the ~~reviews~~settlement of ~~such interim financial statements by various regulatory authorities~~the SEC’s and the Ontario Securities Commission’s (“OSC”) investigations of the Restatements and legal costs defending shareholder class action complaints brought against us as a result of the 2019 restatement (see Part II, Item 1 “Legal Proceedings” of this Quarterly Report for a discussion of the ~~regulatory reviews and~~ shareholder class action complaints relating to the restatement of the 2019 interim financial statements and the ~~regulatory reviews relating to the restatements~~settlement of the ~~second quarter 2021 interim financial statements)~~SEC’s and the OSC’s investigations of the Restatements). Results are reported as total consolidated results, reflecting our reporting structure of one reportable segment.

Management believes that Adjusted EBITDA provides the most useful insight into underlying business trends and results and provides a more meaningful comparison of period-over-period results. Management uses Adjusted EBITDA for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets.

Adjusted EBITDA is reconciled to net income (loss) as follows:

(In thousands of U.S. dollars) Three months ended June 30, 2022
United States Rest of World Corporate Total
Net loss $ (4,498) $ (8,759) $ (7,081) $ (20,338)
Interest income, net (426) (3,349) — (3,775)
Income tax expense — (308) — (308)
Share of income from equity method investments — (5,197) — (5,197)
Gain on revaluation of derivative liabilities(iii)
— (3,410) — (3,410)
Loss on revaluation of financial instruments(v)
— 2,112 — 2,112
Foreign currency transaction loss — 2,852 — 2,852
Other, net(vii)
— (2) — (2)
Restructuring costs(ix)
292 978 — 1,270
Share-based compensation(x)
473 2,143 — 2,616
Financial statement review costs(xi)
— — 1,154 1,154
Depreciation and amortization 282 3,945 — 4,227
Adjusted EBITDA $ (3,877) $ (8,995) $ (5,927) $ (18,799)

(In thousands of U.S. dollars) Three months ended June 30, 2021
United States Rest of World Corporate Total
Net income (loss) $ (247,847) $ 79,627 $ (11,133) $ (179,353)
Interest income, net (20) (2,273) — (2,293)
Share of loss from equity method investments — 1,115 — 1,115
Impairment loss on goodwill and indefinite-lived intangible assets(i)
234,914 — — 234,914
Impairment loss on long-lived assets(ii)
1,214 — — 1,214
Gain on revaluation of derivative liabilities(iii)
— (115,248) — (115,248)
Transaction costs(iv)
— — 2,758 2,758
Gain on revaluation of financial instruments(v)
— (77) — (77)
Other, net(vii)
— (1,050) — (1,050)
Loss from discontinued operations(viii)
— 561 — 561
Share-based compensation(x)
822 1,743 — 2,565
Financial statement review costs(xi)
— — 1,932 1,932
Depreciation and amortization 206 2,997 — 3,203
Adjusted EBITDA $ (10,711) $ (32,605) $ (6,443) $ (49,759)

3936

Table of Contents

(In thousands of U.S. dollars) Six months ended June 30, 2022
United States Rest of World Corporate Total
Net loss $ (26,714) $ (6,745) $ (19,532) $ (52,991)
Interest income, net (455) (5,366) — (5,821)
Income tax expense — 54 — 54
Share of income from equity method investments — (5,197) — (5,197)
Impairment loss on long-lived assets(ii)
— 3,493 — 3,493
Gain on revaluation of derivative liabilities(iii)
— (13,829) — (13,829)
Gain on revaluation of financial instruments(v)
— (2,156) — (2,156)
Impairment loss on other investment(vi)
11,238 — — 11,238
Foreign currency transaction loss — 4,724 — 4,724
Other, net(vii)
— (137) — (137)
Restructuring costs(ix)
1,345 3,009 — 4,354
Share-based compensation(x)
2,909 3,393 — 6,302
Financial statement review costs(xi)
— — 5,216 5,216
Depreciation and amortization 714 6,337 — 7,051
Adjusted EBITDA $ (10,963) $ (12,420) $ (14,316) $ (37,699)


	Three months ended June 30, 2023
	Continuing Operations		Discontinued Operations		Total
Net loss	$	(5,663)	$	(2,834)	$	(8,497)
Interest income, net	(12,471)		(3)		(12,474)
Income tax benefit	(180)		—		(180)
Depreciation and amortization	2,265		115		2,380
EBITDA	(16,049)		(2,722)		(18,771)
Share of income from equity method investments	(270)		—		(270)
Impairment loss on long-lived assets(i)	—		205		205
Gain on revaluation of derivative liabilities(ii)	(43)		—		(43)
Gain on revaluation of financial instruments(iii)	(5,193)		—		(5,193)
Foreign currency transaction loss	3,174		—		3,174
Other, net(v)	26		163		189
Restructuring costs(vi)	—		534		534
Share-based compensation(vii)	2,331		5		2,336
Financial statement review costs(viii)	119		—		119
Inventory write-down(ix)	—		839		839
Adjusted EBITDA	$	(15,905)	$	(976)	$	(16,881)

(In thousands of U.S. dollars) Six months ended June 30, 2021
United States Rest of World Corporate Total
Net loss $ (259,939) $ (62,520) $ (18,519) $ (340,978)
Interest income, net (23) (4,599) — (4,622)
Share of loss from equity method investments — 2,758 — 2,758
Impairment loss on goodwill and indefinite-lived intangible assets(i)
234,914 — — 234,914
Impairment loss on long-lived assets(ii)
2,955 — — 2,955
Loss on revaluation of derivative liabilities(iii)
— 1,626 — 1,626
Transaction costs(iv)
— — 3,259 3,259
Loss on revaluation of financial instruments(v)
— 123 — 123
Other, net(vii)
— (1,034) — (1,034)
Loss from discontinued operations(viii)
— 582 — 582
Share-based compensation(x)
1,567 3,497 — 5,064
Financial statement review costs(xi)
— — 3,937 3,937
Depreciation and amortization 305 4,778 — 5,083
Adjusted EBITDA $ (20,221) $ (54,789) $ (11,323) $ (86,333)


	Three months ended June 30, 2022
	Continuing Operations		Discontinued Operations		Total
Net loss	$	(17,527)	$	(2,811)	$	(20,338)
Interest income, net	(3,775)		—		(3,775)
Income tax benefit	(308)		—		(308)
Depreciation and amortization	3,944		283		4,227
EBITDA	(17,666)		(2,528)		(20,194)
Share of income from equity method investments	(5,197)		—		(5,197)
Gain on revaluation of derivative liabilities(ii)	(3,410)		—		(3,410)
Loss on revaluation of financial instruments(iii)	2,112		—		2,112
Foreign currency transaction loss	2,852		—		2,852
Other, net(v)	(49)		47		(2)
Restructuring costs(vi)	978		292		1,270
Share-based compensation(vii)	2,583		33		2,616
Financial statement review costs(viii)	1,154		—		1,154
Adjusted EBITDA	$	(16,643)	$	(2,156)	$	(18,799)

Table of Contents


	Six months ended June 30, 2023
	Continuing Operations		Discontinued Operations		Total
Net loss	$	(23,698)	$	(4,056)	$	(27,754)
Interest income, net	(23,646)		(8)		(23,654)
Income tax benefit	(1,616)		—		(1,616)
Depreciation and amortization	4,541		244		4,785
EBITDA	(44,419)		(3,820)		(48,239)
Share of loss from equity method investments	226		—		226
Impairment loss on long-lived assets(i)	—		205		205
Loss on revaluation of derivative liabilities(ii)	22		—		22
Loss on revaluation of financial instruments(iii)	2,565		—		2,565

Foreign currency transaction loss	4,817		—		4,817
Other, net(v)	(59)		163		104
Restructuring costs(vi)	—		534		534
Share-based compensation(vii)	4,866		21		4,887
Financial statement review costs(viii)	395		—		395
Inventory write-down(ix)	—		839		839
Adjusted EBITDA	$	(31,587)	$	(2,058)	$	(33,645)


	Six months ended June 30, 2022
	Continuing Operations		Discontinued Operations		Total
Net loss	$	(45,892)	$	(7,099)	$	(52,991)
Interest income, net	(5,820)		(1)		(5,821)
Income tax benefit	54		—		54
Depreciation and amortization	7,051		715		7,766
EBITDA	(44,607)		(6,385)		(50,992)
Share of income from equity method investments	(5,197)		—		(5,197)
Impairment loss on long-lived assets(i)	3,493		—		3,493
Gain on revaluation of derivative liabilities(ii)	(13,829)		—		(13,829)
Gain on revaluation of financial instruments(iii)	(2,156)		—		(2,156)
Impairment loss on other investments(iv)	11,238		—		11,238
Foreign currency transaction loss	4,724		—		4,724
Other, net(v)	(184)		47		(137)
Restructuring costs(vi)	3,009		1,345		4,354
Share-based compensation(vii)	6,199		103		6,302
Financial statement review costs(viii)	5,216		—		5,216
Adjusted EBITDA	$	(32,094)	$	(4,890)	$	(36,984)

(i)For the three and six months ended June 30, ~~2021,~~2023, impairment loss on ~~goodwill and indefinite-lived intangible assets relates to impairment on goodwill and indefinite-lived intangible~~long-lived assets related to certain leased properties associated with the Company’s U.S. ~~segment.~~

~~(ii)~~operations. For the six months ended June 30, 2022, impairment loss on long-lived assets related to the Company’s decision to seek a sublease for leased office space in Toronto, Ontario, Canada during the first quarter of 2022. For the three months ended June 30, 2021, impairment loss on long-lived assets relates to an impairment on property, plant and equipment in the U.S. segment. For the six months ended June 30, 2021, impairment loss on long-lived assets relates to the aforementioned impairment loss on property, plant and equipment as well as an impairment loss on leased premises in the U.S. segment from the first quarter of 2021. See Note 1312 “Impairment Loss on Long-lived ~~Assets~~Assets.” ~~to the condensed consolidated interim financial statements under Item 1 of this Quarterly Report.~~

~~(iii)~~(ii)For the three and six months ended June 30, ~~2022~~2023 and ~~2021,~~2022, (gain) loss on revaluation of derivative liabilities represents the fair value changes on the derivative liabilities. See Note 6 “Derivative ~~Liabilities~~Liabilities.” ~~to the condensed consolidated interim financial statements under Item 1 of this Quarterly Report.~~

~~(iv)~~(iii)For the three and six months ended June 30, ~~2021, transaction costs represent legal, financial~~2023 and other advisory fees and expenses incurred in connection with various strategic investments. These costs are included in general and administrative expenses on the condensed consolidated statements of net loss and comprehensive loss.

~~(v)For the three and six months ended June 30,~~ 2022, (gain) loss on revaluation of financial instruments related primarily to the Company’s equity securities in ~~Cronos Australia. See Note 3 “Investments~~” to the condensed consolidated interim financial statements under Item 1 of this Quarterly Report. For three and six months ended June 30, 2021, (gain) loss on revaluation of financial instruments related primarily to revaluations of financial liabilities resulting from DSUs.Vitura.

~~(vi)~~(iv)For the six months ended June 30, 2022, impairment loss on other investments related to the PharmaCann Option for the difference between its fair value and carrying amount. See Note 34 “~~Investments~~Investments.” ~~to the condensed consolidated interim financial statements under Item 1 of this Quarterly Report.~~

~~(vii)~~(v)For the three and six months ended June 30, 2023 and 2022, other, net related to (gain) loss on disposal of assets. ~~For the three and six months ended June 30, 2021, other, net primarily related to the gain recorded on sale~~

Table of ~~our Winnipeg facility previously designated as held-for-sale in the first quarter of 2021.~~Contents

~~(viii)~~(vi)For the three and six months ended June 30, ~~2021, loss from discontinued operations~~2023, restructuring costs related to ~~the discontinuance of OGBC.~~

~~Table of Contents~~

~~(ix)~~employee-related severance costs and other restructuring costs associated with our U.S. operations as described in Note 2 “Discontinued Operations.” For the three and six months ended June 30, 2022, restructuring costs related to the employee-related severance costs and other restructuring costs associated with the Realignment, including the ~~planned exit~~change in nature of operations at the ~~Stayner Facility.~~Peace Naturals Campus. See Note 7 “~~Restructuring~~Restructuring.” ~~to the condensed consolidated interim financial statements under Item 1 of this Quarterly Report.~~

~~(x)~~(vii)For the three and six months ended June 30, ~~2022~~2023 and ~~2021,~~2022, share-based compensation related to the ~~vesting~~non-cash expenses of share-based compensation awarded to employees under the Company’s share-based award plans as described in Note 8 “Share-based ~~Compensation~~Compensation.” ~~to the condensed consolidated financial statements under Item 1 of this Quarterly Report.~~

~~(xi)~~(viii)For the three and six months ended June 30, ~~2022~~2023 and ~~2021,~~2022, financial statement review costs include costs and reserves taken related to the ~~restatements of the Company’s 2019 and second quarter 2021 interim financial statements,~~Restatements, costs related to the Company’s responses to requests for information from various regulatory authorities relating to ~~such restatements~~the Restatements and legal costs incurred defending shareholder class action complaints brought against the Company as a result of the 2019 restatement.

(ix)For the three and six months ended June 30, 2023, inventory write-downs relate to product destruction and obsolescence associated with the exit of our U.S. operations as described in Note 2 “Discontinued Operations.”

Constant Currency

To supplement the consolidated financial statements presented in accordance with U.S. GAAP, we have presented constant currency adjusted financial measures for net revenues, gross profit, gross profit margin, operating expenses, net income (loss) and Adjusted EBITDA for the three and six months ended June 30, 2023, as well as cash and cash equivalents and short-term investment balances as of June 30, 2023 compared to December 31, 2022, which are considered non-GAAP financial measures. We present constant currency information to provide a framework for assessing how our underlying operations performed excluding the effect of foreign currency rate fluctuations. To present this information, current and comparative prior period income statement results in currencies other than U.S. dollars are converted into U.S. dollars using the average exchange rates from the three and six month comparative periods in 2022 rather than the actual average exchange rates in effect during the respective current periods; constant currency current and prior comparative balance sheet information is translated at the prior year-end spot rate rather than the current period spot rate. All growth comparisons relate to the corresponding period in 2022. We have provided this non-GAAP financial information to aid investors in better understanding the performance of our operations. The non-GAAP financial measures presented in this Quarterly Report should not be considered as a substitute for, or superior to, the measures of financial performance prepared in accordance with U.S. GAAP.

Table of Contents

The table below sets forth certain measures of consolidated results from continuing operations on a constant currency basis for the three and six months ended June 30, 2023 compared to the three and six months ended June 30, 2022 as well as cash and cash equivalents and short-term investments as of June 30, 2023 and December 31, 2022, both on an as-reported and constant currency basis (in thousands):


	As Reported										As Adjusted for Constant Currency
	Three months ended June 30,						As Reported Change				Three months ended June 30,			Constant Currency Change
	2023			2022			$		%		2023			$		%
Net revenue	$	19,021		$	21,602		$	(2,581)	(12)	%	$	20,219		$	(1,383)	(6)	%
Gross profit	3,099			4,322			(1,223)		(28)	%	3,322			(1,000)		(23)	%
Gross margin	16		%	20		%	N/A		(4)	pp	16		%	N/A		(4)	pp

Operating expenses	23,719			29,624			$	(5,905)	(20)	%	25,216			(4,408)		(15)	%
Net loss	(5,663)			(17,527)			11,864		68	%	(6,716)			10,811		62	%
Adjusted EBITDA	(15,905)			(16,643)			738		4	%	(16,968)			(325)		(2)	%

	Six months ended June 30,						As Reported Change				Six months ended June 30,			Constant Currency Change
	2023			2022			$		%		2023			$		%
Net revenue	$	38,516		$	44,307		$	(5,791)	(13)	%	41,223			$	(3,084)	(7)	%
Gross profit	6,026			11,032			(5,006)		(45)	%	6,520			(4,512)		(41)	%
Gross margin	16		%	25		%	N/A		(9)	pp	16		%	N/A		(9)	pp

Operating expenses	47,415			68,094			$	(20,679)	(30)	%	50,571			(17,523)		(26)	%
Net loss	(23,698)			(45,892)			22,194		48	%	(25,738)			20,154		44	%
Adjusted EBITDA	(31,587)			(32,094)			507		2	%	(33,883)			(1,789)		(6)	%

	As of June 30,			As of December 31,			As Reported Change				Six months ended June 30,			Constant Currency Change
	2023			2022			$		%		2023			$		%
Cash and cash equivalents	$	409,428		$	764,644		$	(355,216)	(46)	%	$	407,775		$	(356,869)	(47)	%
Short-term investments	431,510			113,077			318,433		282	%	421,577			308,500		273	%
Total cash and cash equivalents and short-term investments	$	840,938		$	877,721		$	(36,783)	(4)	%	$	829,352		$	(48,369)	(6)	%

Table of Contents

Net revenue


	As Reported								As Adjusted for Constant Currency
	Three months ended June 30,				As Reported Change				Three months ended June 30,		Constant Currency Change
	2023		2022		$		%		2023		$		%
Cannabis flower	$	14,014	$	15,739	$	(1,725)	(11)	%	$	14,955	$	(784)	(5)	%
Cannabis extracts	4,926		5,582		(656)		(12)	%	5,178		(404)		(7)	%
Other	81		281		(200)		(71)	%	86		(195)		(69)	%
Net revenue	$	19,021	$	21,602	$	(2,581)	(12)	%	$	20,219	$	(1,383)	(6)	%


	As Reported								As Adjusted for Constant Currency
	Six months ended June 30,				As Reported Change				Six months ended June 30,		Constant Currency Change
	2023		2022		$		%		2023		$		%
Cannabis flower	$	27,142	$	34,364	$	(7,222)	(21)	%	$	29,158	$	(5,206)	(15)	%
Cannabis extracts	11,227		9,570		1,657		17	%	11,909		2,339		24	%
Other	147		373		(226)		(61)	%	156		(217)		(58)	%
Net revenue	$	38,516	$	44,307	$	(5,791)	(13)	%	$	41,223	$	(3,084)	(7)	%


	As Reported								As Adjusted for Constant Currency
	Three months ended June 30,				As Reported Change				Three months ended June 30,		Constant Currency Change
	2023		2022		$		%		2023		$		%
Canada	$	13,595	$	14,389	$	(794)	(6)	%	$	14,293	$	(96)	(1)	%
Israel	5,426		7,213		(1,787)		(25)	%	5,926		(1,287)		(18)	%


Net revenue	$	19,021	$	21,602	$	(2,581)	(12)	%	$	20,219	$	(1,383)	(6)	%


	As Reported								As Adjusted for Constant Currency
	Six months ended June 30,				As Reported Change				Six months ended June 30,		Constant Currency Change
	2023		2022		$		%		2023		$		%
Canada	$	28,029	$	27,965	$	64	—	%	$	29,701	$	1,736	6	%
Israel	10,487		16,342		(5,855)		(36)	%	11,522		(4,820)		(29)	%


Net revenue	$	38,516	$	44,307	$	(5,791)	(13)	%	$	41,223	$	(3,084)	(7)	%

For the three months ended June 30, 2023, net revenue on a constant currency basis was $20.2 million, representing a 6% decrease from the three months ended June 30, 2022. For the six months ended June 30, 2023, net revenue on a constant currency basis was $41.2 million, representing a 7% decrease from the six months ended June 30, 2022. On a constant currency basis, net revenue decreased for the three and six months ended June 30, 2023 primarily due to lower cannabis flower sales in Israel due to competitive activity, the slowdown in patient permit authorizations and geopolitical unrest, and an adverse price/mix in Canada in the cannabis flower category driving increased excise tax payments as a percentage of revenue.

Gross profit

For the three months ended June 30, 2023, gross profit on a constant currency basis was $3.3 million, representing a 23% decrease from the three months ended June 30, 2022. For the six months ended June 30, 2023, gross profit on a constant currency basis was $6.5 million, representing a 41% decrease from the six months ended June 30, 2022. On a constant currency basis, gross profit decreased for the three and six months ended June 30, 2023 primarily due to lower cannabis flower sales in the Israeli medical market and adverse price/mix on cannabis flower sales in Canada resulting in higher excise taxes as a percentage of revenue.

Table of Contents

Operating expenses

For the three months ended June 30, 2023, operating expenses on a constant currency basis were $25.2 million, representing a 15% decrease from the three months ended June 30, 2022. For the six months ended June 30, 2023, operating expenses on a constant currency basis were $50.6 million, representing a 26% decrease from the six months ended June 30, 2022. On a constant currency basis, operating expenses decreased for the three and six months ended June 30, 2023, primarily due to lower professional fees, largely related to financial statement review costs, lower bonus expense, lower insurance costs, lower costs associated with the achievement of Ginkgo milestones and impairment loss on long-lived assets recognized in the prior year.

Net loss

For the three months ended June 30, 2023, net loss on a constant currency basis was $6.7 million, representing a 62% reduction in net loss from the three months ended June 30, 2022. For the six months ended June 30, 2023, net loss on a constant currency basis was $25.7 million, representing a 44% reduction in net loss from the six months ended June 30, 2022.

Adjusted EBITDA

For the three months ended June 30, 2023, Adjusted EBITDA on a constant currency basis was $(17.0) million, representing a 2% decrease from the three months ended June 30, 2022. For the six months ended June 30, 2023, Adjusted EBITDA on a constant currency basis was $(33.9) million, representing a 6% decrease from the six months ended June 30, 2022. The decrease in Adjusted EBITDA for the three and six months ended June 30, 2023 on a constant currency basis was primarily driven by lower cannabis flower sales in the Israeli medical market and adverse price/mix on cannabis flower sales in Canada resulting in higher excise taxes as a percentage of revenue, partially offset by decreases in general and administrative expenses due primarily to lower bonus expense, insurance costs and professional fees as well as lower costs associated with the achievement of Ginkgo milestones.

Cash and cash equivalents & short-term investments

Cash and cash equivalents and short-term investments on a constant currency basis decreased 6% to $829.4 million as of June 30, 2023 from $877.7 million as of December 31, 2022. The decrease in cash and cash equivalents and short-term investments is primarily due to cash flows used in operating activities in the six months ended June 30, 2023.

Liquidity and Capital Resources

As of June 30, ~~2022,~~2023, we had ~~$789.5~~$409.4 million in cash and cash equivalents and ~~$155.4~~$431.5 million in short-term ~~investments, which comprise the majority of the Company’s cash position.~~investments. We believe that the existing cash and cash equivalents and ~~the~~ short-term investments will be sufficient to fund the business operations and capital expenditures over the next twelve months. The following table summarizes the cash flows from operating, investing and financing activities:


(In thousands of U.S. dollars)	(In thousands of U.S. dollars)	Six months ended June 30,				(In thousands of U.S. dollars)	Six months ended June 30, 2023
		2022		2021			2023		2022
Cash flows used in operating activities	Cash flows used in operating activities	$	(51,191)	$	(86,197)	Cash flows used in operating activities	$	(59,467)	$	(51,191)
Cash flows used in investing activities	Cash flows used in investing activities	(40,321)		(106,563)		Cash flows used in investing activities	(298,964)		(40,321)
Cash flows used in financing activities	Cash flows used in financing activities	(2,034)		(8,907)		Cash flows used in financing activities	(782)		(2,034)
Effect of foreign currency translation on cash and cash equivalents	Effect of foreign currency translation on cash and cash equivalents	(3,884)		18,825		Effect of foreign currency translation on cash and cash equivalents	3,997		(3,884)
Net change in cash	Net change in cash	$	(97,430)	$	(182,842)	Net change in cash	$	(355,216)	$	(97,430)

Comparison of cash flows between the six months ended June 30, ~~2022~~2023 and the six months ended June 30, ~~2021~~2022

Operating activities

During the six months ended June 30, ~~2022,~~2023, we used ~~$51.2~~$59.5 million of cash in operating activities as compared to cash used of ~~$86.2~~$51.2 million in the six months ended June 30, ~~2021,~~2022, representing ~~a decrease~~an increase in cash used of ~~$35.0~~$8.3 million. This change is primarily driven by a ~~$46.0~~$32.8 million decrease in income taxes payable as a result of a tax payment connected to the previously disclosed relinquishment by Altria of its warrant to purchase additional shares of the Company and a $6.8 million increase in interest receivable, partially offset by a $28.6 million increase in net income after adjusting for non-cash items during the six months ended June 30, ~~2022~~2023 compared to the six months ended June 30, ~~2021.~~2022.

Investing activities

During the six months ended June 30, ~~2022,~~2023, we used ~~$40.3~~$299.0 million of cash in investing activities, compared to ~~$106.6~~$40.3 million of cash used in investing activities during the six months ended June 30, ~~2021,~~2022, representing ~~a decrease~~an increase of ~~$66.2~~$258.6 million in cash used by investing activities. This change is primarily driven by ~~the purchase~~purchases of ~~the PharmaCann option during~~short-term investments in the six months ended June 30, ~~2021, lower purchases~~2023.

Table of ~~property, plant and equipment and a decrease in disbursements related to loans receivable with related parties, partially offset by higher levels of short-term investments.~~Contents

Financing activities

During the six months ended June 30, ~~2022,~~2023, cash used in financing activities was ~~$2.0~~$0.8 million, compared to ~~$8.9~~$2.0 million of cash used in financing activities during ~~the~~ six months ended June 30, ~~2021,~~2022, representing a decrease of ~~$6.9~~$1.3 million in cash used in financing activities. This change is primarily driven by a decrease of ~~$6.8~~$1.3 million in withholding taxes paid on share-based awards during ~~the~~ six months ended June 30, ~~2022~~2023 compared to ~~the~~ six months ended June 30, ~~2021.~~2022.

Cash Requirements

The Company’s cash requirements have not changed significantly since the filing of the Annual Report.

Critical Accounting Policies and Estimates

Our critical accounting policies and estimates are discussed in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report. Our critical accounting policies and estimates have not changed significantly since the filing of the Annual Report.

~~Table of Contents~~

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

The Company is exposed to certain market risks, including changes from foreign currency exchange rates related to our international operations. ~~The~~Except as updated below, the Company’s market risks have not changed significantly from ~~that~~the market risk disclosed in Item 7A, “Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report.

Foreign currency risk

The Company’s condensed consolidated financial statements included in Part I, Item 1. “Financial Statements” of this Quarterly Report are expressed in U.S. dollars. The Company is exposed to foreign currency risk based on its net assets, liabilities, and revenues denominated in foreign currencies, including Canadian dollars and Israeli new shekels. As a result, we are exposed to foreign currency translation gains and losses. Revenue and expenses of all foreign operations are translated into U.S. dollars at the foreign currency exchange rates that approximate the rates in effect during the period when such items are recognized. Appreciating foreign currencies relative to the U.S. dollar will positively impact operating income and net earnings, while depreciating foreign currencies relative to the U.S. dollar will have an adverse impact.

A 10% change in the exchange rates for the Canadian dollar would have affected the carrying amount of the net assets by approximately $76.9 million and $77.4 million as of June 30, 2023 and December 31, 2022, respectively. The corresponding impact would be recorded in accumulated other comprehensive income. We have not historically engaged in hedging transactions and do not currently contemplate engaging in hedging transactions to mitigate foreign exchange risks. As we continue to recognize gains and losses in foreign currency transactions, depending upon changes in future currency rates, such gains and losses could have a significant, and potentially adverse, effect on the Company’s results of operations.

During the three and six months ended June 30, 2023, the Company had foreign currency gain on translation of $16.6 million and $19.0 million, respectively. During the three and six months ended June 30, 2022 the Company had foreign currency loss on translation of $24.2 million and $8.2 million, respectively.

Table of Contents

Item 4. Controls and Procedures.

(a)Evaluation of Disclosure Controls and Procedures.

The Company’s management, with the participation of the Chief Executive Officer and the Chief Financial Officer, performed an evaluation of the disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”), as of June 30, ~~2022.~~2023. Based on that evaluation, management has concluded that, as of June 30, ~~2022,~~2023, due to the existence of a material ~~weaknesses~~weakness in the Company’s internal control over financial reporting described below, the disclosure controls and procedures were not effective to provide reasonable assurance that the information required to be disclosed by us in reports we file or submit under the Exchange Act were recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and to ensure that the information required to be disclosed by us in reports that we file or submit under the Exchange Act, is accumulated and communicated to management, including the principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Material Weakness in Internal Controls Over Financial Reporting

A material weakness is a deficiency, or combination of deficiencies in internal ~~controls~~control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. As previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2021~~2022 (the “Annual Report”), we have identified the following material ~~weaknesses:~~weakness:

•~~Control Environment~~ITGCs - User Access:

We did not maintain an effective control environment. Specifically, our control environment (i) did not ensure that senior personnel in our accounting function engaged consistently in appropriate professional conduct and conduct consistent with our Code of Business Conduct and Ethics; and (ii) lacked personnel in our accounting function with appropriate level of knowledge and experience in U.S. GAAP sufficient to properly assess evidence and interpret accounting rules.

None of the personnel in the accounting function that engaged in misconduct were current or former executive officers of the Company. The control environment material weakness contributed to the goodwill and indefinite-lived intangible asset material weakness described below.

•~~Goodwill and Indefinite-lived Intangible Asset Impairment Testing~~:

~~We identified the following material weakness with respect to goodwill and indefinite-lived intangible asset impairment testing.~~ We did not design and maintain effective controls over Information Technology General Controls (“ITGC”), pertaining to ~~assess goodwill~~user access management and ~~indefinite-lived intangible assets for potential impairment as changes in~~ the ~~performance~~provisioning and monitoring of user access, including privileged access. We believe this weakness to be the result of ineffective monitoring of security administrator activities, insufficient retention of documentation to support access requests and ~~prospects for our U.S. reporting unit occurred. Specifically, we~~lack of training on the importance of ITGC. This material weakness did not ~~design~~impact any information derived from information systems and ~~maintain effective controls~~did not result in any identified misstatements to ~~sufficiently assess the overall~~our financial performance of and expectations for our U.S. reporting unit and certain macroeconomic, industry and market conditions when evaluating goodwill associated with our U.S. reporting unit and our Lord Jones® ~~brand indefinite-lived intangible asset for potential impairment.~~

The material weakness in the control environment contributed to material misstatements related to the impairment of goodwill and indefinite-lived intangible assets that led to the restatement of the Company’s condensed consolidated interim financial statements for the three and six months ended June 30, 2021. The material weaknesses create a reasonable possibility that a material misstatement to the consolidated financial statements would not be prevented or detected on a timely basis. The lack of personnel in our accounting function with appropriate level of knowledge and experience in U.S. GAAP sufficient to properly assess evidence and interpret accounting principles described above resulted in immaterial misstatements related to the accounting for derivatives, share-based compensation, earnings per share, and long-lived asset impairment.

~~Table of Contents~~

statements.

Remediation Plan and Status

As discussed above, we have identified a material weakness related to ITGCs in user access management and the provisioning and monitoring of privileged access. As of the filing date, the Company ~~has implemented or~~ is in the process of implementing various initiatives intended to address the identified material ~~weaknesses and strengthen our overall control environment.~~weakness. In this regard, some of our key remedial initiatives include:

Material Weakness

Control, Control Enhancement or Mitigant

Implementation Status

Management Testing Status

Remediation Status

~~Control Environment~~ITGCs

•~~The Company’s Chief Executive Officer~~Train security administrators on access provisioning and Chief Financial Officer have reinforced and will continue to reinforce on an ongoing basis the importance of adherence to the Company’s policies, procedures and standards of conduct, including identifying misconduct and raising and communicating concerns;approval protocols.

~~In Progress~~Completed

~~In Progress~~Tested

Not Remediated

•~~All accounting personnel that engaged in unprofessional conduct have been terminated~~Align approval requirements for all privileged access for consistency and appropriate visibility within the IT function.

Completed

Tested

Not Remediated

•Implement a process to identify instances where privileged access roles or ~~resigned from~~profiles are assigned and, when identified, review activities performed during the ~~Company and are in the process~~period of ~~being replaced with qualified personnel;~~assigned privileged access.

Completed

In Progress

Not Remediated

•~~We have enhanced our existing sub-certification process~~Implement a periodic control to ~~include additional certifications regarding certain complex accounting topics and~~compare each user’s system access to ~~include additional employees to increase accountability amongst Company personnel;~~their responsibilities.

Completed

In Progress

Not Remediated

•~~We have expanded our compensation claw back provisions to incorporate all personnel who are subject to our enhanced sub-certification process;~~Implement an oversight control over security administrator actions.

~~Completed~~

In Progress

Not ~~Remediated~~

•We have identified and are in the process of implementing organizational enhancements including (i) evaluating the sufficiency, experience and training of personnel within our accounting function and (ii) hiring accounting personnel with appropriate knowledge and experience in U.S. GAAP;

~~In Progress~~

~~Not Remediated~~

•We are in the process of developing and implementing a training program for accounting and finance personnel to enhance their knowledge of U.S. GAAP outlined in our accounting policies, which are used in the preparation of the Company’s consolidated financial statements; and

~~In Progress~~

~~Not Remediated~~

~~Asset Impairment Testing~~

•We have evaluated and will continue to regularly evaluate our policies and procedures relating to certain complex accounting topics and have begun implementing improvements in those policies and procedures.

~~In Progress~~

~~In Progress~~Tested

Not Remediated

~~The Company will continue to review, optimize, and enhance its financial reporting controls and procedures. As the Company~~ continues to evaluate and work to improve its internal control over financial reporting, the Company may implement additional measures to address the material weaknesses or certain of the remediation measures described above may be enhanced or modified. The material weaknesses will not be considered remediated until the applicable remediated controls operate for a sufficient period of time and management has concluded, through further testing, that these controls are operating effectively.

(b)Changes in Internal Control over Financial Reporting

Other than ~~those~~the material ~~weaknesses~~weakness identified above and measures described above to remediate ~~the~~such material ~~weaknesses identified in the prior year,~~weakness, there were no changes in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act), that occurred during the quarter ended June 30, ~~2022,~~2023, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Table of Contents

PART II
OTHER INFORMATION

Item 1: Legal Proceedings.

The information set forth under ~~Note~~ 11(b), Contingencies, to the Company’s condensed consolidated interim financial statements included in Part I, Item 1. “Financial Statements” of this Quarterly Report is incorporated herein by reference.

Item 1A: Risk Factors.

An investment in us involves a number of risks. A detailed discussion of our risk factors appears in Part I, Item 1A. Risk Factors of the Annual Report. Any of the matters highlighted in the risk factors described in the Annual Report ~~and the risk factors below~~ could adversely affect our business, results of operations and financial condition, causing an investor to lose all, or part of, its, his or her investment. The risks and uncertainties described in the Annual Report ~~and below~~ are those we currently believe to be material, but they are not the only ones we face. If any of the risks described in the Annual Report, ~~the following risk factors,~~ or any other risks and uncertainties that we have not yet identified or that we currently consider not to be material, actually occur or become material risks, our business, prospects, financial condition, results of operations and cash flows and consequently the price of our securities could be materially and adversely affected.

~~Our business, financial condition, results of operations and cash flows could be adversely affected by disruptions in the global economy caused by the ongoing conflict between Russia and Ukraine.~~

The global economy has been negatively impacted by the military conflict between Russia and Ukraine. Furthermore, governments in the U.S., Canada, United Kingdom, and European Union have each imposed export controls on certain products and financial and economic sanctions on certain industry sectors and parties in Russia. Although we do not have any customers or direct supplier relationships in Russia or Ukraine, businesses in the United States and globally have experienced shortages in materials and increased costs for transportation, energy, and raw material due in part to the negative impact of the Russia-Ukraine military conflict on the global economy. Further escalation of geopolitical tensions related to the military conflict, including increased trade barriers or restrictions on global trade, could result in, among other things, cyberattacks, supply disruptions, lower consumer demand, and changes to foreign exchange rates and financial markets, any of which may adversely affect our business, financial condition, results of operations and cash flows.

We are continuing to monitor the situation in Ukraine and globally and assessing its potential impact on our business. Although our business has not been, to the date of this Quarterly Report, materially impacted by the ongoing military conflict in Ukraine, it is impossible to predict the extent to which our operations, or those of our suppliers and vendors, will be impacted in the short and long term, or the ways in which the conflict may impact our business. The extent and duration of the military action, sanctions and resulting market disruptions are impossible to predict, but may be substantial. In addition, the effects of the ongoing conflict could heighten any of our known risks described in our Annual Report.

There can be no assurance of continued growth in Israel and our performance in Israel depends on, among other things, our ability to continue to import cannabis into Israel and our joint venture partners.

While our revenue in Israel has experienced a recent period of significant growth, our prior performance is not indicative of any potential future results in Israel. There can be no assurance that our recent growth in the Israeli market can be sustained or will continue. Our ability to manage and sustain revenue growth in Israel will depend on a number of factors, many of which are beyond our control, including, but not limited to, our ability to continue to import cannabis into Israel, changes in laws and regulations respecting the cultivation, production and marketing of dried flower, pre-rolls and oils in Israel, increased competition, our ability to produce sufficient volumes of our products to meet customer demand and our ability to maintain or grow our market share in Israel. Any of these factors could materially and negatively impact our growth in Israel.

In connection with the Realignment, we have begun to further leverage our strategic joint venture with Cronos GrowCo. Our current efforts to wind-down and ultimately exit the Stayner Facility has increased the importance of Cronos GrowCo to our business and operations. Once the Stayner Facility is closed, Cronos GrowCo’s production facilities will be our principal source of raw materials. Therefore, our performance in Israel is reliant on our ability to acquire such raw materials on a timely and cost-effective basis from Cronos GrowCo and to continue to import such raw materials and cannabis products to Israel from Cronos GrowCo. There is no guarantee that we will be able to successfully execute our strategy to expand production at Cronos GrowCo or that we will be able to obtain the regulatory approvals, licenses and permits required for both the export of cannabis from Canada and the import of cannabis into Israel. See “ ~~–We may not successfully execute our production capacity strategy” included under Part I, Item 1A “Risk Factors” of the Annual Report.~~

Additionally, our performance in Israel depends on the results of Cronos Israel, which holds the certificates and corresponding permits required for the cultivation, production and marketing of cannabis in Israel and is responsible for distributing PEACE NATURALS®

~~Table of Contents~~

branded cannabis products to the Israeli medical cannabis market. Cronos Israel is a strategic joint venture operating in a foreign country and is therefore subject to the all the risks normally associated with an investment in a joint venture and the conduct of business in a foreign country, any of which could materially and negatively impact the performance of Cronos Israel. See “~~– Our use of joint ventures may expose us to risks associated with jointly owned investments” and “~~– Investments and joint ventures outside of Canada and the U.S. are subject to the risks normally associated with any conduct of business in foreign countries, including varying degrees of political, legal, regulatory and economic risk~~” included under Part I, Item 1A “Risk Factors” of the Annual Report for a discussion of the risks relating to joint ventures and foreign investments.~~

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

~~None.~~Rule 10b5-1 Trading Plans

Securities Trading Plans of Directors and Executive Officers

During the three months ended June 30, 2023, no directors or executive officers entered into, modified or terminated, contracts, instructions or written plans for the sale or purchase of the Company’s securities that were intended to satisfy the affirmative defense conditions of Rule 10b5-1.

Certain of our officers or directors have made, and may from time to time make, elections to have shares withheld to cover withholding taxes or pay the exercise price of options, which may be designed to satisfy the affirmative defense conditions of Rule 10b5-1 under the Exchange Act or may constitute non-Rule 10b5–1 trading arrangements (as defined in Item 408(c) of Regulation S-K).

Item 2.05 Costs Associated with Exit or Disposal Activities.

On August 4, 2023, the Company’s Board of Directors (the “Board”) approved plans to wind-down operations at its Winnipeg, Manitoba facility (“Cronos Fermentation”), and list the Cronos Fermentation facility for sale. The Company expects to incur approximately $1.2 million in restructuring costs associated with the exit of Cronos Fermentation facility. These charges include employee-related costs such as severance, relocation and other termination benefits, as well as contract termination and other related costs, which are expected to be incurred primarily in the second half of 2023, but do not include any impairment charges to property, plant or equipment. These anticipated charges are subject to a number of assumptions, including the ability to wind down Cronos Fermentation efficiently and effectively, the length of the sales process, the bids received in the sale process, market factors and others. As a result of these assumptions, actual results may differ materially. The Company cannot, at this time, quantify the impairment charges, if any, to long-lived assets associated with the wind-down of Cronos Fermentation.

Also on August 4, 2023, the Board approved additional organization-wide cost reductions. Expected restructuring costs of approximately $2.0 million, with the majority expected to be incurred in the second half of 2023, include mostly one-time employee-related severance charges. These anticipated costs are subject to a number of assumptions, including the ability of the Company to

Table of Contents

effectively and efficiently further streamline operations, the number of employee reductions, the timing of employee reductions, the level of the Company’s operations, market factors and others. As a result of these assumptions, actual results may differ materially.

Item 2.06 Material Impairments.

The information disclosed above under Item 2.05 is hereby incorporated by reference.The Company cannot, at this time, quantify the impairment charges, if any, to long-lived assets associated with the wind-down of Cronos Fermentation.

Item 6. Exhibits

The exhibits listed in the Exhibit Index immediately below are filed as part of this Quarterly Report, which Exhibit Index is corporate by reference herein.


Exhibit Number						Exhibit Index
3.1						Certificate of Continuance, Notice of Articles and Articles of Cronos Group Inc. (incorporated by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q of Cronos Group Inc., filed August 6, 2020).

31.1*						Certification of the Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*						Certification of the Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**						Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**						Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.


101.INS*						XBRL Instance ~~Document~~Document.
101.SCH*						XBRL Taxonomy Extension Schema Document.
101.CAL*						XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*						XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*						XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*						XBRL Taxonomy Extension Presentation Linkbase Document.

† Management contract or compensatory plan or arrangement.

* Filed herewith.

** Furnished herewith and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	CRONOS GROUP INC.

	By:	/s/ ~~Robert Madore~~James Holm
		~~Robert Madore~~James Holm Chief Financial Officer
August ~~9, 2022~~8, 2023




	By:	/s/ ~~Carlos Cortez~~Jimmy McGinness
		~~Carlos Cortez~~Jimmy McGinness Vice President, Controller, and Principal Accounting Officer
August ~~9, 2022~~8, 2023


Table of Contents

Condensed Consolidated Balance Sheets as of June 3 030 , ~~2022~~2023 (Unaudited) and December 31, ~~202~~20221			4
Condensed Consolidated Statements of Net Loss and Comprehensive Loss for the three and six months ended June 3 0 30 , ~~2022~~2023 and ~~2021~~2022 (Unaudited)			5
Condensed Consolidated Statements of Changes in Equity for the three and six months ended June 3 0 ~~, 2022~~ 30, 2023 and ~~2021~~2022 (Unaudited)			6
Condensed Consolidated Statements of Cash Flows for the six months ended June 3 0 ~~, 2022~~ 30, 2023 and ~~2021~~2022 (Unaudited)			7
Notes to Condensed Consolidated Financial Statements (Unaudited)			8


	Useful life (in years)	As of June 30, 2022
		Cost		Accumulated amortization		Accumulated impairment charges		Net
Software	5	$	6,065	$	(2,137)	$	(80)	$	3,848
Health Canada licenses	17	8,706		(1,865)		(6,841)		—
Ginkgo exclusive licenses(i)	10	23,655		(865)		(4,668)		18,122
Israeli codes(ii)	20	294		(42)		—		252
Total definite-lived intangible assets		38,720		(4,909)		(11,589)		22,222
Lord Jones® brand	N/A	64,000		—		(62,500)		1,500

Total intangible assets		$	102,720	$	(4,909)	$	(74,089)	$	23,722


	As of June 30, 2022
Remainder of 2022 (6 months)	$	1,539
2023	3,034
2024	3,016
2025	2,716
2026	2,109
2027	1,924
Thereafter	7,884
	$	22,222


	As of April 1, 2022		Revaluation gain		Exercise of rights		Foreign exchange effect		As of June 30, 2022
(a) Altria Warrant	$	3,845	$	(3,245)	$	—	$	(109)	$	491
(b) Pre-emptive Rights	67		(49)		—		(2)		16
(c) Top-up Rights	187		(116)		—		(4)		67
	$	4,099	$	(3,410)	$	—	$	(115)	$	574


	As of April 1, 2021		Revaluation gain		Out-of-period adjustment		Foreign exchange effect		As of June 30, 2021
(a) Altria Warrant	$	234,656	$	(85,778)	$	—	$	1,205	$	150,083
(b) Pre-emptive Rights	20,173		(6,360)		—		113		13,926
(c) Top-up Rights	17,471		(23,110)		11,278		(85)		5,554
	$	272,300	$	(115,248)	$	11,278	$	1,233	$	169,563


	As of January 1, 2021		Revaluation (gain)/loss		Exercise of rights		Foreign exchange effect		As of June 30, 2021
(a) Altria Warrant	$	138,858	$	7,186	$	—	$	4,039	$	150,083
(b) Pre-emptive Rights	12,095		1,473		—		358		13,926
(c) Top-up Rights	12,457		(7,033)		—		130		5,554
	$	163,410	$	1,626	$	—	$	4,527	$	169,563


	10% decrease as of June 30, 2022
	Altria Warrant		Pre-emptive Rights		Top-up Rights
Share price	$	219	$	8	$	19
Weighted-average expected life	196		16		24
Expected annualized volatility	318		11		27


	10% decrease as of December 31, 2021
	Altria Warrant		Pre-emptive Rights		Top-up Rights
Share price	$	3,970	$	80	$	123
Weighted-average expected life	2,971		171		133
Expected annualized volatility	5,402		96		155


	Weighted-average exercise price (C$)		Number of warrants
Balance as of January 1, 2021	$	0.25	7,987,349
Exercise of warrants	0.25		(7,987,349)

Balance as of June 30, 2021	$	—	—


	Three months ended June 30, 2022
	United States		Rest of World		Corporate		Total
Cannabis flower	$	—	$	15,739	$	—	$	15,739
Cannabis extracts	1,459		5,582		—		7,041
Other	—		281		—		281
Net revenue	$	1,459	$	21,602	$	—	$	23,061

Share of income from equity method investments	$	—	$	5,197	$	—	$	5,197

Total assets	$	430,455	$	285,902	$	615,856	$	1,332,213
Depreciation and amortization	$	87	$	1,324	$	—	$	1,411



Adjusted EBITDA	(3,877)		(8,995)		(5,927)		(18,799)


	Three months ended June 30, 2021
	United States		Rest of World		Corporate		Total
Cannabis flower	$	—	$	11,597	$	—	$	11,597
Cannabis extracts	2,227		1,531		—		3,758
Other	—		267		—		267
Net revenue	$	2,227	$	13,395	$	—	$	15,622

Share of loss from equity method investments	$	—	$	(1,115)	$	—	$	(1,115)

Total assets	$	473,828	$	386,805	$	741,850	$	1,602,483
Depreciation and amortization	68		975		—		1,043



Adjusted EBITDA	(10,711)		(32,605)		(6,443)		(49,759)


	Six months ended June 30, 2021
	United States		Rest of World		Corporate		Total
Cannabis flower	$	—	$	21,031	$	—	$	21,031
Cannabis extracts	4,668		2,234		—		6,902
Other	—		300		—		300
Net revenue	$	4,668	$	23,565	$	—	$	28,233

Share of loss from equity method investments	$	—	$	(2,758)	$	—	$	(2,758)

Total assets	$	473,828	$	386,805	$	741,850	$	1,602,483
Depreciation and amortization	139		1,639		—		1,778



Adjusted EBITDA	(20,221)		(54,789)		(11,323)		(86,333)